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"Life handed him a lemon, 
As Life sometimes will do. 
His friends looked on in pity, 
Assuming he was through. 
They came upon him later, 
Reclining in the shade 
In calm contentment, drinking 
A glass of lemonade." 
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Summary 
 
Histone deacetylase inhibitors (HDACi) have been designed to alter the actions 
of epigenetic modifiers with the aim of 'reprogramming' the epigenome of diseased 
tissues back to their normal disease-free state. These inhibitors were designed to be non-
DNA reactive and therefore considered safe from a genetic toxicology point of view. 
However, HDACi’s have been shown to induce DNA damage in healthy cells through 
unknown mechanisms, thereby posing significant risks to human health. Studies suggest 
that HDAC inhibitor-induced DNA damage is partly associated with changes in 
transcription and replication. Consequently, collisions between these events can result in 
the formation of DNA lesions and stable DNA:RNA hybrid structures (R-loops), which 
are implicated in the onset of cancer and various neurological diseases. Therefore, the 
aims of the current study were to better understand the mechanisms by which HDAC 
inhibitors may induce DNA damage and to identify potential endpoints for safety 
assessment:  
 
Chapter III: Efforts to study the effects of HDAC inhibition through a chemical 
approach proved unsuccessful in the yeast model organism but identified 
the HDAC mutant, rpd3Δ, showing histone hyper-acetylation compared 
to the wild type. 
Chapter IV:  ChIP-chip was established for the TK6 lymphoblastoid cell line as a 
genome-wide tool for measuring the genotoxicity of HDAC inhibitors. 
Chapter V: Application of the ChIP-chip method showed that Trichostatin A-induced 
changes in histone H4 acetylation led to the re-distribution of transcription 
and replication on chromosome 17 in TK6 cells. This resulted in their co-
localisation, suggestive of potential collisions. However, further efforts to 
determine this by mapping γH2AX and R-loop formation proved 
unsuccessful.   
Chapter VI: The yeast genetic mutant rpd3Δ was used to mimic the effects of treating 
with an HDAC inhibitor. The loss of RPD3 resulted in significantly higher 
levels of γH2A, predominantly at telomere regions. 
 
In conclusion, this thesis presents strong evidence to show that Trichostatin A promotes 
the co-localisation of transcription and replication, suggesting that there is a greater 
possibility of these processes colliding to form DNA damage. 
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Preface  
 
Histone deacetylase (HDAC) inhibitors represent a class of prototypical 
epigenetic modifying drugs aimed at treating cancer. Recent developments using these 
compounds, have shown promising results in treating animal models for 
neurodegeneration, inflammation and metabolic diseases. However, non-clinical safety 
assessment indicates HDAC inhibitors to elicit genetic damage through unknown 
mechanisms. While this may not be significant for cancer, the prospect of using these 
inhibitors for non-life threatening conditions poses a risk to human health. Current testing 
strategies used, provide little information on the mechanism by which test chemicals 
exactly generate genetic damage. A better understanding of these mechanisms would 
allow for thresholds to be set under which certain chemicals may be safe to use. Such 
initiatives have already begun (Adeleye 2015) based on concepts proposed by AOP 
(Adverse Outcome Pathways) (Ankley 2010) and TT21C (Toxicity testing in the 21st 
century) (Bhattacharya 2011), envisaging the use of large-scale genome-wide approaches 
with greater focus on the mechanism of action.  
The pharmaceutical industry has made large investments into the development of 
HDAC inhibitors and interests lie in trying to understand the mechanism of genetic 
toxicity to better address the risks to human health but also to further the development of 
next generation HDAC inhibitors. The current study stems from the collaboration 
between Glaxo-Smith Kline (GSK) Safety Assessment and Cardiff University, supported 
by funding from the Biotechnology and Biological Sciences Research Council (BBSRC) 
and GSK Collaborative Awards in Science and Engineering (CASE). The aim is to 
combine expertise in genetic toxicology from industry with genome-wide technologies 
available in academia to address the question of how drugs targeting the epigenome, such 
as HDAC inhibitors, can lead to damage at the genome level.   
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1.1 Non-clinical safety assessment  
 
Safety assessment is carried out by the pharmaceutical industry on all newly 
developed compounds or ‘test articles’ to screen for potential hazards to human health. A 
key aspect of this is to assess if the test article can produce changes in the genetic 
sequence, in which case it is mutagenic, a fundamental event underpinning 
carcinogenicity. Mutations in germ line cells can lead to hereditary disorders, whereas 
those in somatic cells can increase the risks of developing cancer. In living cells, various 
repair mechanisms help to protect the genome from endogenous and exogenous sources 
of damage. As such, the potential genotoxicity of test articles may not necessarily 
manifest as mutations. Therefore, genotoxicity testing entails a battery of tests to assess, 
with greater coverage, the ‘capacity’ of a compound to damage the genome, classing the 
actions as being mutagenic (change in genetic material), clastogenic (chromosomal 
breakages) and/or aneugenic (unequal number of chromosomes in daughter cells). These 
regulatory tests take into account the ‘mode of action’ (MoA), which describes 
phenotypic changes elicited by test articles at the cellular level that can be readily scored 
and reliably performed between different laboratories. A positive result in these tests 
however, does not provide information on the molecular mechanisms of DNA damage. 
 
1.1.1 Core tests  
 
The exact compositions of tests used are specific to the industry sector, but 
generally the core battery consists of a bacterial gene mutation test, followed by an in 
vitro and in vivo assay evaluating chromosomal damage. Liver homogenate or S9 fraction 
is also widely used in conjunction with the tests since some compounds require metabolic 
activation to become mutagenic.  
The Ames test is the most frequently used in vitro test for mutagenicity. Strains 
of Salmonella typhimurium are auxotrophic, carrying pre-existing mutations in genes 
responsible for synthesising histidine. The DNA reactivity of a test compound generates 
revertants, leading to colony formation in histidine-free medium. Different strains of S. 
typhimurium or in combination with E. coli are used to detect base-pair substitutions and 
frameshift mutations (Tejs 2008).   
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The chromosome aberration assay uses microscopy to look for gross structural 
changes in metaphase cells following treatment with a test compound. These changes can 
be symmetrical (chromosome breaks) or asymmetrical (chromatid breaks). 
The micronucleus (MN) assay scores the formation of small membrane enclosed 
chromosome fragments or entire mis-segregated chromosomes known as micronuclei, 
formed in the cytoplasm of daughter cells. The in vitro MN assay can be seen as an 
equivalent of the chromosome aberration assay since it is able to detect both clastogens 
and aneugens. Cytochalasin-B can be used to inhibit cytoplasmic division, allowing 
identification of divided cells.  
Applying the same principles as in vitro MN and chromosome aberration tests, 
the in vivo versions of these assays are carried out in rodent models, of which the bone 
marrow MN is the most common (Raffaella Corvi 2016).  
 
1.1.2 Supplementary tests 
 
Supplementary tests can be performed on a case-by-case basis to further support 
the data gathered from core tests. 
The TK assay, carried out in either mouse lymphoma cells (L5178Y) or human-
derived lymphoblastoid TK6 cells is used to detect mutagenic and clastogenic events at 
the heterozygous thymidine kinase locus. Reactive test chemicals causing a forward 
mutation would give rise to mutant cells (TK-/-), deficient in thymidine kinase (Lloyd and 
Kidd). In the presence of a selective agent such as triflourothymide (TFT), cells 
heterozygous for TK are sensitive to the toxic effects of TFT whereas mutants are 
resistant, able to proliferate and form colonies (Lloyd and Kidd, 2012). 
The alkaline comet assay involves electrophoresing cells under alkaline 
conditions through low-melting point agarose. As the nucleic acid migrates, damaged 
DNA can be seen progressing in front of the main nuclear body. The assay collectively 
measures DNA single and double strand breaks, in addition to abasic and alkali liable 
sites. It provides an alternate measure of clastogenicity that may involve repairable 
damage but does not provide information on mutagenicity or aneugenicity of a test 
compound and is therefore recommended as a follow up assay.   
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1.1.3 Cytotoxicity assays  
 
The highest concentration of a test chemical used in any genotoxicity test is 
limited by its solubility or a threshold of cytotoxicity. While there is no overall consensus, 
a measure of general cytotoxicity is carried out complementary to the genotoxicity test 
used with the aim of limiting false positives associated with excessive toxicity 
(O'Donovan 2012). The recommended cytotoxicity test also differs. For instance, at least 
20% reduction in cloning efficiency (CE) or relative total growth (RTG) is suggested for 
mutation assays, while in vitro micronuclei assays suggest up to 50% cytotoxicity 
measured by relative increase in cell counts (RICC) or proliferation index in the absence 
of cytochalasin B, otherwise a replicative-index (RI) or cytokinesis-block proliferation 
index (CBPI) is used in the presence of cytochalasin B (O'Donovan 2012).  
1.2 Novel genome-wide approaches to study mechanisms 
 
The advent of genome-wide analysis tools such as chromatin 
immunoprecipitation coupled to microarrays (ChIP-chip) or sequencing (ChIP-seq) has 
allowed for high-resolution genome-wide mapping of protein-DNA binding, significantly 
advancing our understanding of their functions. More importantly genomic datasets are 
rich with information, allowing associations be to drawn leading to a mechanistic insight 
(Yu et al, 2009), thereby providing a more informative tool in the interests of the current 
study. 
ChIP-chip was originally developed over a decade ago in yeast (Ren B et al, 2000) 
and has since been used with a number of different organisms ranging from prokaryotes 
to eukaryotes (Figure 1.1). ChIP-chip links the application of chromatin 
immunoprecipitation of chemically cross-linked protein-DNA complexes with 
microarray analysis of the bound DNA. DNA microarrays were originally developed to 
measure gene expression changes and contain printed features of the genome as short 
oligonucleotides probes. Resolution therefore is typically limited by the probe converge 
and length of the hybridising DNA fragment. The resolution of ChIP-seq data on the other 
hand is not restricted by probe density and sequencing of smaller fragments offers greater 
coverage and resolution (Ho et al, 2011). With the rapidly reducing costs of sequencing, 
ChIP-seq has largely replaced ChIP-chip over the past years (Ho et al, 2011). However, 
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as it stands, ChIP-chip is a well-established technique with extensive bioinformatics tools 
available and the flexibility in array design offers an economic platform for human 
studies.  
Analysis of ChIP-chip data has long been limited to binary interpretations, 
entailing the presence or absence of factors at various genomic sites under different 
experimental conditions, in part owing to the original application of microarray in gene 
expression analysis (Bennett 2015). Provided these inherent bioinformatic challenges in 
analysing large datasets, recent efforts from our lab have resulted in a novel method of 
normalising ChIP-chip data to allow relative comparisons to be made (Bennett 2015). 
This feature within the ‘Sandcastle’ software (Bennett 2015) allows additional 
information to be extracted from experiments and is particularly useful when measuring 
features such as histone acetylation, which tend to take on values within a biologically 
relevant continuum in response to environmental changes. Therefore, an established 
ChIP-chip workflow consisting of the necessary bioinformatic tools allows epigenetic 
changes to be fully examined in response to HDAC inhibitor treatment.  
1.3  Epigenetics  
 
The rapidly expanding field of epigenetics emerged more than half a century ago 
when Conrad Hal Waddington (1905 – 1975) first coined the term ‘epigenetics’ in 1942 
(Van Speybroeck 2002). Drawing from the long-standing debate surrounding epigenesis 
vs. preformation in neoclassical embryology (Van Speybroeck 2002), Waddington 
described epigenetics in the context of embryonic development, as a process (epigenesis) 
which utilises the interactions between existing information (preformation, also known 
as genetics) within the zygote to give rise to a wide array of new characteristics. As 
suggested in the use of the Greek prefix ‘epi-’, simply meaning ‘close to’ or ‘near’. This, 
in Waddington’s view of Neo-Darwinism portrays:  
 
“a breach between organism and nature as complete as the Cartesian dualism of 
mind and matter; an epigenetic consideration of evolution would go some way 
toward healing it” (Counce 1958)  
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Figure 1.1. Overview of the ChIP-chip workflow. Protein or modification of interest is 
chemically cross-linked to DNA and fragmented to an average size of 500bp. Highly specific 
ChIP-grade antibody are coupled to superparamagnetic beads and used to enrich for target protein 
or modification of interest. The resulting bound fragments are de-crosslinked and purified to yield 
DNA (IP) fragments representative of binding location. The DNA is then amplified, differentially 
labelled and hybridised onto a DNA microarray with non-immunoprecipitated fragmented 
genomic DNA (IN) as background. The DNA microarray contains printed features of the genome 
as short oligonucleotide ‘probes’. Competitive binding between IP and IN DNA for probes results 
in different fluorescent intensities that are scanned and analysed by software. Following data 
normalisation, high IP/IN ratios likely represent probable binding sites which are determined by 
peak detection algorithms. Image adapted from (Powell 2014b). 
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and addresses what many geneticists’ at the time conceived as a simplistic relationship 
between the genotype and the phenotype (Haig 2004).  This concept is illustrated in 
Waddington’s classical work on ‘The Strategy of the Genes: A Discussion of Some 
Aspects of Theoretical Biology’ in the form of an ‘epigenetic landscape’ (Figure 1.2), a 
visual metaphor depicting critical stages in a cell’s development where ‘choices’ are made 
leading to different outcomes.  
Since then, the word ‘epigenetics’ has been broadly assigned to explain seemingly 
unrelated biological phenomena linked to gene regulation, such as position-effect 
variegation in Drosophila (Wakimoto 1998) and paramutations in maize (Kermicle 
1996). In the mid to late 20th century, the meaning of ‘epigenetics’ began to deviate within 
the field of biology. In the study of morphology, Herring (1993) described it as “the entire 
series of interactions among cells and cell products which leads to morphogenesis and 
differentiation” (Herring 1993) and in molecular biology terms it refers to “heritable 
changes in gene function that cannot be explained by changes in DNA sequence” , which, 
to this date, has become the most commonly used definition of ‘epigenetics’ (Riggs A.D. 
1996). Therefore it is not surprising that proper use of the term continues to be the subject 
of much debate (Bird 2007). This in Haig’s view mainly stems from its dual origins (Haig 
2004). Apart from the original meaning coined by Waddington, nearly two decades later 
Nanney adopted the term to describe “messy” inherited traits (Nanney 1958). Throughout 
the course of its history, epigenetics has evolved into a major field in biology, which is 
still used in a Waddingtonian sense. The study of epigenetics, as it currently stands, 
focuses on the mechanisms by which information from the ever-changing environment 
can shape and mold the genetic code to produce different phenotypes without changing 
its fundamental sequence. 
 
1.3.1  Regulating the epigenome 
 
Following the rise of epigenetics as a prominent field in biology, the study of 
epigenetics focuses on potential mechanisms by which such information is propagated 
and stability maintained in cells. To this end, great interest surrounds trying to understand 
how the epigenome is regulated. Central to this is chromatin itself, the nucleoprotein 
structure that makes up our chromosomes, which remains a critical factor in regulating 
DNA accessibility, influencing many key cellular processes such as transcription, 
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replication and DNA repair (Ehrenhofer-Murray 2004). Covalent modification of DNA 
bases, post-translational histone modifications and microRNA regulation have been 
identified as the major mechanisms by which epigenetic information is regulated in living 
cells (Figure 1.3). Of these, modifications to histone proteins are of particular interest in 
the current study, as these form a key part of the HDAC inhibitor response. 
1.4  Histone modifications 
 
In eukaryotes, a principal component of chromatin is histones. Roughly 147bp of 
DNA wrap around these proteins to form the nucleosome core particle (Karolin L 1997). 
Histones are comprised of two copies of H3, H4, H2A; H2B subunits, forming an octamer 
(Figure 1.4) (Kornberg R.D. 1999). The importance of histones were largely dismissed in 
the 1960s, at a time when much of the focus was on the central dogma of biology 
(Gottesfeld and Mukhopadhyay 2012). Vincent G. Allfrey is largely credited as the father 
of epigenetics for his pioneering work showing the presence of acetyl-lysine’s on the N-
terminal of histones H3 and H4 (Vidali G 1968). He further went on to hypothesise that 
the acetylation of histone tails would neutralise the positive charge, weakening their 
interaction with DNA (Vidali G 1968). Indeed, later studies have shown this to be the 
case. The removal of histone tails led to greater DNA accessibility either through 
nucleosome instability (Ausio 1989) or enhanced nucleosome dynamics (Polach 2000).  
Histone tail regions are protease sensitive, typically making up 25 - 30% of the total 
histone mass and protrude away from the chromatin (Wolffe AP 1999). The exposed 
surface allows for interactions with other proteins. For example, the Sir3 protein (silent 
information regulator) in yeast binds to deacetylated lysine 16 on the histone H4 tail to 
bring about transcriptional silencing (Hecht 1995). Our knowledge of the different types 
of histone tail modifications have greatly expanded with advances in technologies such 
as Mass-spectroscopy (Wisniewski 2007). Apart from the well-studied association 
between histone acetylation and transcription (Struhl 1998), to date up to 15 different 
types of modifications have been described in mammals leading to over 100 possible 
unique modifications based on their histone locations (Figure 1.5) (Huang 2014).  
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Figure 1.2. Waddington’s epigenetic landscape. Depiction of fate of the cell during 
development and differentiation as shaped and determined by the environment (Noble 2015).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Distinct mechanisms regulating the epigenome. Epigenetics can be coordinated 
from different levels consisting of: 1) covalent modifications to DNA in the form of methylation, 
2) RNA interference and 3) post-translational histone modifications (Hagood 2014). 
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Figure 1.4. Assembly of the histone octamer. Core histone proteins (H3, H4, H2A; H2B) form 
dimers (H3-H4 and H2A-H2B), which assemble into tetramers. DNA wraps around complete 
nucleosomes consisting of two histone tetramers. Image from: en.wikipedia.org.  
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1.4.1 Histone code hypothesis 
 
Early concepts based on prominent histone modifications such as acetylation, 
methylation, phosphorylation and ubiquitination postulated that with such a diverse 
network of modifications decorating the histone tail, various mechanisms would exist to 
‘read’ and ‘write’ this information at the epigenetic level (Mizzen C 1998). This would 
undoubtedly place chromatin activity under differential regulatory mechanisms linked to 
distinct biological processes. For example, histone acetylation and phosphorylation 
coordinate signalling through independent mechanisms to transiently and rapidly regulate 
immediate-early genes (IEG’s) demonstrating an additive effect (Thomson 2001). 
Additionally, phosphorylation of histone H3Ser10 is involved in both transcription and 
cell division, two processes with opposing chromatin conformations. The dual nature of 
this modification is highly dependent on neighbouring methylated (Rea 2000) and 
acetylated (Lo 2000) residues, suggesting that individual histone modifications can be 
regulated by surrounding modifications. Such evidence supported the notion of histone 
marks as a ‘language’ which could ultimately be read by the cell, or as Allis and 
colleagues proposed it – the ‘histone code’ (Strahl BD 2000). 
Although the code metaphor remains a popular topic and favours pro-complexity 
based on various chromatin-modifying proteins with multivalent binding capabilities, 
some refuted this, showing instead a lack of complexity. Given that acetylation of certain 
histone residues (ie. H3K9) are found at actively transcribed genes, single and combined 
lysine to alanine mutations on the tails of histone H3 and H4 exhibit unpredictable and 
insignificant effect on overall gene expression (Dion 2005). Furthermore, as chromatin 
modifiers were thought to recognise specific combinations of histone modifications, 
genome-wide mapping of BPTF (bromodomain PDH finger transcription factor) and 
Chd1 (chromatin helicase DNA binding protein 1) remodelling factors found additional 
bindings sites that could not be explained by histone marks alone (Ruthenburg 2011). 
Instead, it has been proposed that histone modifications may act as allosteric modulators 
under certain circumstances to regulate the activity of chromatin binding proteins. 
Noticeably, the removal of such marks has no effect on its binding (Morettini 2011). 
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Figure 1.5. Histone modification landscape. Use of mass spectroscopy has led to the discovery of many new post-translational modifications beyond 
the conventional few. Amino acids sequences of various histones shown in coloured boxes, with modifiable amino acids shown in bold. Post-translational 
histone modifications: Me – methylation, Ac – acetylation, Ph – phosphorylation, Pr – propionylation, Bu – butyrylation, Cr – crotonylation, Hib – 2-
hydroxyisobutyrylation, Ma – malonylation, Su – succinylation, Fo – formylation, Ub – ubiquitination, Cit – citrullination, OH – hydroxylation, Og – O-
GlcNAcylation,Ar–ADPribosylation (Huang 2014).
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1.4.2 Interpreting the code  
 
Of the myriad histone post-translational modifications described to date, their 
presence/absence and biological effects are dictated by chromatin targeting enzymes with 
the ability to “read”, “write” and “erase” such marks. Regions of DNA must be made 
more accessible before the onset of transcription. To achieve this, histone-DNA 
interactions must first be dissolved and this is partly accomplished by proteins such as 
histone acetyl-transferases (HATs) that help to add (“write”) acetyl groups on histone 
tails, making it more negatively charged.  On the other hand, histone deacetylase (HDAC) 
enzymes have the opposite effect of removing (“erasing”) these acetyl groups and 
suppressing the genetic information. While the effects of chromatin “writers” and 
“erasers” are refractory, “reader” proteins function solely to interpret existing histone 
modifications and relay biological signals. Acetylation is only one of the many possible 
histone PTM’s and with each distinct type of mark, unique classes of enzymes exists, 
responsible for its inscription, interpretation and removal (Figure 1.6). For instance, the 
enzyme SUV39H1 is responsible for methylating H3K9 (Rea 2000), which in turn is read 
by HP1 (heterochromatin protein 1) helping to stabilise heterochromatin (Bannister AJ 
2001). Acetylation can also occur at the same residue and is read by BRD4 (Chiang 2009), 
family bromodomain modules, leading to the recruitment of the transcription factor p-
TEFb (positive transcription elongation factor) (Brès V 2008). 
Over the past decade, many families of conserved protein domains have been 
identified using techniques such as histone peptide screening (Garske AL 2010), protein 
microarrays (Nady N 2008) and more recently SILAC-MS (Stable Isotope Labelling by 
Amino acids in Cell culture) (Vermeulen M 2010), helping to distinguish between 
specific histone modifications. Once bound, the reader module serves as an intermediary 
scaffold, signalling the recruitment of downstream proteins involved in cellular processes 
such as transcription, replication and DNA damage/repair. 
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Figure 1.6. Writers, erasers and readers of histone modifications. Enzymes exist to deposit (write) or remove (erase) histone marks. These 
modifications are recognised (read) by various proteins through specific domains to signal cellular events. Modified residue(s) with corresponding reader 
domains shown below histones: PHD – plant homeodomain, MBT - malignant brain tumor, AKR – ankyrin repeats, PWWP - proline-tryptophan-
tryptophan-proline, WD40 - tryptophan-aspartic acid dipeptide 40 repeats, BRCT - BRCA1 C-terminal, UIM – ubiquitin-interacting motif; SIM – SUMO-
interacting motif. Readers and writer: HATs – histone acetyltransferases, HDACs – histone deacetylases, HMTs – histone methyltransferases, HDMs – 
histone demethylases, PRMTs – protein arginine methyltransferases, JMJD6 - jumonji domain containing protein 6, DUB –de-ubiquitinating enzymes, 
SENP - Sentrin/SUMO-specific protease. Histone post-translational modifications: Ac – acetylation, Me – methylation, P – phosphotylation, Ub – 
ubiquitylation, SU – sumoylation. 
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1.4.3 Histone modifications & cellular function 
 
Histone modifications are present in abundance throughout the genome, helping 
to establish regions of euchromatin (relaxed structure) and heterochromatin (compact 
structure), influencing key DNA-based processes such as transcription, replication and 
repair locally.   
 
1.4.3.1 Transcription 
 
Generally speaking, histone acetylation is associated with transcriptional 
activation, whereas sumoylation, deamination and proline isomerisation are associated 
with transcriptional repression. Methylation, phosphorylation and ubiquitination can 
either promote or inhibit transcription depending on the chromatin context. For instance, 
histone H3K4, K36; K79 methylation is linked with gene activation while histone H3K9, 
K27, and histone H4K20 methylation is linked with gene repression (Vakoc CR 2005). 
Apart from correlating various histone modifications with transcriptional state, recent 
studies demonstrate the presence of heterochromatin protein 1-gamma (HP1γ) and H3K9 
methylation in the coding region of actively transcribed genes (Vakoc CR 2005), 
highlighting further complexities.  
Expression of genes by the transcription machinery requires access to the DNA 
template, an event that requires extensive chromatin remodelling and can be achieved by 
enzymes that post-transcriptionally modify histone tails and ATP-dependent remodelling 
complexes. The presence of histone marks such as H3K9ac correlates universally with 
active promoters and can be found together with H3K14ac to recruit transcription factors 
such as TFIID (Transcription Factor II D), a general transcription factor involved in the 
formation of the RNA polymerase II pre-initiation complex (Agalioti 2002). 
Phosphorylation of H3S10, S28 and histone H2BS32 were identified in the regulation of 
proliferation-associated genes. Interestingly, H3S28p has been shown to displace 
polycomb-repressive complex (PRC), a histone methyltransferase, leading to the 
demethylation and acetylation of adjacent H3K27 and subsequent transcription (Lau and 
Cheung 2011). H3S10p is also a well-documented event observed widely in eukaryotes 
connected to chromatin condensation during mitosis and meiosis (Wei 1999).  
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1.4.3.2 DNA Replication 
 
Given the importance of histones and their ability to shape transcriptional 
readouts, it has become apparent that the reliable inheritance of chromatin states is equally 
important as the DNA itself. Various mechanisms have been put forward describing the 
transmission of histones during DNA replication. An earlier idea, initially proposed by 
Weintraub et al. implicated the segregation of parental histone tetramers into H3-H4 
dimers, these parental dimers would then form tetramers with newly synthesised dimers, 
thereby acting as template for the transmission of histone post-translational modifications 
(Weintraub H. 1976). In contrast to this, an alternative mechanism could involve a loss 
of histone PTMs during replication and the re-establishment of these marks on de novo 
histone tetramers by histone modifying enzymes following S-phase (Jackson 1987).  
The interactions of histone modifying enzymes with the DNA replication 
machinery as well as DNA binding proteins have been well described for the propagation 
of pericentric heterochromatin (Sarraf and Stancheva 2004). Chromatin assembly factor 
(CAF-1) is a histone chaperone recruited by proliferating cell nuclear antigen (PCNA), a 
processivity factor for the replicative DNA polymerase δ. CAF-1 forms a complex with 
heterochromatin protein 1 (HP1) and the histone methyltransferase SETDB1, recruited 
by MBD1 (Sarraf and Stancheva 2004). H3K9 undergoes mono-methylation by 
SETDB1, followed by di-/tri-methylation by SUV39H (Fujita 2003). The dependence of 
SETDB1 on MBD1 demonstrates the requirement of methylated CpG-sequences in 
establishing regions of repressive chromatin following replication. On the other hand, 
Proteins of the polycomb group (PcG) accumulate and enhance H3K27me3 levels at 
repressed regions prior to DNA replication and are inherited by dilution, as opposed to 
de novo maturation (Lanzuolo 2011).  
Although much debated, recent evidence supports both scenarios. Using stable 
isotope labelling-based quantitative mass spectrometry and affinity purification Xu et al. 
showed that the bulk of H3.1-H4 tetramers separated in a conserved fashion, although a 
substantial proportion of H3.3-H4 tetramers took part in splitting events (Xu 2010). 
Therefore mechanisms of epigenetic inheritance may be unique to regions of eu- and 
hetero-chromatin, considering that H3.3 is enriched in actively transcribed regions (Xu 
2010). Distinct from the single semi-conservative mechanism of DNA replication, 
reproducing the epigenetic information appears more difficult and may involve several 
different mechanisms. Such a strategy would ideally allow for flexibility in how “local” 
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chromatin environments are re-established, which may have significant implications for 
how a single genome can be interpreted in many ways giving rise to different cell types.    
Apart from being able to faithfully reproduce epigenetic information, histone 
modifications also influence the timing and firing of replication origins. In both 
eukaryotes and prokaryotes, H3K4 di- and tri-methylation marks are present at origins of 
replication (Rondinelli 2015). Demethylation of H3K4me3 by KDM5C, a family of 
Jumonji C (JmjC)-domain containing demethylase, is required for initiating the assembly 
of the pre-initiation complex on the chromatin, at early origins (Rondinelli 2015).  
Additionally, monomethylation of H4K20 in mammalian cells by KMT5A, a histone 
methlytransferase, aids the loading of the pre-replication complex (pre-RC) during origin 
licensing (Tardat 2010). In budding yeast, acetylation of histone H3 and H4 is required 
for origin activation during replication (Unnikrishnan 2010).  
Particularly, acetylation of H3K56 increases the affinity of histone chaperones 
CAF-1 (chromatin assembly factor 1) and Rtt106 (regulator of Ty1 transposition) to H3, 
favouring nucleosome assembly (Sun et al. 2009). Disruptions to H3K56ac affect the 
completion of DNA replication, sensitising cells to DNA damaging agents that hinder 
replication fork progression (Wurtele 2012). More so, histone modifications and 
chromatin remodelling are crucial in facilitating the events leading to the proper repair of 
DNA damage generated from various sources.  
 
1.4.3.3 DNA Repair 
 
Unlike DNA replication, scheduled to take place in the S phase, the repair of DNA 
is poised to occur throughout the cell cycle in response to damage. Repair of damaged 
DNA takes place on the chromatin and as such these events are regulated by histone 
modifications and remodelling of the chromatin. The initial “access-repair-restore” model 
proposed by Smerdon et al. views chromatin largely as an obstacle to repair (Smerdon 
1991), first requiring an “opening” around the site of DNA damage to allow access for 
repair factors. Interestingly, accumulating evidence suggests the transient formation of 
heterochromatin is a prominent feature of DNA damage, supported by the recruitment of 
proteins such as HP1 (Luijsterburg 2009), PRC1, PRC2 (Campbell 2013) and HDAC1, 
HDAC2 (Miller 2010). On the other hand, failure of chromatin to condense properly leads 
to improper DNA damage response (DDR) (Campbell 2013). Recently it was shown that 
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in the context of double strand breaks, HP1 is recruited alongside KAP-1 and SUV39H1 
to regions of euchromatin (Ayrapetov 2014). The resulting H3K9me3 lead to activation 
of ATM (Ayrapetov 2014), a key signalling protein in the DDR. The ensuing 
phosphorylation of KAP-1 by ATM represents a negative feedback loop, dictating a brief 
period of chromatin condensation with the release of the HP1/KAP-1/SUV39H1 complex 
(Ayrapetov 2014). The momentary appearance of repressed chromatin may function to 
inhibit local transcription and potentially avoid encounters with the repair process (Soria 
2012). In light of this, early perturbations in chromatin events was described to effectively 
“prime” the DNA for subsequent repair (Soria 2012).  
Numerous histone modifications have been described in the various stages and 
pathways of DNA repair. Of these, phosphorylation of Ser139 on histone H2AX 
(γH2AX) is the most extensively characterised modification to date affiliated with 
double-strand break (DSB) repair (Rogakou EP 1998).  The formation of γH2AX in 
response to DSB constitutes a rapid response, helping to recruit the all-important MRE11-
Rad50-Nbs1 (MRN) repair complex via MDC1 binding (mediator of DNA damage 
checkpoint protein 1). Activation of ATM by MRN further stimulates the 
phosphorylation of H2AX, amplifying the signal and leading to the formation of “γH2AX 
foci”, visible using fluorescent microscopy (Kuo LJ 2008). Microarray studies have also 
revealed that γH2AX distributes asymmetrically around the site of DSB, dependent upon 
transcription (Iacovoni 2010) and cohesion binding (Caron 2012). Interestingly, 
deficiencies in γH2AX formation have only minor effects on DSB repair, suggesting that 
it functions mainly to promote signal retention at sites of DNA damage (Celeste 2003). 
Nevertheless, given its role in DDR, γH2AX is widely employed as a biomarker of DNA 
damage and acts cooperatively with other histone modifications to drive the repair 
process. 
Acetylation of histones plays a key role in the proper repair and recovery of DNA 
after damage. In yeast, following UV exposure, histone Htz1 enhances GCN5 (General 
Control Non-derepressible 5) acetyltransferase binding at the sites of UV-induced DNA 
damage leading to hyperacetylation at H3K9/14. This results in the recruitment of Rad14, 
a damage recognition protein in the nucleotide excision repair (NER) pathway (Yu 2013). 
Recent studies also demonstrated that H3K14ac serves as an anchor for the chromatin 
remodelling complex RSC (Remodels Structure of Chromatin), which functions to relax 
tightly positioned nucleosomes, assisting the repair of CPD’s (Cyclo- Pyrimidine Dimers) 
formed as a result of UV-damage (Duan and Smerdon 2014).  
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H3K56ac is an abundant mark present on newly synthesised histones throughout the 
genome of budding yeast (Simoneau 2015). Its presence signals for chromatin assembly 
following the completion of DSB repair and DNA replication (Simoneau 2015). Absence 
of this mark leads to replication stress and the formation of spontaneous DNA damage 
(Simoneau 2015). Following DSB repair, Rtt109 (regulator of Ty1 transposition) 
acetylates H3K56 through Asf1 (anti-silencing function) stimulation (Chen 2008). Yeast 
asf1 mutants exhibit normal DSB repair and DNA synthesis but lack detectable histones 
around sites of induced DNA damage (Chen 2008). Additionally, H3K56ac deficiency 
results in persistent activation of Rad53, a DNA damage checkpoint protein (Chen 2008). 
Therefore, Asf1 stimulated H3K56ac is not only crucial for restoring chromatin structure 
around the damaged DNA but more importantly signifies the recovery from checkpoint 
arrest and re-entry into the cell cycle (Chen 2008). H3K56ac was also identified as a 
factor along with Rad52 in the selection of sister chromatid recombination as the means 
of repair for replication-derived DSBs (Munoz-Galvan et al. 2013). 
In mammals, BRCA1 (breast cancer early onset 1) and 53BP1 (p53 binding 
proteins 1) are two key proteins involved in DNA end-resection and act as determinants 
of homologous recombination (HR) or non-homologous end joining (NHEJ), respectively 
(Tang et al. 2013). H4K20me2 favours the binding of 53BP1, which is subsequently 
diminished by H4ac to enhance BRCA1 binding, representing a role of histone PTMs in 
driving DSB repair choice (Tang et al. 2013). Similarly, the HAT activity of the 
mammalian chromatin re-modeller Tip60 (60kDa Tat-interactive protein), regulated by 
H3K9me (Ayrapetov 2014), acetylates both histone H4K16 to promote HR and ATM to 
phosphorylate H2AX (Ayrapetov 2014). Tip60 can also form a complex with UBC13 
(ubiquitin-conjugating enzyme) to acetylate H2AXK5, allowing ubiquitination of 
H2AXK119 to take place (Ikura et al. 2007). Acetylation and ubiquitination occurs 
independent of the initial phosphorylation response on histone H2AX and functions in its 
release as part of the chromatin re-organisation process after DNA repair (Ikura et al. 
2007). Furthermore, monoubiquitination of H2A also functions in chromatin remodelling 
in response to UV-induced lesions (Bergink et al. 2006). In yeast, H2BK123 
ubiquitination is shown to be necessary for cell cycle arrest following DNA damage 
(Giannattasio et al. 2005); highlighting the diversity of modifications and functions 
associated with histone H2A and its variants in the DNA damage response.  
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Post-DNA repair involves proper packaging of histones and DNA. Recently, 
CAF-1 was shown to mediate deposition of newly synthesised H3.1 variants following 
NER, while additionally acting as a novel regulator in preserving somatic cell identity 
(Bergink et al. 2006). Also, HIRA (histone chaperone histone regulator A) primes sites 
of UVC-induced lesions by installing H3.3, serving as a marker for transcriptional 
recovery after repair (Bergink et al. 2006). Intriguingly, such studies question whether 
histone turnover contributes to the formation of “damage imprints” as an adaptive 
mechanism for future DNA damage. Likewise, recovering damaged cells to the pre-
damage state is key to maintaining cell identity as deregulation may lead to changes in 
cell fate such as cancer. 
 
1.4.4 Histone core modifications   
 
Much of the studied histone modifications to date focused on those solely present 
on histone tails. This is primarily due to technical limitations of the Edman degradation 
method, restricting the sequencing of amino acids to less than 30 in practice (Mersfelder 
and Parthun 2006). However, with the advent of mass-spectroscopy based methods a 
greater understanding of the histone modifications in the core globular domain was made 
possible (Mersfelder and Parthun 2006). The contributions of histone tail modifications 
to DNA-based processes have been characterised. These marks are easily accessible and 
have been shown to exert their effects mainly through “reader” proteins. Given that DNA 
wrapped around the nucleosome core particle is in close contact with the histone and that 
removal of the N-terminal tail has no significant impact on nucleosome stability (Ausio 
1989), it is hypothesised that histone core modification may be key determinants of 
chromatin function.  
Core modifications fall into three groups based on their location within the histone 
structure: (1) solute-accessible surface, (2) lateral surface and (3) histone-histone 
interface. Those that are solute accessible are predicted to function in a similar manner to 
tail modifications, given the largely exposed surface area. H3K79 methylation is 
evolutionarily conserved from yeast to mammals and represents one of the first studied 
modifications present on the nucleosome face (Li 2005). Methylation of H3K79 is not 
required for silencing; instead it prevents silencing of euchromatin by excluding the yeast 
SIR (silent information regulator) protein from these regions (van Leeuwen 2002). 
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Accessing the portion of DNA that is tightly packaged around histones presents a major 
challenge. Though, short periods (few milliseconds) of spontaneous unwrapping events 
have been detected, potentially by remodelling factors, allowing transient exposure of the 
DNA and modifications on the lateral histone surface (Li 2005). Such unwrapping events 
are introduced at DNA entry-exit points, regions between the histone tail and core, 
facilitated by the cooperative phosphorylation and acetylation of surrounding residues 
(Brehove 2015). The close proximity of lateral residues to DNA is expected to greatly 
impact histone-DNA interactions, directly affecting chromatin structure and function. 
Recent finding on H3K112 supports this idea, showing that acetylation of H3K112 alone 
was sufficient to trigger transcription of chromatin DNA in vitro, whereas histone tail 
modifications were previously incapable of doing so (Tropberger et al. 2013). Other 
lateral surface modifications discovered also influence nucleosome dynamics and DNA-
based processes. Core modifications also extend to those present exclusively between 
histone-histone boundaries with the potential to regulate histone octamer dynamics.  
Mass-spectroscopy screens have identified a number of such modifications but 
their exact function remains to be characterised (Zhang L 2003). Of these, only H4K91ac 
carries enough evidence to implicate a role in nucleosome deposition (Li et al. 2008). A 
mutation in this residue affects the interaction between H3-H4 tetramer and the H2A-
H2B dimer, leading to destabilisation of the histone octamer and defects in chromatin 
assembly (Li et al. 2008). Emerging data on histone core modifications suggest that these 
are equally important and have diverse functions similar to those readily accessible on 
the histone N-terminal. 
1.5  Histone deacetylases  
 
Histone deacetylase enzymes represent a class of epigenetic erasers with the 
specific function of removing acetylated histone marks. The growing body of evidence 
exposing HDACs as potential therapeutic targets for cancer and various other diseases 
has fuelled interests in these enzymes. Following the first human HDACs identified in 
the late 1990’s (Taunton 1996), current efforts have uncovered 18 different isoforms in 
mammals. These enzymes are identified as part of an ancient superfamily, sharing a 
common lineage with prokaryotes. Classification based on sequence homology with their 
yeast counterparts provided two main groups consisting of four classes (Figure 1.7).  
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1.5.1 Classical HDACs 
1.5.1.1 Class I 
 
The first group of ‘classical’ HDACs (class I, II; IV) requires Zn2+ as a cofactor 
for its catalytic function and can be inhibited by Zn2+ chelating compounds. Class I 
consists of HDACs 1, 2, 3 and 8 homologous to yeast RPD3 (reduced potassium 
deficiency) (Figure 1.7). Structurally they comprise the highly-conserved deacetylase  
domain flanked by relatively short carboxyl- and amino-terminals. While expressed 
ubiquitously in different cell types, they are found primarily in the nucleus where they 
target histone proteins. Because of this class I HDACs of all, display the most distinctive 
role in regulating gene expression. Knockout studies in mice demonstrated the 
importance of class I HDACs in cell survival and proliferation. For instance, HDAC1 
knockout mice display developmental retardation and proliferation defects resulting in 
early embryonic lethality (Lagger 2002), while HDAC2 knockout mice survive 
development but suffer from a range of cardiac defects (Montgomery et al. 2007). 
Deletion of both these enzymes in mouse T-cells resulted in a loss of half the total HDAC 
activity, establishing HDAC1 and HDAC2 as the predominant isoforms (Dovey OM 
2013). The relative expression of HDAC1 and HDAC2 was shown to vary significantly 
with cell type. HDAC1 is found abundantly expressed in rat glial cells whereas HDAC 
was more predominant in neurons (Broide et al. 2007). Conversely HDAC2 level in 
Jurket cells were negligible compared to HDAC (Hassig et al. 1998). HDAC3 was shown 
to be required for the survival of murine embryonic fibroblasts (MEFs) (Bhaskara et al. 
2008). More recently a study of patients with loss-of-function HDAC8 mutations 
revealed phenotypes typical of Cornelia de Lange syndrome (CdLS), a rare genetic 
congenital malformation disorder (Kaiser et al. 2014). HDAC8 is responsible for 
deacetylating SMC3, a subunit of the cohesion complex, which helps to create the 
cohesiveness of chromatin-loaded cohesion (Deardorff et al. 2012). Loading of 
hyperacetylated SMC3 in the absence of HDAC8 activity results in reduced cohesion 
binding and transcriptional changes reminiscent of CdLS cell lines (Deardorff et al. 
2012).  
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1.5.1.2 Class II 
 
Class II HDACs possess larger amino-terminals and additional catalytic domains. 
These can be further subdivided into IIa (HDACs 4, 5, 7; 9) and IIb (HDACs 6; 10) 
sharing homology with yeast HDA1 (histone deacetylase 1) (Figure 1.7). The ability of 
class IIa HDACs to shuttle between the nucleus and cytoplasm is regulated through its 
interactions with the 14-3-3 protein. Phosphorylation of serine by kinases on the N-
terminal domain facilitates binding of 14-3-3, resulting in a conformational change in the 
HDAC and its expulsion from the nucleus (Healy, Khan, and Davie 2011). Additionally, 
class IIa can interact with other factors such as the CtBP (C-terminal binding protein) 
corepressor and transcription factor MEF2 (myocyte enhancer factor-2) to bring about 
targeted repression (Zhang et al. 2001). In contrast to class I HDACs, class II HDACs 
display tissue-specific expression with HDAC4, HDAC5 and HDAC9 being 
predominantly found in the brain, heart and skeletal muscle (Moresi et al. 2010) and 
HDAC7 mostly in thymocytes (Dequiedt 2003). Although HDACs are known for their 
deacetylase functions, biochemical studies have shown that members of the class IIa 
HDACs lack the conserved tyrosine residue at the catalytic core, instead replaced by a 
histidine (Lahm et al. 2007). This change leads to more than 1000-fold decrease in 
deacetylase activity (Lahm et al. 2007). To compensate for this, class IIa HDACs act as 
adapters recruiting class I HDACs and HP1 to bring about its repressive functions (Zhang, 
McKinsey, and Olson 2002). 
On the other hand, HDAC6 and HDAC10 are solely cytoplasmic deacetylases. 
HDAC6 contains two catalytic domains and its targets include α-tubulin, cortactin, 
chaperones and the interferon receptor IFNαR (Tang et al. 2007). HDAC10 was 
demonstrated to interact with HDAC3 and possess a leucine-rich C-terminal region, 
suggesting possible diversity in function (Kobe B 2001). HDAC10 was also recently 
shown to exclusively deacetylate MSH2 (MutS homolog 2) at Lys73, part of the MutSα 
or MutSβ complex involved in the initial DNA mismatch repair (MMR) process 
(Radhakrishnan et al. 2015). Overexpression and knockdown of HDAC10 in HeLa cells 
resulted in increases and decreases in DNA MMR activity, respectively (Radhakrishnan 
et al. 2015).   
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Figure 1.7 Mammalian histone deacetylases. Mammalian HDAC enzymes consist of several 
isoforms characterised to different classes based on their sequence homology. Similarities in 
homology are also found in the yeast counterparts. Key co-factors are necessary for enzyme 
activity with the majority dependent on Zn2+ whereas sirtuins are dependent on NAD+. These 
exhibits either general or specific expression patterns dependent on the cell/tissue type. Sub-
cellular localosation: N – nucleus, C – cytoplasm, M – mitochondria (Shirakawa K 2013). 
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1.5.1.3 Class IV 
 
HDAC11 is the only member of class IV and shares homology with both classes 
I and II. HDAC11 negatively regulates the gene encoding for interleukin-10 (IL-10) in 
human antigen-presenting cells (APC), influencing both immune activation and tolerance 
responses (Villagra et al. 2009). Expression of HDAC11 transcripts were found mainly 
in the heart, brain, kidney, skeletal muscle and testis (Gao et al. 2002). Interactions with 
HDAC6 have also been reported in vivo (Gao et al. 2002).      
 
1.5.2  Sirtuins 
 
The class III HDACs or sirtuins are most similar to yeast Sir2 (silent information 
regulator 2). Zn2+ dependent HDACs are also described as being sensitive to one of the 
early naturally isolated inhibitors, trichostatin A (TSA), where NAD+ dependent sirtuins 
do not display this characteristic. Human sirtuins consists of SIRT1-7, each with its own 
unique cellular localisation and function. SIRT1 interacts with p53 to regulate cell stress 
and survival (Villagra et al. 2009). SIRT2 is cytoplasmic and much like HDAC6, targets 
α-tubulin. SIRT3, SIRT4 and SIRT5 are present in the mitochondria with a role in energy 
metabolism (Lombard DB 2011). SIRT6 and SIRT7 bring about transcriptional silencing 
in regions of heterochromatin (Lombard DB 2011). The activities of these enzymes are 
not limited to deacetylation alone. In fact, only SIRT1-3 have strong deacetylase activity. 
SIRT4 and SIRT6 contain ADP-ribosyltransferase activity (Ahuja N 2007), while SIRT5 
has a mixture of demalonylation, desuccinylation and deacetylation activities (Du J 
2011).  
Perhaps the most intriguing aspect of sirtuins is their association with aging. Early 
studies in yeast showed that up regulation of Sir2 slowed the effects of aging through 
caloric restriction (CR) (Kaeberlein M1 1999), the same was observed by manipulating 
orthologs of Sir2 in worms (Tissenbaum HA1 2001). Since caloric restriction can delay 
the onset of aging-related diseases, such as cancer, hypertension and Alzheimer’s, this 
led to the identification of human sirtuins as new therapeutic targets. However, years of 
research surrounding this topic resulted in much controversy. While some reports have 
refuted these claims (Burnett C 2011), more recent findings support the role of sirtuins in 
CR and aging. Male transgenic mice overexpressing SIRT6 (al 2012), rather than SIRT1 
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(Daniel Herranz 2010) have increased lifespans. Furthermore, increasing SIRT1 
specifically in the brain delays aging in both male and female mice (Satoh A 2013).  
 
1.5.3  HDAC complexes 
 
Members of class I and II HDACs are commonly found as part of multiprotein 
complexes. Components of these complexes include DNA/chromatin binding proteins 
and transcription factors, helping to localise HDACs to chromatin. Aside from the core 
components, non-catalytic subunits with associated functions in DNA methylation, 
histone methylation and chromatin remodelling can be recruited to the complex 
(Silverstein and Ekwall 2005). This allows the cell to assemble the required enzyme 
conformation at each locus rather than having a specialised enzyme for each, making 
these complexes extremely flexible in function and modular (Silverstein and Ekwall 
2005). Apart from early embryogenesis and brain development, HDAC1 and HDAC2 are 
functionally redundant, since only mouse models harboring deletions in both genes 
express a significant phenotype (Montgomery et al. 2007). This may be a consequence of 
both enzymes being present in the same corepressor complex which include: Sin3 (switch 
independent 3), NuRD (nucleosome remodelling HDAC) and CoREST (REST 
corepressor 1) (Figure 1.8) (Kaiser et al. 2014).  
The Sin3 complex is highly conserved from yeast to mammals and contains the 
core subunits: Sin3A/B, HDAC1/2, SAP18, SAP30, RbAp46 and RbAp48 (Figure 1.8). 
The C-terminal of Sin3 forms the histone deacetylase interaction domain (HID) 
responsible for recruiting HDAC1/2 (Kaiser et al. 2014) and this interaction is stabilised 
by the Sin3 associated proteins (SAP) (Zhang et al. 1997). Retinoblastoma proteins 
(RbAp) are predicted to stabilise the Sin3/nucleosome interactions given their ability to 
bind histone H4. Like Sin3, the NuRD complex also consists of the same retinoblastoma 
proteins and additional structural/regulatory proteins such as MTA2 and p66 (Figure 1.8). 
NuRD is the only complex to comprise of both deacetylase and remodelling activities, 
provided by the SWI2/SNF2-related ATPase remodelled Mi-2 (Wang and Zhang 2001). 
Purification of NuRD found the methyl-CpG binding domain proteins MBD2 and MBD3 
to occur separately, suggesting they formed distinct complexes with NuRD (Le 
Guezennec et al. 2006). Since only MBD2 is able to recognise methylated DNA, 
MBD2/NuRD complexes are mostly found at methylated inactive promoters whereas 
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MBD3/NuRD complexes are found at unmethylated active promoters (Gunther et al. 
2013). The function of these corepressors depend very much on the chromatin context 
since their recruitment is determined by histone-binding motifs and/or transcription 
factors. This may also account for the lack of specificity seen in some HDAC1-HDAC2 
complexes since each complex may contain a number of these chromatin localising 
proteins. Sin3 and NuRD are broad acting corepressor complexes while CoREST is 
exclusive to neurons (Lakowski, Roelens, and Jacob 2006). The CoREST complex, also 
known as neuron-restrictive silencing factor (NRSF), is recruited to RE1 DNA motifs by 
the repressor element-1 silencing transcription factor (REST) to regulate aspects of 
neuronal development (Lakowski, Roelens, and Jacob 2006). Suppression of genes at 
RE1 sites is achieved through methylation of H3K9 by the LSD1 recruited G9a 
methyltransferase. Conversely, in embryonic and neural stem cells LSD1 recruits H3K4 
methyltransferase to functionally coactivate genes (Adamo A1 2011). In any case, the 
homo/hetero-dimerisation of HDAC1 and HDAC2 is a key requirement for deacetylase 
activity. HDAC3 on the other hand, exists within the nuclear hormone corepressor 
NCoR/SMRT complex along with members of class II HDACs (Figure 1.8) (EA, 2014). 
Transcriptional repression by NCoR/SMRT is achieved via cooperative interaction of 
HDAC3 with a combination of class II HDACs and class I HDAC containing complexes 
(EA, 2014). Mutational studies have shown NCoR (nuclear receptor corepressor) and 
SMRT (Silencing mediator for retinoid and thyroid receptor) to be crucial for neural and 
heart development, respectively. TBL1 (transducin β-like 1) is a core interacting protein 
that mediates corepressor/coactivator switching through ubiquitin activities (Perissi V 
2004). Purification of the NCoR subunit also identified several lysine demethylases, 
namely KDM4A and KDM5C, which support transcriptional repression through histone 
modifications (Zhang D 2005). Unlike classical HDACs, evidence showing sirtuin-based 
complexes are lacking although few proteins interactions have been described. The 
binding of SIRT7 to RNA polymerase 1 is required for transcription of rDNA (Zhang D 
2005). AROS (active regulator of SIRT1) stimulates whereas DBC1 (deleted in breast 
cancer 1) represses SIRT1 deacetylation of p53 (Kim 2008). The interaction of SIRT1 
and p53 has important implications for regulating cell survival, metabolism, cell cycle 
and genome stability. Apart from the better-known chromatin corepressors, several novel 
complexes have been described. MiDAC (mitotoic deacetylase complex) is a distinct cell 
cycle-associated complex, containing HDAC1 and HDAC2 (Bantscheff M 2011). NODE 
(Nanog and Oct4 associated deacetylase) is a unique HDAC1/2 complex described in 
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mouse embryonic stem cells (ESC) with a role in differentiation. Recent efforts have also 
identified SHIP1 (spermatogenic cell HDAC1 interacting protein 1) as a HDAC1 specific 
complex acting to remodel chromatin during spermatogenesis (Choi et al. 2008).   
 
1.5.4  Non-histone targeted effects of HDACs 
 
Since these enzymes were first studied in the context of histones they came to be 
known as histone deacetylases. However, phylogenetic studies in bacteria revealed 
HDAC enzymes to pre-date the evolution of histones (Gregoretti IV1 2004). Proteomic 
studies also identified large numbers of acetyl-lysine containing substrates, some of 
which are the targets of HDACs (Kim SC1 2006). Together these lines of evidence point 
towards non-histone proteins as the primary target of HDACs and for this reason histone 
deacetylase and lysine deacetylase (KDAC) are often used interchangeably in literature. 
cell motility. While some argued for a renaming of the enzyme to better reflect their 
targets, such notions were deterred to avoid confusion (Allis CD 2007). Nevertheless, 
acetylation remains one of the most common modifications in eukaryotes and is regulated 
by HDAC enzymes. The extracellular targets of HDACs include a diverse set of proteins 
with functions in apoptosis, angiogenesis, cell cycle control, metabolism, and 
inflammation. 
 
1.5.5  Histone deacetylases in cancer and other diseases 
 
Considering their profound role in regulating numerous biological processes such 
as cell development and growth, it is not surprising then that abnormal expression and/or 
mutations of HDAC enzymes have been identified as a major feature of many human 
disease, particularly cancer. Studies have reported the broad overexpression of HDAC1, 
HDAC2 and HDAC3 in a variety of cancers including: colorectal, renal, prostate, gastric, 
breast and Hodgkin’s lymphoma (Adams H 2010; Choi JH 2001) . On the other hand, 
HDAC8 deregulation has only been described in T-cell lymphoma and childhood 
neuroblastoma (Oehme I1 2009). Since class II HDACs have both proliferative and 
tumour suppressor functions their roles in cancer development are varied. For instance, 
overexpression of HDAC4 in gliablastoma cells supresses the cyclin-dependent kinase  
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Figure 1.8. HDAC enzymes function within multiprotein co-repressor complexes. HDAC1 
is a key component of NuRD, SHIP1, Sin3, CoREST/REST co-repressor complexes whereas 
HDAC2 is found in NuRD, Sin3 and CoREST/REST. HDAC3 has so far been discovered in the 
N-CoR/SMRT co-repressor complex which also contains class II HDACs. Mi2 – chromatin 
remodeller, MTA2 - Metastasis-associated gene family member 2, MBD2/3 - methyl CpG 
binding domain 2/3, RbAp46/48 – Retinoblastoma protein associated protein 46/48, KCTD19 - 
Potassium channel tetramerisation domain containing 19, SHIP1 – spermatogenic cell HDAC-
interacting protein 1, HSPA2 – Heat shock 70kDa protein 2, SAP18/30 – Sin3 associated proteins 
18/30, LSD1 – lysine-specific demethylase, ZNF217 – Kruppel-like zinc-finger 217, KDM4A – 
lysine-specific demethylase, SMRT – Silencing Mediator for Retinoid and Thyroid receptor, N-
COR – Nuclear receptor CoRepressor, TBL1 – transducin β-like 1 (EA, 2014). 
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inhibitor p21(WAF1/Cip1) to enhance proliferation (Mottet D. 2008), whereas 
downregulation of HDAC4 is correlated with increased levels of VEGF and angiogenesis 
in chondrosarcoma cells (Xiaojuan Sun 2009). Similarly, HDAC7 is overexpressed in 
patients with pancreatic cancer but under expressed in mouse models of pro-B acute 
lymphoblastic leukemias and Burkitt lymphomas (Barneda-Zahonero B 2015). Androgen 
receptor (AR) signalling leads to the activation of genes responsible for driving the 
development of prostate cancer and is regarded as the predominant pathway (Gao L 
2010). Common interventions involve androgen receptor-ligand disruption or deprivation 
but such methods eventually succumb to castrate-resistance (Gao L 2010). Though 
studies connecting deacetylation of HSP90 by HDAC6 and AR stability may provide 
alternative routes to treatment (Gao L 2010).  
 Comparably sirtuins appear also to exhibit a dual role in cancer. Overexpression 
of SIRT1 is reported in the vast majority of cancers such as acute myeloid leukemia 
(AML), hepatocellular and colorectal cancers, but is downregulated in some, such as 
gastric cancer (Yang Q 2013). SIRT1 is known to confer drug resistance in cancer cells 
by increasing the expression of multidrug resistance protein 1 (MDR1), enhancing the 
rate of detoxification, while also promoting anti-apoptotic factors, DNA repair and 
acquisition of mutations (Wang Z 2013). SIRT2 is important for cell cycle G2/M phase 
transition and mutations in its active site resulting in a loss of activity is observed in 
melanomas (Lennerz V 2005). In fibrosarcoma HT1080 cells, SIRT3 and SIRT4 help 
prevent the onset of apoptosis and promote cell survival by maintaining mitochondrial 
levels of NAD+ (Yang H1 2007). More recently, SIRT5 overexpression in non-small cell 
lung cancer (NSCLC) was identified as a contributing factor in acquiring drug resistance 
while SIRT6, previously considered a tumour suppressor, upregulates the 
proinflammatory factor COX-2 (cyclooxygenase-2) in skin cells leading to cell 
proliferation (Ming M1 2014).  
 Aberrant changes in HDACs undoubtedly reshape the global acetylation 
landscape with direct consequences on gene expression. The reported loss of H4K16ac 
and enhanced H4K20me3 is a common characteristic of many tumour phenotypes (Fraga 
MF 2005). Dysregulation of HDACs makes them suitable prognostic markers of cancer 
progression. Simultaneous overexpression of HDAC5 and HDAC9 in high-risk 
medulloblastoma is associated with low survival and may serve as a useful indicator for 
risk stratification. While tissue microarray studies showed that overexpression of HDACs 
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1-3 correlated with lower survival rates and lymph-node metastasis in patients with 
gastric cancer (Kanai 2008).  
 Aside from cancer, HDACs also present a potential therapeutic target for long-
term non-life threatening illnesses. Fibrosis is the thickening and scaring of tissue in 
response to injury and pathological feature of many chronic inflammatory diseases. 
Particularly, increased HDAC1 and HDAC2 levels observed in fibrosis-related kidney 
diseases correspond to the production of pro-fibrotic factors, such as CSF-1 (colony 
stimulating factor 1) (Hashioka 2012). HDAC1/2 knockdown or inhibition significantly 
reduce CSF-1 levels, providing a means of tackling the inflammatory response during 
tubule-interstitial injury (Hashioka 2012). Numerous studies in rodent models 
demonstrate transient histone acetylation as a key event in learning and memory 
formation, supported by the observation that disruptions to HATs in the mice 
hippocampus leads to memory impairment, while HDAC inhibition in wild-type mice has 
the opposite effect of helping to promote synaptic plasticity and learning (Vecsey CG 
2007). Such findings form the basis for supporting the development of HDAC targeted 
therapies for Alzheimer’s disease (Hashioka 2012).  
 The large family of HDAC erasers cover a diverse range of both histone and non-
histone targets in the cell and regulate genes and extracellular proteins involved in many 
key cellular processes. As such, disorders resulting from abnormal changes in these 
processes often involve or can be remedied by targeting the associated HDAC enzyme, 
making them prime targets for pharmaceutical intervention.    
1.6  Chemical inhibitors of HDAC enzymes 
 
Early studies of the HDAC1 homologue HDLP (histone deacetylase-like protein) 
in hyperthermophilic bacterium A. aeolicus with inhibitors such as trichostatin A (TSA) 
and suberoylanilide hydroxamic acid (SAHA) (Finnin MS 1999) and the crystal structure 
of the HDAC8/hydroxamate complex helped to identify the structural interactions 
between classical HDACs and their inhibitors (Vannini A 2004). The active domains of 
class I, II and IV HDACs consists of a zinc-binding site, tubular pocket and Asp-His 
dyads. A collection of both naturally occurring and synthetic inhibitors specific for zinc-
dependent HDACs exert their inhibitory effects by disrupting enzyme-metal ion 
interactions. Consequently, this feature sets apart the class III NAD+-dependent sirtuins, 
 34 
which do not respond to the Zn2+ class of HDAC inhibitors. The pharmacophore of 
HDAC inhibitors consists of a variable Zinc-binding domain (ZBD) connected via a 
‘linker’ region to either a hydrophobic or aromatic ‘surface recognition/cap domain’ 
(Vannini A 2004). Typical classification of inhibitors is based on the structure of the 
metal-binding group, belonging to one of the major hydroxamic acid, cyclic peptide, 
aliphatic acid or benzamide groups (Figure 1.9).  
 
1.6.1  Hydroxamic acids  
 
The trichostatin family of compounds are natural hydroxymates originally 
isolated as antifungals from species of Streptomyces. Trichostatin A exhibits inhibitory 
activities at low nanomolar concentrations in vitro and remains one of the most potent 
pan-HDAC inhibitors available (Figure 1.9). Suberanilohydroxamic acid (SAHA) or 
vorinostat is structurally similar to TSA and was the first HDAC inhibitor to be approved 
by the U.S. Food and Drug Administration (FDA) for the treatment of cutaneous T-cell 
lymphoma (CTCL) (Mann BS1 2007) (Figure 1.9). Vorinostat was marketed under the 
trade name Zolina® by Merck & Co. Inc. in 2006 and is recommended as a follow-up 
treatment for patients with progressive or persistent forms of CTCL (Mann BS1 2007). 
More recently, the hydroxamic derivative Belinostat (BELEODAQ®, Spectrum 
Pharmaceuticals Inc.) was approved for the treatment of patients with peripheral T-cell 
lymphoma (PTCL), a rare and aggressive form of non-Hodgkin’s lymphoma (NHL). 
 
1.6.2  Cyclic peptides  
 
Depsipeptide (romidepsin, ISODAX® Celgene) is the most notable member of the 
structurally complex class of cyclic peptide inhibitors, also approved for the treatment of 
CTCL (Figure 1.9). Depsipeptide is administered as a pro-drug and activated 
intracellulary by the process of reduction, targeting HDAC1 and HDAC2 more 
favourably than class II enzymes (Furumai R 2002). The complexity of the surface 
recognition domains in this group of molecules allow for varying iterations of inhibitors 
which recognise different amino acids on the surface of HDAC isoforms, thus presenting 
a potential for subclass specificity.  
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Figure 1.9. Structural features of the main HDAC inhibitor classes. Four major classes of 
HDAC inhibitors with varying potencies, consisting of: 1) hydroxamates, 2) cyclic peptides, 3) 
benzamides and 4) aliphatic acids. SAHA - Suberoylanilide hydroxamic acid, TSA – trichostatin 
A. Image from (Bae 2011). 
 
 
 
 
 
 
 36 
1.6.3  Benzamides  
  
Benzamide containing inhibitors show both in vitro and in vivo anti-cancer 
activities. Entinostat (MS-275/SNDX-275, Syndax Pharmaceutical Inc.) is a synthetic 
bezamide derivative specific for class I HDACs (Figure 1.9). Having undergone trials for 
a range of different cancers it recently achieved the FDA’s ‘Breakthrough Therapy’ status 
for the treatment of advanced breast cancer in combination with the hormonal therapy 
drug exemestane (Aromasin® Pfizer) (Yardley DA 2013). Mocetinostat (MGCD0103, 
Mirati Therapeutics) is another compound of this class, targeting class I and IV HDACs 
(Figure 1.9), demonstrating safe use and anti-leukemic activities in patients with 
myelodysplastic syndrome (MDS) (Garcia-Manero G 2008).  
 
1.6.4  Aliphatic acids 
 
The aliphatic acid group of inhibitors generally targets HDACs with millimolar 
affinities with the likes of valproic acid (VPA) and sodium phenylbutyrate (Figure 1.9). 
Generally considered a weak inhibitor of HDACs, valproic acid alone shows little 
efficacy against cancers but is widely used in the maintenance and treatment of bipolar 
disorders (Cipriani A 2013).  
 
1.6.5  HDAC inhibitors in the clinic 
 
HDAC inhibitors have received the most attention in areas of oncology. Recent 
reports estimate that at least 20 different HDAC inhibitors were involved in clinical trials 
for varying types of cancers in the past couple of years. Arguably, these inhibitors 
received the most clinical success in the treatment of leukaemias and lymphomas while 
their effectiveness in solid malignancies is rather limited (Slingerland M1 2014). The 
mechanisms behind these observations remain largely unknown but considering many of 
the first generation pan-HDAC inhibitors were developed based on their ability to induce 
tumour differentiation rather than utilising a mechanism-based approach, the resulting 
low enzyme specificity is thought to underpin the lack of efficacy in solid tumours (Bae 
2011). The identification of deregulated HDAC isoforms in cancer subtypes promoted 
the development of inhibitors aimed at achieving greater efficacy through improved target 
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specificity. Much of the ensuing second-generation HDAC inhibitors have chemical 
structures based off agents with demonstrated clinical efficiency such as vorinostat 
(hydroxymates) and entionostat (benzamides). Of these CHR-3996 is a class I selective 
inhibitor undergoing trials for solid refractory tumours having successfully completed 
phase I trials showing encouraging pharmacokinetic, pharmacodynamics and toxicity 
profiles (Banerji U 2012). Similarly, the phase I trial of chidamide demonstrated 
preliminary anti-tumour activity in patients with advanced solid tumours or lymphomas, 
warranting further investigation (Dong M 2012).  
While continued efforts are underway to improve the efficacy of HDAC inhibitors 
in solid tumours, this current shortfall strictly limits the use of these inhibitors as 
monotherapies in cancer. Instead HDAC inhibitors have shown great potential in 
improving response rates when synergised with a variety of existing and new anti-cancer 
agents including platinum-based drugs, DNA cross-linking agents and radiotherapy. The 
combination of vorinostat with direct DNA interacting agents such as cytarabine and 
idarubicin resulted in a high overall recovery rate of 85% in patients with acute 
myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) (Garcia-Manero G 
2012). Given the ability of HDAC inhibitors to supress oestrogen and androgen receptor 
expression, combined treatments using vorinostat and tamoxifen demonstrated a partial 
or complete recovery in 19% of patients with hormone-therapy resistant breast cancer 
(Munster PN 2011).  
Yet, long before the molecular targets of these drugs were identified, leading to a 
turn of attention to oncology, early HDAC inhibitors were used for the treatment of 
psychiatric and neurodegenerative disorders. Valproic acid (VPA) was licensed as an 
anticonvulsant for the treatment of seizures in the late 1970’s and is still used today, 
widely for treating migraines, depression and schizophrenia (TR 2003). Knowledge of 
the effects of HDAC inhibition on gene expression has allowed for a rational approach 
towards disease targeting. The demonstrated ability of HDAC inhibitors to re-activate the 
SMN1 (survival motor neuron 1) gene proved a promising therapeutic against 
neuromuscular degeneration; as such VPA has shown promising results in trials for spinal 
muscular atrophy (SMA) (Helmrich, Ballarino, and Tora 2011).  
There is mounting evidence to suggest that HDAC inhibitors can provide 
beneficial anti-inflammatory effects, irrespective of apoptosis or cytotoxicity. Sodium 
butyrate was recognised as a potent suppressor of cytokine activity in the treatment of 
acute gout (Cleophas MC 2016). Inflammation is also attributed to the pathogenesis of 
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hypertensive nephropathy, a condition resulting in kidney damage from sustained high-
blood pressure. HDAC6 was identified as a potential therapeutic target in hypertensive 
mice models using the specific inhibitor tubastatin A, which effectively prevented fibrosis 
and inflammation (Choi SY 2015). Lipopolysaccharides (LPS) from many species of 
bacteria are powerful triggers of acute inflammatory reactions as a result of infection or 
injury. Recent studies demonstrated the ability to alleviate LPS-induced inflammatory 
responses by specifically targeting class II HDACs. Li et al. showed that the HDAC8 
specific inhibitor ITF3056, a derivative of the orally active hydroxamate givinostat 
(ITF2357), significantly reduced LPS-induced cytokines in human peripheral blood 
mononuclear cells (PBMCs) as well as in mice (Li S 2015). While givinostat has similar 
anti-inflammatory properties it is highly cytotoxic (Li S 2015). ITF3056 on the other 
hand, displays no cellular toxicities at concentrations showing reduced inflammation (Li 
S 2015), suggesting that target specific interactions with HDACs may present safer 
therapies.  
 
1.6.6  HDAC inhibitor-related side effects 
 
The most commonly reported clinical toxicities of HDAC inhibitors include 
nausea, vomiting and fatigue (Subramanian S 2010). Antiemetics are used to combat 
nausea and vomiting, while fatigue typically subsides following withdrawal of the drug 
(Subramanian S 2010). Acute decreases in white blood cell and thrombocyte counts have 
also been reported in addition to cardiac arrhythmias observed from ECGs 
(electrocardiograms) (Subramanian S 2010). Some of the metabolic side effects range 
from severe liver toxicities, electrolyte imbalances to minor renal problems (Subramanian 
S 2010). In extreme cases, patient deaths have been reported from experimental trials of 
HDAC inhibitors (Subramanian S 2010). A phase II trial of mocetinostat in patients with 
relapsed or refractory classical Hodgkin's lymphoma resulted in the deaths of four 
patients, two of which were related to the effects of the drug (Younes A 2011). These 
side-effects reflect on the toxicity of HDAC inhibitors at the cellular level, with emphasis 
on developing safer and more effective therapies based on a greater mechanistic 
understanding. 
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1.7 Genetic approaches to study HDAC function 
 
Aside from clinical interests, HDAC inhibitors have also been extensively used to 
study HDAC function. The genetics of single celled eukaryotes such as yeast can be easily 
manipulated compared to that of higher eukaryotes and therefore provides a useful tool 
for research. The role of HDAC enzymes on histone acetylation has been well studies in 
yeast using HDAC mutants. Deletions in RPD3 and/or HDA1 (homologue of human class 
I and II HDACs, respectively) have been shown to increase global levels of histone H3 
and H4 acetylation in budding yeast (Rundlett SE 1996). This effect was also reproduced 
in fission yeast treated with the HDAC inhibitor TSA (Ekwall et al. 1997).  
Gene specific analysis using chromatin immunoprecipitation showed a high 
degree of redundancy amongst yeast HDACs in regulating heterochromatin formation at 
distinct subset of genes. Such arrangements are thought to organise genes so that a 
collective response can be produced in response to an external stimulus. An example of 
this can be found in Hda1 targeted HAST (Hda1-affected subtelomeric) domain 
containing genes, which are activated to regulate growth during stress (Robyr et al. 2002). 
Deletion in RPD3 but not HDA1 increases histone H4K5/K12 acetylation and expression 
of IME2, SPO13 and INO1 genes (Rundlett SE 1998). By contrast, Tup1 is a general 
repressor in yeast and interacts with Hda1 to silence specific genes (Wu J 2001). HDA1 
deletion results in H3/H2B-specific hyperacetylation and expression of TUP1 controlled 
genes, including GAL1 (Wu J 2001).  
Genome-wide analysis of fragile sites in yeast using γH2A, an epigenetic marker 
of DNA damage, suggest that a large proportion of the γH2A signal observed corresponds 
to sites which present barriers to replication forks (Szilard RK 2010). It is known that 
obstacles to DNA replication can lead to fork collapse and DNA damage. Interestingly, 
the HDAC mutants rpd3Δ and hst1Δ show abolished γH2A at regulated genes compared 
to the wild type, suggesting that condensed chromatin imposed by HDAC enzymes may 
present obstacles to replication (Szilard RK 2010). Similar approaches were later used to 
examine fragile sites in human cells (Jungmin S 2012). Much of the knowledge 
surrounding human biology is derived from earlier pioneering work in model organisms 
such as yeast. 
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1.8  Evidence for HDAC inhibitor induced DNA damage 
 
HDAC inhibitors are highly cytotoxic agents, exerting their effects on a variety 
of cellular targets leading to cell cycle arrest, apoptosis and differentiation. The observed 
cytotoxicity was suggested to be in part due to the effects of genotoxicity. The results of 
several independent studies supported this idea by demonstrating that various HDAC 
inhibitors tested positive in standard genotoxicity assays. Apicidin and its derivatives 
(SD-0203 AND SD-2007) induced chromosome aberrations and micronuclei in Chinese 
hamster ovary (CHO) cells but were not mutagenic in the Ames test (Yoo EJ 2005). A 
comparison of the effects of sodium butyrate between CHO and mouse (L929) cells 
showed differences in sensitivity but aneuploidy was observed in both. Additionally 
sodium butyrate treated cells displayed less intense staining for heterchromatin relative 
to untreated cells, suggesting potential changes in chromatin structure (Gomez V.P. and 
Vig B.K. 2002). Trichostatin A (TSA) tested negative in the Ames and positive in the 
chromosome aberration, micronuclei, γH2AX and alkaline comet assay in TK6 cells 
(Olaharski AJ 2006). The genotoxicity of the aforementioned HDAC inhibitors were 
further substantiated using the non-regulatory GreenScreen® HC reporter assay, showing 
significant increases in fluorescence of the DNA-damage inducible GFP (green 
fluorescent protein)-tagged GADD45a gene (Johnson and Walmsley 2013). Vorinostat 
showed weak mutagenic effects in Ames, in addition to testing positive for chromosome 
aberrations in CHO cells and MN in in vivo mouse models (Johnson and Walmsley 2013). 
Drug safety data published by the FDA on the hydroxamates Vorinostat, Belinostat and 
Panobinostat also indicate mutagenicity (LH 2006). Shen and Kozikowski recently 
reviewed evidence surrounding the mutagenicity of FDA-approved HDAC inhibitors, 
proposing that hydroxamates can be converted into unstable isocyanates in vivo and react 
with nucleophilic groups of DNA (Shen S 2016). This effect however has not been 
reported for TSA or other non-hydroxamate based HDAC inhibitors and therefore the 
mutagenicity may be limited to a specific structural class. The existing body of evidence 
present in the literature to date strongly substantiates HDAC inhibitors as genotoxic 
agents, although the mechanisms behind this are unknown.  
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1.8.1 Potential mechanisms of HDACi-induced DNA damage 
 
Of the limited evidence surrounding how HDAC inhibitor may generate genetic 
damage, oxidative DNA damage has been reported in response to Vorinostat in acute 
myeloid cells (AML) cells, implicated as an important mechanism of cancer cell lethality 
(Petruccelli 2011). Another HDAC inhibitor LAQ-824, also stimulated the production of 
reactive oxygen species (ROS) in various human leukaemia cell lines (Rosato RR 2008). 
In both reports, the addition of the ROS scavenger N-acetyl cysteine (NAC) led to a 
reduction in γH2AX levels stimulated by HDAC inhibition but not down to baseline 
levels equivalent to untreated cells (Petruccelli 2011; Rosato RR 2008). This suggests 
that ROS only accounts for a proportion of the DNA damage induced by HDAC 
inhibitors. Mechanistically, HDAC inhibitors downregulate thioredoxin (Bose, Dai, and 
Grant 2014), a ROS scavenger and depolarise mitochondrial membranes (Rosato RR 
2008), which can lead to increased ROS.  
Structural changes in chromatin following HDAC inhibitor treatment were 
implicated in the formation of DNA damage, since early γH2AX induction was observed 
in parallel with histone hyperacetylation (Gaymes et al. 2006). Conti and colleagues used 
single DNA molecule analysis to demonstrate that pharmacological concentration of 
Vorinostat reduced replication velocity and promoted the activation of dormant origins 
in human cancer cells (Conti et al. 2010). Additionally, pre-treatment with the 
transcription inhibitor flavopiridol or the replication inhibitor aphidicolin reduced the 
γH2AX signal elicited by Vorinostat, indicating that the DNA damage observed is 
transcription and replication-dependent (Conti et al. 2010).  
1.9 Transcription and replication conflicts as a source of genome instability 
1.9.1 Eukaryotic transcription 
 
Syntheses of all protein-coding and non-coding RNAs are carried out by distinct 
polymerases in eukaryotes. RNA polymerase I specifically transcribes ribosomal RNAs 
(rRNA), the largest being 28S, 18S and 5.8S. RNA polymerase II on the other hand 
transcribes protein-coding mRNAs and non-coding ncRNAs, which make up most of the 
transcriptome. Lastly RNA polymerase III is responsible for transcribing transfer RNA 
(tRNA) and smaller species of rRNA. All RNA polymerases are confined within the 
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nucleus and localise to different promoters as multi-complex proteins, consisting up to a 
dozen unique subunits.   
RNA polymerase II (RNA pol II) has received the most attention due to its 
dominant role in gene expression; in addition its largest subunit contains an extended C-
terminal domain (CTD) consisting of YSPTSPS tandem repeats (Geyer 2013). Serine 
(Ser2, Ser5, Ser7), tyrosine (Tyr1) and threonine (Thr4) residues located within the repeat 
sequence are liable to phosphorylation, making it a post-transcriptional modification-rich 
region (Geyer 2013). The CTD does not contribute towards the activity of the polymerase 
but instead has a role in regulating RNA processing, chromatin structure and docking of 
various binding proteins (Geyer 2013). Eukaryotic transcription is a highly complex 
process, orchestrated through a series of stages entailing: pre-initiation, initiation, 
promoter pausing, elongation and termination (Figure 1.10).  
Interaction with transcription factors represents an essential step in initiating 
transcription. General transcription factors universally bind to TATA-promoter 
sequences and help in assembling the RNA pol II pre-initiation complex (PIC), with the 
core components consisting of the TATA-binding protein (TBP) and various transcription 
factor II proteins (TFIIB, TFIIE, TFIIF, TFIIH) (Lodish H 2000). Specific transcription 
factors on the other hand, can bind to regulatory sites to either promote or inhibit 
transcription. Upon initiation, the ATP-dependent helicase activity of TFIIH unwinds the 
double stranded DNA (dsDNA) (Guzmán E 1999), and with the aid of TFIIB stabilises 
the separate DNA strands within the ‘transcription bubble’. In addition, the CDK7 
(cyclin-dependent kinase) activity of TFIIH phosphorylates Ser5 and Ser7 on the CTD, 
with phopsho-Ser5 being a pre-requisite for recruiting 5’-capping factors (McCracken S 
1997). Not all initiating events surmount to active transcription. Short unstable transcripts 
are generated in cycles of ‘abortive initiation’ where RNA Pol II terminates prematurely 
before leaving the promoter and re-engages until its escape. During this process, as the 
failed transcript is evicted, the RNA Pol II complex reseals and pushes the DNA segment 
back downstream, whereas in progressive transcription the DNA is pushed upstream. 
Therefore abortive initiation involves a ‘scrunching’ mechanism where RNA Pol II 
remains stationary (Kapanidis AN 2006). Lengthening of the RNA-bound DNA hybrid 
makes contact with protein loops near the RNA-exit region, the stabilising effect is 
thought to induce structural changes in the transcription complex to facilitate ‘promoter 
escape’ (Saunders A 2006). The complex in this state is also referred to as the early 
elongation complex (EEC) and exhibits unique pausing at the proximal-promoter. RNA 
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Pol II pausing is believed to prime genes for a rapid and synchronised response to stimuli 
(Dao P 2016). A key mechanism coordinating this event involves inhibition of RNA Pol 
II progression by NELF (negative elongation factor) and DSIF (DRB sensitivity inducing 
factor) (Saunders A 2006). To alleviate the blockade, phosphorylation of both NELF and 
DSIF by the cyclin-dependent kinase (CDK9) component of P-TEFb (positive 
transcription elongation factor) is required (Saunders A 2006).  
The advancement of RNA Pol II into the elongation phase is signified by the loss 
of phospho-Ser5 and gain of phosphor-Ser2 (Komarnitsky P 2000). This signal is 
maintained until the end of transcription and functions to recruit splicing, elongation as 
well as termination factors (Komarnitsky P 2000). Brief RNA:DNA hybrid interactions 
help to tether the transcribing RNA Pol II complex to the DNA template, sustaining 
processivity and preventing early termination (Kireeva ML 2000). Fidelity is maintained 
during active transcription by ensuring that the correct ribonucleotide triphosphase 
(rNTP) substrate is incorporated into the extending mRNA chain (Sydow JF 2009). 
Removal of a mis-incorporated substrate is aided by TFIIS stimulated intrinsic nuclease 
activity, and occurs only secondary to error detection mechanisms (Sydow JF 2009). 
The final step in the transcription process is the termination of RNA Pol II and proceeds 
through a poly(A)- or Nrd1–Nab3–Sen1-dependent pathway based on available 
termination factors and 3’-end signals (Kuehner JN 2011). A poly(A)-dependent 
mechanism is common for all protein-coding genes, during which ser2-phosphorylated 
CTD attracts the termination complexes CPSF (cleavage and adenylation specificity 
factor) and CstF (cleavage stimulator factor) to facilitate mRNA cleavage (Kuehner JN 
2011). Alternatively, for non-protein coding RNA with different 3’-end processing, the 
helicase activity of Sen1 coupled with binding proteins Nrd1 and Nab3 is thought to 
terminate transcription by unwinding the RNA-DNA hybrid (Kuehner JN 2011).  
 
1.9.2 Eukaryotic replication 
 
Accurate duplication of the genetic material is critical to maintaining genome 
stability and the faithful transmission of information onto successive generations (Figure 
1.11). To achieve this level of fidelity, eukaryotic replication is governed by cell cycle 
checkpoints, defined by the coordinated actions of phase-specific cyclins and their 
kinases along with other factors. Given the size of genome, time to complete replication 
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can differ from ~1.4 hours in simple eukaryotes (yeast) to ~24 hours in higher eukaryotes 
(mammals). To ensure a timely completion, DNA synthesis initiates from multiple 
positions on each chromosome at defined ‘origin’ sites. Since only a single duplication 
of the genome is required per round of cell division, each origin site is given the license 
to fire once. During G1-phase, the factors CDC6 (cell division cycle 6), CDT1 (chromatin 
licencing and DNA replication factor 1) and MCM2-7 (mini chromosome maintenance) 
are recruited to origins and form the pre-replication complex (pre-RC). Replication is 
initiated upon entry into S-phase (Figure 1.11). As the pre-RC is phosphorylation by 
CDK2 (cyclin-dependent kinase 2) and DDK (Dbf4/Drf1-dependent CDC7 kinase), 
licensing factors are inactivated effectively limiting the origin to a single firing event. In 
addition, CDC45 (cell division cycle 45), GINS (go-ichi-ni-san) are loaded onto the 
complex (Pacek M 2006) to trigger activation of the candidate MCM2-7 ring helicase, 
which unwinds the double stranded DNA (Takahashi TS 2005). Replication protein A 
(RPA) assists in the process by attaching to single stranded DNA (ssDNA) and preventing 
re-annealing and formation of secondary DNA structures that can potentially block 
replication. DNA polymerase alpha (DNA Pol α) follows suit, using its primase activity 
to generate a short RNA primer, which is further extended by the polymerase. RFC 
(replication factor C) then recruits the sliding PCNA (Proliferating cell nuclear antigen) 
clamp and mediates the switch to DNA polymerase delta/epsilon dimer (DNA Pol δ/ε). 
Due to the 5’ to 3’ processivity of DNA polymerases, DNA is synthesised continuously 
on the leading strand by DNA Pol ε and semi-discontinuously on the lagging strand by 
DNA Pol δ. As new portions of the dsDNA are unwound lagging strand synthesis is 
continually primed by DNA Pol α and as a result leaves behind periodic short RNA inserts 
between DNA (Okazaki fragments). The removal of these obsolete RNA primers is 
thought to occur through redundant mechanisms involving RNase H2 digestion, DNA 
Pol δ-mediated displacement and  other potential enzymes (Balakrishnan L 2013). The 
remaining 5’ overhangs are excised by FEN1 (flap endonuclease-1) and sealed by DNA 
ligase I. Replisomes proceed bi-directionally away from the origin and terminate when 
two opposing replication forks converge (Fachinetti D 2010). Besides this, the removal 
of topological constraints mediated by topoisomerase II and replication fork barriers 
(RFB) formed by non-nucleosomal proteins also aid termination (Fachinetti D 2010).  
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Figure 1.10. Progression of RNA Polymerase II in eukaryotic transcription. From left to right: A) transcription is initiated following the recruitment 
of general transcription factors and RNA polymerase II to promoter regions. TFIIH phosphorylates RNA Pol II at Ser5 on the C-terminal tail. B & C) 
prior to elongation within a region of 20 – 40nt, RNA Pol II can undergo abortive initiation or escape, mediated by DSIF and NELF. D) kinase activity 
of p-TEFb phosphorylates NELF to facilitate its removal, DSIF and Ser2 on the tail of RNA Pol II to start elongation. E) progressive reduction in Ser5 
relative to Ser2 as elongation proceeds until termination. GFT (light green) – general transcription factors. TBP (green) – TATA-binding protein. TFIIS 
(peach) = transcription factor II A. TFIIH (dark green) – transcription factor II H. Pol II (blue) – RNA polymerase II. DSIF (yellow) – DRB Sensitivity 
Inducing Factor. NELF (light yellow) – negative elongation factor. P-TEFb (red) – positive transcription elongation factor b. Direction of RNA Pol II 
progression shown as black arrows (Koch F 2008).
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1.9.3 Regulating transcription and replication  
 
Since both transcription and replication machineries make use of the same 
template, conflicts between the two are inevitable. The genome is most susceptible to 
DNA damage during the S-phase because replication requires extensive de-condensation 
of the chromatin structure and exposes DNA to the harmful effects of endogenous and 
exogenous factors. In addition to this, topological constrains and DNA-associated 
proteins, such as those involved in transcription present natural barriers to replication, if 
unresolved these can lead to fork arrest prompting recombination and spontaneous 
chromosome rearrangements. Consequently, to protect against such conflicts eukaryotic 
cells have developed means of coordinating transcription and replication to maintain 
genome integrity. RFBs are found at gene dense rDNA sites in eukaryotes and are best 
characterised in yeast. RNA Pol I is highly active in these regions with the continuous 
transcription of rRNA presenting a challenge to replication. To coordinate this, yeast 
utilises RFB downstream of rDNA genes to arrest replication forks and prevent collisions 
with oncoming transcription machinery. 
Similar mechanisms involving replication fork pause (RFP) sites have been 
described at tRNA genes in yeast (Deshpande AM 1996). Besides physical barriers, 
transcription and replication are compartmentalised on a global scale template 
(Chakalova L 2005). RNA Pol II is distributed unevenly throughout the genome, 
organised into foci or ‘factories’ (Chakalova L 2005). The same can also be said for 
replication and proposes a model where transcripts or DNA are synthesised by pulling 
the template through ‘immobile’ factories as opposed to polymerases moving along 
‘immobile’ stretches of template (Chakalova L 2005). Studies support this view by 
revealing that the majority (95%) of replication foci do not overlap with transcription 
foci. Moreover, genome-wide mapping showed that highly transcribed regions exhibit 
very few replication events (Martin MM 2011). Therefore, by limiting replication to the 
S-phase and separating regions of transcription with replication, cells are able to limit 
conflicts in a spatial- and temporal-dependent manner. However, adaptive response to 
cellular stress requires changes in transcription, which can potentially undermine 
physiological mechanisms partitioning its coincidence with replication. Recently Hog1, 
a stress-activated protein kinase (SAPK) in yeast was shown to phosphorylate Mrc1 upon 
osmostress to prevent Cdc45 recruitment  
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Figure 1.11. Eukaryotic replisome assembly and activation. A) putative Mcm2-7 helicase and 
ORC are loaded onto DNA to start replication. B) Cdc45 associated with Mcm2-7 and DDK-
mediated phosphorylation inactivates further licencing. C) GINS and Cdc45 activates the putative 
Mcm2-7 helicase with Mcm10 coordinating the assembly of the replication fork. D) Pol α/primase 
activity primes the DNA template with RNA primers for Pol ε-driven synthesis on the leading 
strand and Pol δ-driven synthesis on the lagging strand. Newly synthesised strand in shown in 
red. Mcm2-7 – mini chromosome maintenance 2-7. ORC – origin replication complex. DDK - 
Dbf4/Drf1-dependent CDC7 kinase. Cdc45 - cell division cycle 45. GINS - go-ichi-ni-san. 
Mcm10 – mini chromosome maintenance 10. Pol α/primase – DNA polymerase alpha/primase. 
Pol ε – DNA polymerase epsilon. Pol δ – DNA polymerase delta. Image from: biology.mit.edu.  
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therefore delaying replication (Martin MM 2011). Activation of Hog1 is independent of 
the DNA-damage response and represents a means of preventing transcription and 
replication conflicts during stress (Martin MM 2011). 
Regardless of these efforts, collisions do occur in cells, albeit at a low frequency. 
Replication sites prone to stress are termed common fragile sites (CFS) with a subset of 
these identified as early replicating fragile sites (ERFS) (Barlow 2013). ERFS co-occur 
in regions of actively transcribed genes, rich in CpG and repeat sequences, posing as 
typical hotspots for transcription and replication collisions (Barlow 2013). Additionally, 
conflicts are deemed inevitable at human genes greater than 800kb, as these require a 
longer time to transcribe and overlap with replication in S-phase (Helmrich 2011). As a 
consequence of these collisions, genome stability becomes severely compromised with 
the induction of DNA-damage and formation of stable RNA:DNA hybrid structures 
called R-loops.  
1.10 R-loops 
1.10.1 Physiological functions of R-loops  
 
R-loops are found abundantly in the genomes of prokaryotes and eukaryotes and 
perform physiological roles when correctly regulated but can be detrimental to genome 
integrity when formed unintentionally. R-loop structures are generated by transcription 
when the RNA transcript threads back on the complementary template DNA and forms a 
stable interaction displacing the non-template strand as ssDNA. The presence of negative 
supercoiling behind the progressing RNA polymerase (Drolet 2006), DNA nicks (Roy D 
2010) and G-quadruplex structures are factors favouring the formation of R-loops. In 
particular, C-rich DNA and G-rich RNA interactions constitute a thermodynamically 
stable structure exceeding that of dsDNA (Roy D 2010).  
Physiologically, R-loops affect transcription in a context dependent manner. Their 
formation at unmethylated CpG islands in human NTERA2 (pluripotent embryonal 
carcinoma) cells help cap the promoter sequences and protect genes from being silenced 
by the de novo methytransferase DNMT3B1 (Ginno PA 2012). Phospho-H3S10, a marker 
of chromatin condensation, is also well correlated with the formation of R-loops 
(Castellano P.M. 2013). Conversely R-loops and head-to-head antisense transcription are 
required to maintain expression of the intermediate filament vimentin (Sastre R.B. 2014). 
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Apart from starting transcription, termination was also shown to involve R-loops at the 
ends of gene-rich regions (Ginno PA 2013). This was believed to prevent RNA Pol II 
from running into closely spaced genes by helping to slow the complex through an R-
loop mediated anchor. In the case of replication, RNA Pol I pausing in yeast led to R-
loop dependent RNA-primed DNA synthesis at the rDNA locus, irrespective of origins 
(Stuckey R 2015). Furthermore, R-loops are implicated in class-switch recombination 
(CSR), which alters the isotope of immunoglobulin (Ig) through removal of genes in the 
heavy chain locus (Roy D 2008). A key part of this process requires single stranded DNA 
as substrates for the enzyme activation-induced cytidine deaminase (AID) and is provided 
by the displaced strand following R-loop formation (Roy D 2008).  
 
1.10.2 Mechanisms regulating R-loop formation 
 
While R-loops are important for certain cellular processes, careful regulation is 
required to prevent these structures from forming outside of their intended context (Figure 
1.12). Cells have developed ways of preventing the aberrant formation of R-loops as well 
as mechanisms to remove then in case they do form. Given that negative supercoiling 
behind the elongating RNA polymerase provides room for the RNA transcript to thread 
back onto the complementary DNA strand, topoisomerase I counteracts this by relieving 
the topology, ensuring that ssDNA is re-sealed (Hage A 2010). Additionally, proper 
transcript packaging and processing facilitated by RNA biogenesis proteins such as the 
THO complex (Aguilera 2010) and ASF1/SF2 (alternative splicing factor 1/pre-mRNA 
splicing factor 2) supplementary to surveillance mechanisms can help to prevent R-loop 
formation (Gavaldá S 2013). In the event that R-loops escape prevention mechanisms, 
cells employ several enzymes to resolve these structures. The human senataxin helicase 
and yeast Sen1, help to unwind RNA:DNA hybrids (Mischo HE 2011). Subsequent 
inactivation of Sen1 in yeast leads to R-loop accumulation (Mischo HE 2011). The 
specificity of RNase H for degrading RNA was also shown to protect against R-loops 
(Huertas P 2003). Therefore, controlling the balance of R-loops is important as emerging 
evidence suggest its accumulation gives rise to genome instability    
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1.10.3 R-loops as a source of genetic and epigenetic instability 
 
Co-transcriptional R-loops have been linked to genomic instability arising from 
recombination, mutations and chromosome segregation and loss. For instance, in B 
lymphocytes AID can deaminate cytosine to uracil on the ssDNA of R-loops leading to 
hypermutation. The converted uracil base can also be targeted by components of the base-
excision repair (BER) machinery, such as uracil-DNA glycosylase to produce DNA nicks 
and/or abasic endonuclease (ABE), which gives rise to abasic sites. DNA nicks can 
generate double strand breaks (DSB), whereas replication past abasic sites leads to 
incorporation of random nucleotides and hence mutations. Since AID is only expressed 
in B cells, these mechanisms may not apply in other cell types.  
Evidently, defects in proteins that process R-loops can lead to its accumulation 
and threaten genome stability. Yeast THO-TREX (suppressors of the transcription defects 
of hpr1Δ mutants by overexpression-transcription and export) mutants lacking mRNA 
maturation and packing capabilities, demonstrate high recombination rates which can be 
rescued by overexpression of RNase H. This suggests that the build-up of R-loops leads 
to DNA damage (Huertas P 2003). Similarly, DT40 chicken cells depleted of the mRNA-
splicing factor ASF/SF2 lose the ability to supress R-loops formation and display 
hypermutation phenotypes (Li X 2005). Recent findings implicate a role for human 
BRCA1 (breast cancer 1) and BRCA2 (breast cancer 2) in supressing R-loop formation 
(Hatchi E 2015; Bhatia V 2014). BRCA1 was shown to direct senataxin to gene 
termination regions containing R-loops. Disruption of this interaction leads to 
accumulation of γH2AX foci and DNA damage (Hatchi E 2015). BRCA2 on the other 
hand interacts with the TREX-2 mRNA export complex and is required for the processing 
of R-loops (Bhatia V 2014). Notably BRCA1 and BRCA2 mutations underlie risks of 
developing human breast cancer.   
The structure-specific endonucleases XPF (xeroderma pigmentosum F) and XPG 
(xeroderma pigmentosum G) belong to the transcription-coupled nucleotide excision 
repair (TC-NER) pathway, which is involved in the removal of DNA alterations that 
inhibit the progression of transcribing polymerases. Aside from their main role in TC-
NER, more recent studies point towards the XPF and XPG in converting R-loops to DNA 
damage (Sollier J 2014), It is thought XPF and XPG may cut the RNA:DNA hybrid, in 
which case single strand breaks are created and can be processed into DSB by incoming  
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Figure 1.12. Mechanisms regulating R-loop A) removal and B) formation. A) Helicase such 
as SETX (humans), Sen1 (yeast), Rho (bacteria) help to unwind RNA:DNA hybrids whereas 
RNase H recognise and degrade RNA:DNA hybrids. B) TOP1 relieves negative supercoiling 
behind the progressing RNA Pol II while RNA biogenesis and surveillance mechanisms help 
package the transcribed strand to prevent treading-back. SETX/sen1 – senataxin. TOP1 – 
topoisomerase 1. SRSF1 – serine/arginine-rich splicing factor 1. Pcf11 – cleavage and 
polyadenylation factor subunit. TRAMP – Trf4–Air2–Mtr4p polyadenylation complex. UAP56 
– 56 kDa U2AF65-associated protein (Sub2 in yeast). EXOSC3 – exosome component 3 (Rrp40 
in yeast). EXOSC10 – exosome component 10 (Rrp6 in yeast). Image from: (Aguilera 2015).  
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replication forks or other nucleases (Sollier J 2015). Alternatively, XPF and XPG may 
cut both the ssDNA and the RNA:DNA hybrid, directly giving rise to DSBs (Sollier J 
2015). However, it is still unclear as to whether this mechanism generates inadvertent 
lesions, or if it is intended to remove detrimental R-loops in circumstances where 
processing factors are severely compromised and possibly restore damaged DNA through 
repair pathways.   
Patterns of histone modifications could also be affected by transcription-
replication conflicts. Repressive chromatin and gene silencing is linked to defects in 
replication fork progression, as demonstrated by fork stalling promoted by the anticancer 
drug doxorubicin (Im JS 2014). R-loop formation at mammalian unmethylated CpG 
promoters (Ginno PA 2012) and transcription termination regions  constitute to gene 
silencing and chromatin condensation, respectively. Abnormal accumulation of R-loops 
at these sites may overcome their physiological function and lead to a repressed chromatin 
state. Furthermore, camptothecin-mediated topoisomerase I inhibition promotes R-loop 
formation and H3K9 dimethylation, resulting in direct suppression of the FXN gene (Groh 
M. et al. 2014). The combination of R-loop and repressive histone mark was thought to 
drive the onset of friedreich ataxia (FRDA) in which the FXN gene undergoes a GAA-
repeat expansion (Groh M. et al. 2014). 
 
1.10.4 R-loops and double strand breaks as products of transcription and 
replication conflicts  
 
A more popular view of R-loop induced genome instability arises from the 
collision between transcription and replication. This is widely supported by the 
observation that inhibiting replication greatly abolishes R-loop dependent DNA damage 
(Gan W 2011). In addition, the role of topoisomerase I in ASF/SF2-mediated mRNA 
processing and its ability to relieve supercoiling are important for preventing the 
accumulation of R-loops and DSB in S-phase (Tuduri S 2010). Generally, head-on 
collisions between transcription and replication on the lagging strand present a greater 
threat to genome stability compared to co-directional collisions on the leading strand 
(Ivanova D 2015). This is evident in prokaryotes such as E. coli where most genes are 
encoded on the leading strand and inversion of the rnn operon to a head-on orientation 
with replication leads to reduced fork speeds and activation of DNA damage response 
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(Septenville A.D. 2012). However, no specific patterns of gene orientation have been 
found in humans (Ivanova D 2015). Evidence from prokaryotes suggests R-loops may 
either be the cause or the result of transcription and replication collisions. It is likely that 
R-loop structures extending behind the RNA polymerases may stall oncoming co-
directional replication forks, leading to its collapse and DSB formation (Dutta et al. 2011). 
Alternatively head-on conflicts can lead to formation of R-loops behind the stall RNA 
polymerase, in which case DNA damage may manifest at the site of collision or the 
exposed ssDNA (Mirkin and Mirkin 2005).  
Inevitably, DNA damage would trigger recombination events potentially resulting 
in gross chromosomal changes and as such this can lead to transcription-associated 
recombination (TAR) (Gottipati et al. 2008). The exposed ssDNA in R-loops are also 
subject to DNA damage, leading to transcription-associated mutagenesis (TAM) 
(Zlotorynski 2015). Ultimately, disruptions in either transcription or replication can lead 
to conflicts with disastrous consequences for the genome as well as the epigenome, with 
strong implications in the development of cancer and neurodegenerative diseases 
(Brambati A 2015).   
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1.11 Aims and hypothesis of the present study 
 
Histone deacetylase inhibitors can elicit genotoxic effects through changes in the 
epigenome. Alteration in cellular replication and transcription in response to these 
changes are implicated in the resulting genotoxicity. Independent studies have also shown 
that replication-transcription conflicts can lead to DNA damage and genome instability. 
In light of our current understanding, this study proposes that HDAC inhibitors induce 
changes in histone acetylation, which alters the organisation of chromatin, thereby 
affecting the normal function of processes such as replication and transcription in such a 
way that the frequency of conflicts between the two increases, leading to DNA damage 
induction and genome instability.   
To test this hypothesis, the current study aims to initially make use of budding 
yeast as a model organism, for which the ChIP-chip method has previously been 
established (Teng et al. 2011), to examine the genotoxicity of HDAC inhibitors. 
Additionally, the ChIP-chip method will be established in the human relevant TK6 
lymphoblastoid cell line as a genome-wide genotoxicity. Following this, the established 
method will be used to map chromatin associated events such as histone acetylation, 
transcription and replication in TK6 cells in response to HDAC inhibitor treatment. By 
integrating these datasets together using bioinformatic tools, the question of whether 
HDAC inhibition can induce increases in the frequency of transcription-replication 
conflicts will be examined. Finally, the knowledge gained here will be used collectively 
to address how a mechanistic understanding can be used to identify new endpoints for 
human safety assessment.  
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2.1 Mammalian methods 
2.1.1 Mammalian cell culture and treatment 
 
Human B lymphoblastoid TK6 cells were obtained courtesy of Prof. Anthony 
Lynch (GlaxoSmithKline, Ware, UK). TK6 cells are derived from the WIL-2 cell line 
and are heterozygous at the thymidine kinase locus (Skopek et al. 1978). The cell line 
was maintained in suspension between 1 - 9x105/ml in RPMI 1640 + GlutaMAXTM 
supplement (Gibco, Paisley, UK) containing 10% foetal bovine serum (FBS) (Gibco, 
Paisley, UK). The cells were passaged approximately every 3 days. Cells nearing 
confluency were split by removing ~90% of the cell suspension and replacing with fresh 
media for a final density of ~1x105/ml.  
Human breast adenocarcinoma MDA-MB-231 (p53 mutant) and prostate 
adenocarcinoma PC-3 (p53 null) cell lines were obtained courtesy of Dr Zara Poghosyan 
(Cardiff University, UK) and maintained as adherent cells in DMEM + GlutaMAXTM 
supplement containing 10% foetal bovine serum (Gibco, Paisley, UK) and F-12K 
medium + GlutaMAXTM supplement containing 10% foetal bovine serum (Gibco, 
Paisley, UK), respectively. The cells were maintained between approximately 10% - 80% 
confluency. Cells were passaged by removing the media and incubating at 37oC in the 
presence of 0.5% Trypsin-EDTA solution (Gibco, Paisley, UK) for up to 5mins. The cells 
were then collected by spinning at 1000g for 5mins at room temperature, replacing the 
trypsin solution with fresh media and reseeding a small proportion of the cells. 
All human cell lines were cultured in a copper-lined humidified incubator 
(HeracellTM 150i, ThermoFisher) at 37oC in the presence of 5% CO2. All cell lines are 
cultured for no more than 6 weeks, following which they are disposed of and new cells 
are thawed from the liquid nitrogen stock. Exponentially dividing cells were used at an 
assay dependent-density prior to drug treatment. 
 
2.1.2 Freezing and thawing cells 
 
Cells to be frozen were harvested during the exponential growth phase by 
centrifuging at 1000g at room temperature for 5mins. For adherent cell lines, the cells 
were first detached from the flask surface by incubating with 0.5% Trypsin-EDTA 
solution (Gibco, Paisley, UK) for up to 5mins at 37oC. Freezing mixture was prepared by 
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mixing Hybri-MaxTM dimethyl sulfoxide (DMSO) (Sigma-Aldrich Company Ltd, 
Gillingham, UK) with foetal bovine serum (Gibco, Paisley, UK) in a ratio of 1:4, 
respectively. Cells were re-suspended in media to a concentration of 2x106/ml. 0.5ml of 
the cell suspension was then gently mixed with an equal volume of the prepared freezing 
mix and transferred to a 1.5ml cryogenic tube (NalgeneTM, Thermo Scientific, 
Hempstead, UK). Individual cryotubes were placed in a Mr. FrostyTM container (Thermo 
Scientific, Hempstead, UK) with isopropyl alcohol overnight at -80oC to allow gradual 
cooling (-1oC/min), before transferring to liquid nitrogen (38K CryoStorage System, 
Taylor Wharton, US) for long-term storage.  
To thaw out new cells, the cryotube was removed from the liquid nitrogen store 
and immersed halfway in a 37oC water bath (NE1 Clifton, Thermo Scientific, Hempstead, 
UK), briefly until defrosted. The cryotube was then cleaned in 70% ethanol before 
transferring the contents to a 15ml tube. 9ml of fresh media was then added slowly in a 
drop-wise manner and centrifuged at 1000g for 5mins at room temperature to remove the 
freezing mixture. The cell pellet is then re-suspended in 10ml fresh media and transferred 
to a T75 flask (NuncTM, Thermo Scientific, Hempstead, UK). The media is replaced 
following overnight culture to remove any dead cells and residual DMSO.  
 
2.1.3 Counting cells 
 
To obtain a reliable estimate of cell numbers, cells in culture were diluted 1:10 in 
PBS solution and transferred to a sample cup (Beckman Coulter, High Wycombe, UK) 
before being counted using an automated Vi-CELLTM XR system (Beckman Coulter, 
High Wycombe, UK). Relative cell count (RCC) was used as a measure of general 
cytotoxicity, expressing the number of cells in the treated sample as a percentage of the 
number of cells in the untreated control: 
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2.1.4 Flow cytometry 
2.1.4.1 Apoptosis detection   
 
Annexin V-FITC binding to externalised phosphatidylserine in combination with 
propidium iodide (PI) was used to assess for the induction of apoptosis and cell death. 
The protocol was carried out as specified by the kits’ manufacturer (eBioscience, Vienna, 
Austria) with slight modifications: 0.4 - 1x105 cells were collected following treatment 
and washed once in PBS solution before re-suspending in 200μl of 1X Binding buffer 
containing 5μl anti-Annexin V-FITC dye. The cell suspension was incubated for 10mins 
at room temperature in the dark before adding 10μl propidium iodide and proceeding to 
analysis on the flow cytometer (Accuri C6, BD Biosciences, Oxford, UK). Anti-Annexin 
V-FITC and PI were collected in FL1 and FL3 channels, respectively. A plot of anti-
Annexin V-FITC (log x-axis) vs. PI (log y-axis), gated to exclude the debris (FSC vs. 
SSC), was used to interrogate the percentage of necrotic and apoptotic (early/late) cells 
in the population by applying a quadrant gate relative to the viable population. Cells 
staining positive for either Annexin V-FITC, PI or both were scored.  
 
2.1.4.2 Histone H2AX phosphorylation and Histone H3K9/14 acetylation  
 
Changes in histone modifications were measured using protocol outlined by 
(Smart et al. 2011). 2 - 4x105 cells were harvested and washed once in PBS solution. The 
pellet was then re-suspended in 1ml of pre-chilled lysis buffer (10mM Tris HCl pH8.0, 
2.5mM MgCl2; 320mM sucrose) and incubated on ice for 10mins before centrifuging 
(1000g, 4oC; 5mins). The nuclei were re-suspended in 100μl PBS solution (+ 1mg/ml 
BSA) containing an optimised amount of antibody, either anti-γH2AX-FITC (Millipore, 
Hertfordshire, UK) or anti-acetyl-histone H3-PE (Milli-MarkTM, Millipore, 
Hertfordshire, UK). Anti-γH2AX-FITC (Millipore, Hertfordshire, UK) and anti-acetyl-
histone H3-PE (Milli-MarkTM, Millipore, Hertfordshire, UK) signals were both collected 
in the FL1 channel independently.  
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2.1.4.3 InVitro MicroFlow® assay 
 
The InVitro MicroFlow® assay (Litron laborotaries, Rochester, USA) was used to 
measure the induction of micronuclei in response to DNA damage. The assay was 
conducted in 96-well plates. For each sample, 100μl of pre-warmed media was first added 
to the well. Next, 100μl of media containing the drug of interest, diluted to 2X the desired 
concentration, was added to the well designated as the highest drug concentration. The 
contents of the well were mixed by pipetting and a ½ serial dilution is carried out by 
transferring 100μl of the mixed media to the next well. 100μl of ~2 - 2.5x104 cells were 
added to each well for a final volume of 200μl.  
Following drug treatment, the supernatant was removed by centrifuging the 96- 
well plate at 300g for 5mins. Cells were loosened by gentle tapping and placed on ice for 
20mins before further processing. Staining solutions were prepared from components 
provided in the kit and scaled down based on the number of samples. To stain dead and 
dying cells, 50μl of Dye A working solution was added to each well and mixed with the 
cells by pipetting. The lid was removed and the 96-well plate left on wet ice and exposed 
to a bright light source for 30mins. Following this, cells were washed with 150μl of cold 
1X PBS + FBS solution and the supernatant removed by spinning at 300g for 5mins, 4oC. 
The exposure to light was limited from here on. To stain for total chromatin, cells were 
re-suspended in 100μl Complete lysis solution 1 and mixed before being placed in a 37oC 
incubator for 1h. 100μl Complete lysis solution 2 was then added to each well and the 
samples left overnight at 4oC before analysis. Samples were left to equilibrate at room 
temperature in the dark for 30mins before being analysed on the flow cytometer (Accuri 
C6, BD Biosciences, Oxford, UK). The EMA signal was collected in the FL3 channel 
and the SYTOX Green was collected in the FL1 channel. The data was analysed using 
the C6 Accuri software (Accuri C6, BD Biosciences, Oxford, UK), collecting 10,000 
events per sample. Gating was carried out as described in the manufacturers’ protocol 
(Litron laborotaries, Rochester, USA). 
 
2.1.4.4 Cell cycle analysis 
 
Propidium iodide (PI) was used for cell cycle analysis carried out independently 
of the in vitro Microflow® assay (Litron laborotaries, Rochester, USA). 1x106 cells were 
harvested by centrifuging at 1000g for 5mins at 4oC and washed once in cold PBS 
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solution. To fix cells, pre-chilled 70% ethanol was added drop-wise while vortexing in 
between. Samples were left on ice for at least 1h before washing with cold PBS solution 
(1000g for 5mins at 4oC). The fixed cells are re-suspended in 250μl PBS containing 
0.2mg/ml RNase A (ThermoFisher Scientific, Loughborough, UK) and incubated at 37oC 
for 1h before adding 10μl of 1mg/ml PI (abcam, Cambridge, UK) and analysed on a flow 
cytometer (Accuri C6, BD Biosciences, Oxford, UK). 10,000 events are collected per 
sample point using the Accuri C6 software (Accuri C6, BD Biosciences, Oxford, UK) 
and the data is analysed using FlowJo v10.07 (FLOWJO, LLC, Ashland, USA). Doublets 
are first eliminated by gating on the healthy population (log FSC vs log SSC), followed 
by the exclusion of aggregates (plot of PI FL2-A vs FL2-W). This subset of data is then 
used to generate cell cycle profiles based on the Watson (pragmatic) model (Gaussian fit 
to G1 and G2 phases).  
 
2.1.5 Immunoblot analysis 
2.1.5.1 Whole cell protein extraction 
 
To extract total protein content from cells, ~2.5 - 5x105 cells were seeded in 6-
well plates in a final volume of 2ml. Following treatment, cells were collected and washed 
once with cold PBS solution and lysed on ice for 10mins in 50μl of RIPA buffer (150mM 
NaCl, 0.1% SDS, 1% Triton-X 100, 0.5% sodium deoxycholate, 50mM Tris-HCl pH8.0) 
containing 1X PMSF (Sigma-Aldrich Company Ltd, Gillingham, UK) and 1X PIC 
(Sigma-Aldrich Company Ltd, Gillingham, UK). In order to improve the lysis of nuclear 
components, samples are sonicated using a Bioruptor® Standard sonication device 
(Diagenode, Ougrée, Belgium) for 2 cycles (10s on, 30s off) on ‘High’ settings, then 
centrifuged at 15,000g for 10mins at 4oC to remove debris. The protein concentration was 
determined as previously described using the Bradford assay. 
 
2.1.5.2 Protein quantification 
 
Extracted protein samples were quantified using the Bradford assay. A calibration 
curve was prepared using known concentrations of BSA dilutions against the absorbance 
(A590nm). Up to 5μl of prepared protein extract was diluted to a final volume of 1ml in 1X 
Bio-Rad protein assay reagent (Bio-Rad laboratories Ltd., Hertfordshire, UK). Samples 
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are transferred to micro-cuvettes (Thermo Scientific, Hempstead, UK) and the 
absorbance (A590nm) measured against a reference using a Jenway 6305 
spectrophotometer (Bibby Scientific Ltd., Staffordshire, UK). 
 
2.1.5.3 SDS-Polyacrylamide gel electrophoresis 
 
Proteins were resolved using 4 - 20% gradient Bolt® Bis-Tris Plus gels 
(InvitrogenTM, Life Technologies Ltd., Paisley, UK) assembled in a Mini gel tank 
(InvitrogenTM, Life Technologies Ltd., Paisley, UK) with 1X Bolt® MOPS SDS running 
buffer. 20 - 40μg of whole cell extract was mixed with NuPAGE LDS sample buffer (4X) 
(NovexTM, Life Technologies Ltd., Paisley, UK) and heated for 8mins at 99oC on a 
Mastercycler nexus GX2 (eppendorf, Stevenage, UK). Denatured lysates were then 
loaded sequentially onto the gel, with 5μl of Novex® Sharp pre-stained standard 
(NovexTM, Life Technologies Ltd., Paisley, UK) being loaded separately in the first lane. 
The gel was then run at 150V for up to 15mins using a Bio-Rad PowerPac 300 (Bio-Rad 
laboratories Ltd., Hertfordshire, UK). Once complete, the cassette was disassembled and 
the gel removed and rinsed in dH2O prior to transfer.  
 
2.1.5.4 Western transfer, probing and detection 
 
Transfer of proteins from the electrophoresed gel to the PVDF membrane was 
carried out using an iBlot® 2 Dry blotting system (InvitrogenTM, Life Technologies Ltd., 
Paisley, UK). The gel was placed facing down on the PVDF membrane provided in the 
iBlot® 2 transfer stack (InvitrogenTM, Life Technologies Ltd., Paisley, UK) and covered 
with a filter paper soaked in dH2O. A roller was used to remove any trapped bubbles 
before placing the remaining cathode stack and sponge on top, completing the transfer 
stack. The blotting system was run using the manufacturers’ protocol based on the 
proteins’ molecular weight (InvitrogenTM, Life Technologies Ltd., Paisley, UK).  
After completing the transfer, the PVDF membrane is removed from the stack and 
rinsed in dH2O. Probing of the membrane was carried out using an iBind
TM Western 
device (InvitrogenTM, Life Technologies Ltd., Paisley, UK). Firstly, the working iBind 
solution was prepared by adding 6ml of the 5X iBindTM buffer (NovexTM, Life 
Technologies Ltd., Paisley, UK) with 23.7ml of dH2O and 300μl of 300X additive 
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(NovexTM, Life Technologies Ltd., Paisley, UK). The solution was then mixed by 
vortexing. An optimised concentration of primary and secondary antibody was prepared 
in 2ml of the working iBind solution and mixed by pipetting. To probe the membrane, an 
iBindTM card (NovexTM, Life Technologies Ltd., Paisley, UK) was placed in the iBindTM 
Western device (NovexTM, Life Technologies Ltd., Paisley, UK) and soaked with 5ml of 
the working iBind solution. 1ml of the working iBind solution was pipetted on the centre 
of the card and then PVDF membrane placed on top, with the protein side facing down. 
The iBind device is closed and the antibody solutions were added to the wells of the 
cassette sequentially as outlined in the manufacturers’ instructions (Life Technologies 
Ltd., Paisley, UK). The blot was left to run by lateral flow for at least 3h at room 
temperature or overnight at 4oC. 
After probing, the PVDF membrane was removed from the iBind Western device 
(NovexTM, Life Technologies Ltd., Paisley, UK) and rinsed in dH2O. The membrane was 
then incubated for 5mins in 1ml of SuperSignalTM West Dura Extended Duration 
Substrate (Thermo Scientific, Hempstead, UK) containing a 1:1 mixture of luminol 
enhancer and stable peroxide buffer. Chemiluminescent signals from the blot were 
detected using Labworks software v4.6 (Labworks Inc., Costa Mesa, USA) connected to 
a BioSpectrum 610 Imaging System with an OptiChemi 610 camera (UVP Inc., Upland, 
USA).  
 
2.1.5.5 Membrane stripping 
 
To re-probe the blot, the PVDF membrane is stripped in 10ml of RestoreTM PLUS 
Western Stripping buffer (Thermo Scientific, Hempstead, UK) for 15mins at room 
temperature. The membrane is then washed once in dH2O and the efficiency of the 
stripping checked using SuperSignalTM West Dura Extended Duration Substrate (Thermo 
Scientific, Hempstead, UK) as aforementioned.  
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2.1.6 Chromatin Immunoprecipitation  
2.1.6.1 Chromatin preparation 
 
Chromatin must first be extracted from the cell and sheared to a range of fragment 
sizes before it can be used in immunoprecipitation reactions. TK6 cells are cultured in 
T175 flasks (NUNCTM, Thermo Scientific, Hempstead, UK) to a density of ~5x105 
cells/ml in 100ml RPMI 1640 before being treated with DMSO (solvent control) or 
400nM Trichostatin A (HDACi treated sample) for 6hrs. Cells from 4 - 8 flasks are 
harvested per treatment condition (1000g for 5mins at room temperature) and re-
suspended in the same volume of PBS solution in a 2L erlenmeyer flask at ~5x105 
cells/ml. The flasks are then placed on an InnovaTM 2100 bench top orbital shaker (New 
Brunswick InnovaTM, Fisher Scientific, Loughborough, UK) set at 80rpm to continuously 
mix the cells during fixation at room temperature.  For treated cells, Trichostatin A is 
added to the PBS at a final concentration of 400nM, to maintain the effects of the inhibitor 
during handling. DNA associated proteins are cross-linked by diluting a stock solution of 
37% formaldehyde (Sigma-Aldrich Company Ltd, Gillingham, UK) in the cell/PBS 
solution to a final 1% (v/v) for 8mins. The reaction is quenched by adding 2.5M stock 
glycine to a final concentration of 125mM, for 5mins.  Following this, the fixed cells are 
allowed to cool on ice for 10mins before being transferred to 50ml conical tubes 
(FalconTM, Fisher Scientific, Loughborough, UK) and collected (1000g for 5mins at 4oC). 
Subsequent steps are all carried out on ice or at 4oC, to preserve protein activity. Cells are 
washed 3x in cold PBS solution (1000g for 5mins at 4oC) to remove traces of the 
formaldyhyde fixative. To efficiently shear chromatin from fixed TK6 cells, an additional 
lysis step is necessary to remove cytoplasmic/non-fixed components, this was carried out 
by lysing ~1x107 cells per 1ml ChIP lysis buffer (10mM Tris-HCl pH8, 10mM NaCl, 
0.5% NP-40) on ice for 10mins. After centrifuging (1000g for 5mins at 4oC) and 
removing the supernatant, the ‘nuclear’ pellet obtained is finally re-suspended in 330μl 
ChIP shearing buffer (50mM Tris-HCl pH8, 10mM EDTA pH8, 1% SDS) per ~1x107 
cells in a standard 1.5ml microfuge tube (Fisher Scientific, Loughborough, UK). In order 
to shear the chromatin to an average fragment size of 500bp, samples were sonicated 
using a Bioruptor® Standard sonication device (Diagenode, Ougrée, Belgium) with a 
NESLAB Digital Plus RTE7 circulating water bath (ThermoScientific, Loughborough, 
UK) set to 4oC. Six samples are loaded into the tube holder each time and sonicated for 7 
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cycles of 30s on/off using ‘High’ settings. Following this, the samples are spun at 15,000g 
for 10mins at 4oC to remove any debris resulting from the shearing. The chromatin 
prepared from the same treatment is then pooled together and mixed by vortexing; 50μl 
of the sample is transferred to a new tube and de-crosslinked overnight at 65oC in a water 
bath. This sample is purified using the PureLink® PCR purification kit (InvitrogenTM, Life 
Technologies Ltd., Paisley, UK) and the extent of the shearing assessed using gel 
electrophoresis. The remaining chromatin is aliquoted into lots of 1ml in 1.5ml 
Eppendorf® Protein LoBind tubes (Fisher Scientific, Loughborough, UK), snap-frozen in 
liquid nitrogen and stored at -80oC.  
 
2.1.6.2 DNA gel electrophoresis 
 
The fragment distribution of sheared chromatin is routinely checked after each 
preparation using 1.2% mini agarose gels containing 0.2μg/ml ethidium bromide. The 
gels are electrophoresed at 80V for 50mins in TBE buffer (100mM Tris-base, 100mM 
Boric acid, 20mM EDTA pH8). The image is assessed under UV light using a 
BioSpectrum 610 Imaging System (UVP Inc., Upland, USA).  
 
2.1.6.3 Immunoprecipitation 
 
To estimate the binding locations of proteins/histone marks on a genomic scale, 
the corresponding DNA fragments are isolated using highly specific antibodies against 
the target of interest. This immunoprecipitation (IP) reaction is typically scaled to use 
larger amounts of starting chromatin and antibody to satisfy the requirements for whole 
genome amplification using the WGA2 kit (Sigma-Aldrich Company Ltd, Gillingham, 
UK). The amount of material used greatly depends on the abundance of the target, 
typically for rare events such as γH2AX, 1.2x108 cell equivalent of chromatin is required 
for a single IP, however as few as 3x107 cell equivalent of chromatin is enough for 
studying histone acetylation. The optimal amount of antibody was determined by 
performing a titration experiment. 
To perform immunoprecipitation using chromatin prepared from TK6 cells, the 
ChIP-validated antibody was first bound to superparamagnetic Dynabeads® 
(InvitrogenTM, Life Technologies Ltd., Paisley, UK) from the same species that the 
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antibody is raised in. 50μl per sample of Dynabeads® are washed 3x in PBS solution (+ 
1mg/ml BSA), each time the beads are allowed to collect at the side of the tube by placing 
it in a DynaMagTM-Spin magnet (Life Technologies Ltd., Paisley, UK) for 1min. The 
beads are re-suspended again in the same volume of PBS solution (+ 1mg/ml BSA) and 
transferred to 1.5ml Eppendorf® Protein LoBind tubes (Fisher Scientific, Loughborough, 
UK). The optimised amount of antibody is added to the beads and incubated for 60mins 
at 30oC in a Thermomixer® comfort (Fisher Scientific, Loughborough, UK) set to 
1,300rpm. Based on the manufacturers specifications, 50μl of Dynabeads® have a 
capacity to bind to 0.4 - 4μg of antibody. For larger amounts of antibody, the amount of 
dynabeads used is scaled accordingly. TSA treated and untreated chromatin was defrosted 
on ice and centrifuged at 15,000g for 2mins at 4oC. This step is essential to removing the 
bulk of the SDS present in the ChIP shearing buffer. While SDS is important for shearing 
the chromatin, it negatively affects the ability of antibodies to immunoprecipitate their 
targets. To counteract any residual SDS remaining in the chromatin sample, 500μl of 
ChIP dilution buffer (50mM Tris-HCl pH8, 150mM NaCl, 2mM EDTA pH8, 1% Triton-
X, 0.01% SDS) containing 1% Triton-X100 is added to 1ml of chromatin to sequester the 
SDS. Additionally, fresh phenylmethane sulfonyl fluoride (PMSF) and protease inhibitor 
cocktail (PIC) (Sigma-Aldrich Company Ltd, Gillingham, UK) are added to 1X 
concentration. At this stage 50μl of chromatin is kept as the ‘input’ (IN) sample, 
representing the non-immunoprecipitated background. Once the antibody has been 
coupled to the Dynabeads®, 2 further washes in PBS solution (+ 1mg/ml BSA) are carried 
out to remove any unbound antibody. 50 - 100μl of antibody/Dynabead® mixture 
(antibody dependent) is then added to 1.5ml of chromatin and further incubated in a 
thermomixer for 3hrs at 21oC at 1,300rpm.  
After the incubation is complete, the protein of interest and the corresponding 
DNA fragment will be bound to the antibody/Dynabead® complex. A series of wash steps 
are then carried out for 3mins each on a RevolverTM platform (Labnet International Inc., 
Edison, USA) in 1ml of buffer and collected using a DynaMagTM-Spin magnet as before. 
The IP samples are first washed 1x in low salt solution (20mM Tris-HCl pH8, 150mM 
NaCl, 2mM EDTA pH8, 1% Triton-X, 0.1% SDS), followed by 3x in high salt solution 
(20mM Tris-HCl pH8, 500mM NaCl, 2mM EDTA pH8, 1% Triton-X, 0.1% SDS) and 
1x LiCl solution (250mM LiCl, 0.5% NP-40, 0.5% Na-deoxycholate, 10mM Tris-HCl 
pH8, 1mM EDTA pH8). A final wash in TE buffer (10mM Tris-HCl pH8, 1mM EDTA 
pH8) was carried out to remove residual salts from the wash buffers before eluting in 
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125μl ChIP elution buffer (10mM Tris-HCl pH8, 1mM EDTA, 0.5% SDS) on a 
thermomixer set at 65oC, 1300rpm for 25mins. The eluted IP sample is separated from 
the Dynabeads® using the DynaMagTM-Spin magnet and transferred to a new 1.5ml tube. 
To de-crosslink the protein from the DNA, both the IP and IN sample is left in a 65oC 
water bath overnight. The DNA is then purified using PureLink® PCR purification kit 
(Life Technologies Ltd., Paisley, UK), eluted in 50μl E1 buffer and stored at -20oC.   
 
2.1.6.4 Real-time qPCR 
 
Real-time quantitative PCR was used to measure enrichment in the 
immunoprecipitated sample relative to the input. Using SYBR Green chemistry and 
primers for genes where the protein/histone modification is known to be present/absent, 
the enrichment between treated and untreated samples can be compared. For examining 
background levels of a signal, the comparison was made between IP’s carried out using 
the antibody specific for the target of interest and a matching IgG of the same species. 
This method was used to determine the success of the IP reaction prior to proceeding to 
the microarrays. 10x dilutions of the IP and IN samples were made. 4μl of the IP and IN 
sample was diluted in 36μl of ddH2O. For standards, a 10x serial dilution (1/10 – 
1/100,000) was prepared using 5μl IN in 45μl ddH2O. iTaqTM Universal SYBR® Green 
Supermix (Bio-Rad laboratories Ltd., Hertfordshire, UK) was prepared by adding 
forward and reverse primers at a final concentration of 1mM from a 100mM stock. The 
solutions were mixed by vortexing and 5μl of the diluted DNA (IN, IP or standards) was 
mixed with 5μl of SYBR Green/primer mix in a Hard-Shell® 96-well semi-skirted PCR 
plate (Bio-Rad laboratories Ltd., Hertfordshire, UK). ddH2O was used as a non-template 
control (NTC) and samples were loaded in triplicates. The volumes specified are for the 
analysis of 2 gene loci, typically one positive and one negative, on a single 96-well PCR 
plate. Samples runs were performed on a CFX ConnectTM Real-Time PCR detection 
system (Bio-Rad laboratories Ltd., Hertfordshire, UK) following the cycling protocol 
documented by the manufacturer. The data was then analysed using CFX ManagerTM 
Software v3.1, sample wells within triplicates displaying greater than 0.5 Ct variation was 
removed. Melt curves were checked for non-specific amplicons.  
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2.1.6.4.1 Primer design and optimisation  
 
Primers for real-time qPCR were designed based on the human genome assembly 
hg19 (UCSC Genome Browser) (Appendix, IV). Potential primers with an optimal size 
of 22 - 27bp, GC content of 40 - 60% and Tm between 65 - 70
oC were generated using 
Primer 3 v0.4 based on the target sequence. For real-time qPCR of ChIP samples, primers 
yielding 100 - 200bp amplicons were selected and validated in silico (UCSC Genome 
Browser). Primers were synthesised on a 0.01μmol scale, using HPSF purification 
(Eurofins Genomics, Ebersberg, Germany) and reconstituted in ddH2O to 100mM. To 
efficiently amplify regions of interest, optimisation was first carried out to identify 
parameters under which the primer would perform the best. Tm was determined by 
running a temperature gradient, values displaying low Ct without non-specific 
amplification were deemed suitable. Next, a qPCR run at a defined Tm across a range of 
template concentrations (10ng - 16pg) was used to assess the reaction efficiency. Fully 
optimised primers showed: 1) efficiency and sensitivity: E > 90%, 2) specificity: no non-
specific amplicons; 3) reproducibility: triplicates are within 0.5Ct.  
 
2.1.6.5 Determining optimal antibody conditions for ChIP-chip  
 
Optimal antibody concentration for chromatin immunoprecipitation was 
determined empirically by carrying out a small-scale titration reaction, typically using 0 
- 5μg of antibody with 500μl of chromatin. The binding levels relative to the IgG control 
was assessed using qPCR with primers for regions of expected high (positive control loci) 
and low (negative control loci) enrichment.  
For proteins where the binding location in the genome is unknown based on 
literature searches, a post-IP western was carried out instead to examine whether if the 
antibody is ChIP-grade. To do this, a titration was performed as mentioned above, except 
the beads are re-suspended in 50μl of RIPA buffer after the series of washes in salt 
solution. 20μl of 4X NuPAGE LDS sample buffer (NovexTM, Life Technologies Ltd., 
Paisley, UK) was added and heated at 99oC for 8mins. The beads were separated from 
the IP sample with a DynaMagTM-Spin magnet; 1μl was loaded for western blot analysis 
and the presence of the immunoprecipitated protein examined against the IgG control.  
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2.1.7 ChIP-chip 
2.1.7.1 Whole-genome amplification 
 
The yield of DNA from ChIP is too low for microarray analysis. To overcome 
this, samples are exponentially amplified using the GenomePlex® Complete Whole 
Genome Amplification kit (WGA2) (Sigma-Aldrich Company Ltd, Gillingham, UK). 
The result is a ~500-fold increase in DNA that is representative of the original IP sample.  
The method was performed as outlined in the manufacturer’s instructions with slight 
modifications. 46μl of the IP sample was concentrated to ~11μl using a SavantTM ISS-
100 Speed Vac System (Fisher Scientific, Loughborough, UK). The IN sample 
concentration is quantified on a NanoDrop and diluted to ~2ng/μl. For the preparation of 
the OmniPlex® library, 2μl of 1X Library Preparation Buffer and 1μl of Library 
Stabilisation Buffer are added to 11μl of either the diluted IN or concentrated IP sample. 
The reaction is mixed by vortexing and heated at 95oC for 2mins on a Mastercycler nexus 
GX2 (eppendorf, Stevenage, UK). 1μl of Library Preparation Enzyme was added and 
mixed before returning to incubate following the manufacturers’ instructions.  
Following this, samples are amplified by PCR with the addition of 7.5μl of 10X 
Amplification Master Mix, 47.5μl of ddH2O and 5μl of WGA Polymerase to the 15μl 
reaction and thermocycled. The samples are then purified using the PureLink® PCR 
purification kit (InvitrogenTM, Life Technologies Ltd., Paisley, UK) and eluted in 50μl of 
TE buffer supplied with the BioPrime® Total Genomic Labelling System (Life 
Technologies Ltd., Paisley, UK). The purity and yield of the amplified ChIP DNA is then 
quantified using the NanoDrop and stored at -20oC.  
 
2.1.7.2 Fluorescent labelling 
 
For two colour ChIP-microarrays, IP and IN samples are labelled with two 
different fluorescent dyes and hybridised onto a single array. The ratios of fluorophore 
intensities (IP/IN) are a measure of the relative signal enrichment. Sample labelling was 
carried out using the BioPrime® Total Genomic Labelling System (Life Technologies 
Ltd., Paisley, UK). Briefly, 2μg of amplified IN and IP samples are used as starting 
material for the reaction. The volume was made up to 22μl using TE Buffer and 25μl of 
2X Alexa Flour® 3 was added to the IN and 25μl Alexa Flour® 5 added to the IP. Exposure 
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to light was minimised to reduce photo-induced signal degradation, particularly for Alexa 
Flour® 5. The reaction was mixed by pipetting and incubated on a thermocycler at 95oC 
for 5mins and immediately cooled to 4oC. 3μl of highly concentration Exo-Klenow 
Fragment (40U/μl) was added and further allowed to incubate at 37oC for 2hrs. Once the 
labelling is complete, samples are purified using the PureLink® PCR purification kit 
(InvitrogenTM, Life Technologies Ltd., Paisley, UK) as mentioned previously.  
 
2.1.7.3 DNA quantification 
 
A NanoDrop 1000 Spectrophotometer (Thermo Scientific, Hempstead, UK) was 
used to measure the yield and purity of DNA after PCR amplification. After referencing 
with the appropriate reagent, absorbance was measured at 230nm, 260nm and 280nm. 
For pure DNA, a 260/280nm ratio of ~1.8 and a 230/260nm ratio of 2.0 - 2.2 is expected. 
The degree of labelling and yield can also be measured by using the ‘Microarray’ function 
within the NanoDrop software v3.8.1. In addition to the 260/280nm ratio, the 
excitation/emission maxima, 555/565nm and 650/670nm, are measured as an indication 
of Alexa Flour® 3 and Alexa Flour® 5 incorporation, respectively. Successfully labelled 
IN samples show significantly greater 555/565nm ratio compared to 650/670nm and the 
opposite is true for IP samples. For a starting amount of 2μg, ≥7μg of labelled DNA is 
observed.  
 
2.1.7.4 Array hybridisation 
 
Sample hybridisation was carried out as described in Agilent’s ChIP-on-Chip 
protocol v11.2. For 2x400K arrays, 5μg of correspondingly labelled IN and IP samples 
are combined and made up to 79μl in ddH2O. 25μl of human Cot-1 DNA® (1mg/ml) (Life 
Technologies Ltd., Paisley, UK), 26μl of 10X aCGH Blocking Agent (Agilent 
Technologies Ltd., Cheshire, UK) and 130μl of 2X HI-RPM Hybridisation Buffer 
(Agilent Technologies Ltd., Cheshire, UK) are added sequentially and heated on a 
thermocycler at 95oC for 3mins and 37oC for 30mins. To load the samples onto the array, 
a matching gasket slide is placed on top of a SureHyb Microarray Hybridisation Steel 
Chamber (Agilent Technologies Ltd., Cheshire, UK). 250μl of the mixture is pipetted by 
slowly dragging across centre of the gasket slide, making sure to avoid the rubber lining. 
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The microarray slide is the gently lowered on top, with the Agilent barcode facing up. 
The chamber is sealed and placed in a 65oC Microarray Hybridisation Oven (Agilent 
Technologies Ltd., Cheshire, UK) at 20rpm for 40hrs.  
 
2.1.7.5 Array washing, scanning and feature extraction 
 
Once the hybridisation is complete, the array/gasket sandwich is first removed 
from the steel chamber and disassembled in Array Wash Buffer 1 (300ml of 20X SSPE, 
250μl of 20% sarcosine in 1L ddH2O) using a pair of plastic tweezers. Next, the array 
slides are placed in a holder and moved to a new glass container with 200ml of fresh 
Array Wash Buffer 1 and incubated at room temperature for 5mins with gentle stirring. 
To prevent signal degradation, the amount of light exposure is minimised by covering the 
glass container with aluminium foil. The arrays are then moved to a new container for a 
further 5mins wash with Array Wash Buffer 2 (3ml of 20X SSPE in 1L ddH2O), pre-
warmed to 31oC. Following this, the arrays are dried quickly using a Slide Spinner 
(Labnet International Inc., Edison, USA) and stored in an aluminium wrapped slide 
holder until ready for scanning. Washed arrays are scanned on Agilent type C Scanner 
(Agilent Technologies Ltd., Cheshire, UK) following the recommended parameters 
(Agilent Technologies Ltd., Cheshire, UK).  
The scanned array produces a high-resolution TIFF (tagged image file format) file 
containing the relative intensities of IN (green emission) and IP (red emission) for each 
feature. This data is extracted for quantification as a numerical value (IP/IN ratio) using 
the Feature Extraction Software v10.7 (Agilent Technologies Ltd., Cheshire, UK).  
 
2.1.7.6 Data analysis  
 
Microarray dataset generated in this study are analysed using the Sandcastle R-
package, developed specifically for making comparisons between multiple linked ChIP-
chip experiments (Bennett et al. 2015). The main attraction of the software is the ability 
to compare relative changes in binding following a novel procedure, which normalises 
the datasets to a common background. In addition, scripts for loading, plotting, 
enrichment and peak detection are also presented. An example of the theory behind the 
normalisation process is demonstrated using ChIP-chip data generated in Chapter IV.  
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2.1.7.7 Mammalian microarray design 
 
Microarrays used in the established TK6 cell ChIP-chip method are custom 
designed in Agilent’s’ 2x400K format (design ID: AMADID:074126) using the 
SureDesign database (Agilent Technologies Ltd., Cheshire, UK). These contain 2 printed 
microarrays per slide with 400,000 features representing the entire human chromosome 
17. Such economic design provides optimal genomic coverage of an entire chromosome 
whilst ensuring good data resolution (81.195Mbp/414043 probes ~196bp spacing 
between each probe). 
 
2.1.8 RDIP-Chip 
 
 R-loops in TK6 cells were examined following the published RDIP-Chip protocol 
with minor modifications (Nadel et al. 2015). Briefly, genomic DNA was extracted using 
the salting out method (Miller, Dykes, and Polesky 1988). Samples are then treated with 
RNase A under high salt conditions (500mM NaCl) to digest only single and double 
stranded RNA, as these types of RNA were previously shown to interfere with the proper 
detection of R-loops (Zhang Z.Z. 2015). 5μg of sonicated DNA was immunoprecipitated 
with 10μg of the anti-DNA:RNA hybrid [S9.6] antibody (Kerafast, Boston, USA). 
Subsequent steps using the IP’d DNA were performed with the established ChIP-chip 
workflow as described above. 
2.2 Yeast methods  
2.2.1 Yeast strains and culture  
 
 The S. cerevisiae strains BY4742 (MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0) and 
BY4742 rpd3Δ (MATΔ, his3Δ1, leu2Δ0, lys2Δ0, ura3Δ0, rpd3Δ::KanMX4) were cultured 
in sterilised yeast extract peptone dextrose (YPD) media (1% BactoYeast extract, 2% 
BactoPeptone; 2% Dextrose) at 30oC, 180rpm in an Infors HT multitron incubator (Infors 
HT, Basel, Switzerland).  
Yeast cultures were maintained at -80oC (in 15% glycerol) for long term-storage 
and as streaked colonies on YPD agar plates for short-term use. Pre-cultures were 
prepared by inoculating a single colony from agar plates and culturing overnight in 20ml 
  73 
YPD. A pre-determined volume of pre-culture is added to 50 – 200ml of YPD and grown 
overnight to logarithmic phase (~2x107 cells/ml) before treatment or harvesting. 
  
2.2.2 Growth analysis 
 
 The growth of yeast cells was monitored by measuring the optical density at 
600nm using a Jenway 6305 spectrophotometer (Bibby Scientific Ltd., Staffordshire, 
UK). To monitor growth, yeast cells were cultured to OD600 = 0.1 and the change in OD600 
recorded every hour. Drug treatments were administered at the start of the exponential 
phase, as determined from the growth curve.  
 
2.2.3 Whole cell protein extraction 
 
 To prepare whole cell lysates, yeast cells are grown to a density of 2 – 3x106 
cells/ml in 50ml and harvested by centrifuging at 3000g for 5mins. Cells are washed once 
in PBS and re-suspended in 300μl yeast lysis buffer (30mM HEPES pH7.4, 50mM KCl; 
10 % Glycerol). An equal volume of glass beads is then added and the tube is vortexed at 
maximum speed for 20mins at intervals of 1min on ice. Following this, the supernatant 
was separated by centrifuging at 10,000g for 15mins and stored at -80oC before use. Total 
protein concentrations were measured as previous described using the Bradford assay. 
 
2.2.4 ChIP-chip 
 
 The yeast ChIP-chip protocol follows the same structure as the established TK6 
ChIP-chip protocol, differing only in chromatin preparation, whole genome amplification 
and the arrays used. 
 
2.2.4.1 Chromatin preparation 
 
 To extract chromatin from yeast, 200ml of exponentially growing cells (2 – 3 x106 
cells/ml) were harvested at 3000g for 5mins and cross-linked in 1% formaldehyde and 
phosphate buffered saline (PBS) solution for 10mins, with shaking at room temperature. 
A final concentration of 125mM glycine was used to stop the reaction and the cell pellet 
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was washed 3x in PBS before being re-suspended in 500μl of FA/SDS buffer (50mM 
HEPES-KOH pH7.5, 150mM NaCl, 1mM EDTA, 1% Triton-X, 0.1% Sodium 
deoxycholate, 0.1% SDS) containing 1X PIC and 1X PMSF (Sigma-Aldrich Company 
Ltd, Gillingham, UK) in a 2ml tube. Equal volume of glass beads are added and vortexed 
at maximum speed for 20mins at intervals of 5min on ice. To ensure the greatest recovery 
of chromatin, 2ml tubes were pierced at the bottom and placed in a 15ml falcon tube. The 
supernatant was collected by centrifuging at 2000g for 2mins.  
 Subsequently, whole cell chromatin was fragmented to an average size of 400 – 
500bp using a Bioruptor® Standard sonication device (Diagenode, Ougrée, Belgium) for 
7 cycles (10s on, 30s off) on ‘High’ settings. Chromatin was recovered by centrifuging at 
13,000g for 15mins and 50μl de-crosslinked overnight at 65oC to assess the sonication 
efficiency by gel electrophoresis. To preserve chromatin, samples were snap-frozen using 
liquid nitrogen and stored at -80oC until use.  
 
2.2.4.2 Ligation-mediated PCR (LM-PCR) 
 
Typically, for yeast, 200 – 500μl of chromatin is sufficient for a single ChIP 
reaction and washes are performed in the same manner described for mammalian ChIP. 
The immunoprecipitated (IP) or background DNA (IN) from yeast is amplified using the 
ligation-mediated PCR method, exactly as described in Agilents’ ChIP-on-chip protocol 
v11.3 (Agilent Technologies Ltd., Cheshire, UK) and consists of (i) creating blunt ends, 
(ii) adaptor ligation and (iii) PCR. Briefly, the blunt end mix is added to both the IP and 
the diluted IN DNA separately and incubated in a thermocycler at 12oC for 20mins. The 
DNA is phenol/chloroform extracted once and dissolved in ddH2O. Following this, 
adapters are ligated to the fragmented DNA by an overnight incubation step. Two rounds 
of PCR are performed with the DNA and then purified to check yield. Reagents and 
condition are provided in Agilents’ ChIP-on-chip protocol v11.3 (Agilent Technologies 
Ltd., Cheshire, UK).   
 
2.2.4.3 Yeast microarray design 
 
 Yeast microarrays are custom designed in Agilents’ 4x44K format (design ID: 
AMADID:038550) using the SureDesign database (Agilent Technologies Ltd., Cheshire, 
UK). These contain 4 printed microarrays per slide with 44,000 features representing the 
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entire yeast genome; with an average probe spacing of 275bp (12.1Mbp/44,000 ~275bp 
spacing between each probe).  
 
2.2.5 DRIP-Chip 
 
For mapping the locations of DNA:RNA hybrids (R-loops) in the yeast genome, 
the DRIP-Chip protocol published by Chan and colleagues was adapted and used here 
(Chan et al. 2014). Primarily, DNA instead of chromatin is prepared from yeast cells, 
since R-loops are DNA-associated and easier to prepare compared to chromatin. 
Additionally, the established LM-PCR method is used to amplify ChIP’d material instead 
of using T7-DNA Polymerase method.  
DNA was extracted from yeast cells using the ‘Bust n Grab’ protocol with slight 
modifications (Harju, Fedosyuk, and Peterson 2004). 50ml of logarithmically growing 
yeast cells are harvested and suspended in 2ml tubes containing 1ml lysis buffer (10mM 
Tris-HCl pH8.0, 1mM EDTA pH 8.0, 100mM NaCl, 1% Triton X-100, 1% SDS). The 
tubes are submerged in liquid nitrogen for 2mins and immediately transferred to a 95oC 
water bath. This procedure was repeated again before extracting the DNA with 
phenol/chloroform and dissolving the DNA in 50μl TE buffer. Single and double-
stranded RNA were then removed by incubating with RNase A (Zhang Z.Z. 2015). 
Sonication was performed using 4 cycles to fragment the DNA to 400 – 500bp as with 
chromatin preps. Immunoprecipitation was performed by coupling 10μg of the anti-
DNA:RNA hybrid [S9.6] antibody (Kerafast, Boston, USA) to 80μl of anti-mouse IgG 
Dynabeads® (InvitrogenTM, Life Technologies Ltd., Paisley, UK) for 3 hours at 4oC. 3μg 
of the fragmented yeast genomic DNA was then added and incubated overnight at 4oC on 
a rotor. The resulting immunoprecipitated DNA was washed following the published 
protocol (Harju, Fedosyuk, and Peterson 2004), labelled and hybridised onto microarrays 
in the same way as ChIP-chip, outlined in Agilents’ ChIP-on-chip protocol v11.3 (Agilent 
Technologies Ltd., Cheshire, UK).   
 
2.2.6 Extraction of total RNA 
 
The hot acid phenol method was used to extract RNA from intact yeast cells. 10ml 
of exponentially growing yeast cells are harvested by centrifuging at 4000g for 3mins. 
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The cell pellet is washed once with ice-cold PBS, transferring to a 1.5ml tube. Cells are 
pelleted by centrifuging for 10s at 10,000g and the PBS removed. Following this, cells 
are re-suspended in 400μl of TES buffer (10mM Tris-HCl pH7.5, 10mM EDTA; 0.5% 
SDS) and 400μl of acid phenol is added and mixed by vortexing. The sample is then 
incubated at 65oC for 45mins. After this, the tube is placed on ice for 5mins and 
centrifuged at 10,000g for 5mins at 4oC. The supernatant is transferred to a new tube and 
phenol chloroform extraction was performed, twice using 400μl of acid phenol and once 
with 400μl chloroform. The top aqueous layer is transferred to a new tube and the RNA 
precipitated by adding 40μl of 3M sodium acetate pH5.2 and 1ml of ice-cold ethanol. The 
sample is centrifuged at 10,000g for 5mins at 4oC and washed once with 70% ethanol and 
air-dried. Finally, the pellet is re-suspended in 50μl ddH2O and the yield measured using 
a NanoDrop 1000 Spectrophotometer (Thermo Scientific, Hempstead, UK).  
 
2.2.7 Preparation of cDNA 
 
 Complementary DNA (cDNA) is prepared using 50ng of the extracted total 
RNA following protocols outlined in the iScript cDNA synthesis kit (Bio-Rad 
Laboratories Ltd., Hertfordshire, UK).  
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3.1 Saccharomyces cerevisiae as a model organism 
 
Classical molecular genetics helped to introduce much of the basic concepts 
surrounding cellular organisms (i.e. replication origin, promoters) using simple bacterial 
systems such as E. coli. These rapidly growing prokaryotes are highly manipulable, both 
biochemically and genetically, making them favourable tools in recombinant DNA 
technology (Botstein and Fink 1988). This feature allowed researchers to associate gene 
structure with protein and biological function. While bacteria share many fundamental 
properties of other organisms (i.e. genes, mRNA; ribosomal protein synthesis) they lack 
features of higher order eukaryotes such as subcellular organelles, nuclear compartment 
and alternative splicing (Botstein and Fink 1988). Complex multicellular organisms 
present inherent problems such as genetic tractability, slow growth rates, large genome 
and cell specialisation, thereby prohibiting the direct application of classical bacterial 
molecular genetics (Botstein and Fink 1988) Given these differences, bacteria 
undoubtedly did not fit the role of a model organism for higher eukaryotes, a role, which 
instead could be filled by yeast.  
Saccharomyces cerevisiae, commonly known as budding or baker’s yeast is a 
simple eukaryotic organism carrying the same level of genetic manipulability as bacteria, 
but shares many similarities in its metabolism and cellular pathways as higher eukaryotes. 
Sequencing revealed the genome of S. cerevisiae to consist of approximately 12 million 
base pairs on 16 chromosomes coding for around 6000 genes (Goffeau A 1996).   
3.2 Histone deacetylase enzymes in yeast 
 
Yeast histone deacetylases consists of the Zn2+ dependent (Rpd3, Hda1; Hos1-3) 
and the NAD+ dependent (Sir2, Hst1-4) family of enzymes (Grunstein 2003). Microarray 
studies examining the effect of HDAC mutants on global histone acetylation identified 
Rpd3 and Hda1 as the primary HDACs in yeast, responsible for regulating numerous 
promoters throughout the genome (Robyr et al. 2002). Hos1 and Hos3, on the other hand, 
are largely responsible for deacetylating the locus of ribosomal DNA (Robyr et al. 2002), 
while Hos2 associated binding, in contrast to the actions of other HDACs, is required for 
gene activation (Wang, Kurdistani, and Grunstein 2002). The SIR silencing complex is 
responsible for reinforcing heterochromatin states around telomeric regions and the 
silent-mating type loci in yeast (Rusche, Kirchmaier, and Rine 2002). Sir2, a component 
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of this complex, deacetylates H4K16 to facilitate Sir3-dependent recruitment of Sir4 
(Rusche, Kirchmaier, and Rine 2002). Sir4 further promotes the binding of Sir2 and in 
turn forms a positive feedback loop repressing regional transcription (Rusche, 
Kirchmaier, and Rine 2002). Particularly, sir2 mutants displayed a loss in 
hypoacetylation in regions near the telomere compared to wild type (Kimura, Umehara, 
and Horikoshi 2002).  
3.3 Use of HDAC inhibitors in yeast 
 
Histone deacetylase inhibitors have been used in yeast to study the effect on 
transcription, demonstrating similar changes in gene expression profile as the HDAC 
mutant rpd3Δ (Bernstein, Tong, and Schreiber 2000). The hydroxamate Trichostatin A 
(TSA) has been shown to alter transcription in yeast in a concentration dependent manner 
from 10nM to 31.25μM (Bernstein, Tong, and Schreiber 2000; Wan et al. 2011), while 
members of the short-chain fatty acids, such as sodium butyrate and valproic acid, have 
previously been shown to disrupt cell growth at concentrations of 60mM and 100mM, 
respectively (Nguyen et al. 2011; Mitsui et al. 2005). The demonstrated effect of HDAC 
inhibitors in yeast should allow for comparable observations to be made in this study. 
3.4 Chapter aims 
 
With the ChIP-chip method previously established in yeast (Teng et al. 2011), the 
aim of this chapter is to use a genome-wide approach to model the DNA damaging effects 
of HDAC inhibitors. To achieve this, an HDAC inhibitor will be selected for use which 
demonstrates an effect at the epigenetic level in yeast cells. The effect of the drug on 
genome-wide acetylation along with markers of transcription and replication as well as 
phospho-H2A, a marker of DNA damage, will be examined. Comparison of these results 
are expected to provide further insights into whether HDAC inhibition may lead to an 
increase in the frequency of transcription-replication conflicts and DNA damage, central 
to the hypothesis presented in this thesis. Results obtained in the yeast model are aimed 
at providing a greater insight into the possible actions of HDAC inhibitors in the ensuing 
humans studies.  
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3.5 Effect of HDAC inhibitors on the growth of yeast cells 
 
Studies in the literature have reported varying levels of success in demonstrating 
the effects of HDAC inhibitors in yeast cells (Carmen, Rundlett, and Grunstein 1996; 
Alonso and Nelson 1986; Vu Q.A 1987). Therefore, the initial aim is to utilise an HDAC 
inhibitor at concentrations previously reported which showed an effect in yeast (as 
described above in section 3.3). As such, the exact type or class of pan-inhibitor used here 
is unimportant.    
To first examine the response of S. cerevisiae BY4742 (budding yeast) strain to 
the various HDAC inhibitors, the effect on cell growth was measured as an indicator of 
general toxicity. HDAC inhibitor compounds were selected based on their use in 
literature. Concentrations used here were the highest reported for each compound where 
possible, to ensure that an effect could be observed. By comparison, HDAC inhibitor 
concentrations in yeast are several magnitudes higher that those used in mammalian cell 
lines, possibly to overcome barriers to uptake presented by the cell wall. Wild-type cells 
were independently treated with HDAC inhibitors at the beginning of the exponential 
growth phase (Figure 3.1, asterisk) and changes in optical density (OD600) were monitored 
every hour for 7 hours.  
Following treatment, 100mM Valproic acid (VPA) completely inhibited cell 
growth. Sodium butyrate (Na-B) treatment has an intermediate effect on cell growth at 
100mM (Figure 3.1). Trichostatin A (TSA) on the other hand, showed less of an 
inhibitory effect on cell growth, although the concentration used here is significantly 
lower in comparison with the other inhibitors (Figure 3.1). Together these results show 
that treating yeast cells with a range of HDAC inhibitors impedes cell growth.  
3.6 Effect of HDAC inhibition on histone acetylation 
 
Having demonstrated the cytotoxicity of HDAC inhibitors in BY4742 cells, the 
effect on histone acetylation was examined. The yeast histone deacetylases RPD3 and 
HDA1 are Trichostatin A-sensitive and deletion of these HDACs leads to global and site-
specific increase in histone H3 and H4 acetylation. Therefore, similar observations are 
expected when treating yeast cells with HDAC inhibitors. To test this, cells were treated 
with the HDAC inhibitors under the conditions previously used in the growth assay 
(Figure 3.1). Independent cultures of log phase cells (OD600 = 0.4) were incubated in the 
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Figure 3.1. HDAC inhibitors inhibit the growth of yeast cells. Cells entering the exponential 
growth phase (*) were treated with the selected HDAC inhibitors and OD600 measurements taken 
every hour are plotted over the course of 7 hours. Untreated (blue), Red –TSA (red) – Trichostatin 
A, Na-B (green) – sodium butyrate; VPA (purple) – valproic acid. Error bars as standard error of 
the mean, n = 3. (Raw data available in Appendix, I). 
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presence of each HDAC inhibitor for 1h and whole cell lysates were prepared for western 
blotting. The effect of HDAC inhibitor treatment on global H4K12ac was measured and 
normalised against α-tubulin using densitometry (Figure 3.2B). In comparison to the 
positive rpd3Δ control, which showed a 4-fold higher H4K12ac than the wild type, 
treatment with HDAC inhibitors did not show any significant effect on global H4K12ac 
compared to rpd3Δ (Figure 3.2B). 
Given that the level of H4K12ac in rpd3Δ was only 4-fold higher over the wild 
type, it is conceivable that HDAC inhibitors produced a more subtle effect on histone 
acetylation in comparison to the HDAC mutant. To examine this, changes in histone 
acetylation at specific loci sensitive to either RPD3 or HDA1 deletion was measured using 
quantitative-PCR (qPCR) in response to the HDAC inhibitor sodium butyrate. The ability 
of sodium butyrate to inhibit RPD3 and HDA1 was assessed by monitoring increases in 
H4K12 and H3K9 acetylation at the INO1 and GAL1 gene, respectively. To do this, 
chromatin was first prepared by harvesting and fixing exponentially growing yeast cells 
in formaldehyde. Fixed cells were then lysed in buffer and chromatin was fragmented to 
an average size of 500bp using an ultrasound sonicator (Chapter II, 2.2.5.1). The protein-
DNA crosslinks were reversed from the DNA by de-crosslinking overnight at 65oC and 
the protein removed by addition of pronase (Sigma-Aldrich Company Ltd, Gillingham, 
UK). The extent of fragmentation was checked on an agarose gel following 
electrophoresis of the purified DNA sample (Chapter II, 2.1.6.1). Of the different cycles 
tested, 4 x 30s alternating on/off at ‘High’ settings was determined as the optimal cycle 
number to achieve the desired fragment size of 500bp, which is required for efficient 
immunoprecipitation (Figure 3.3). Next, 0 - 5μg of the anti-H4K12ac and anti-H3K9ac 
antibody was titrated with 200μl of sonicated chromatin. The right arm telomeric region 
of chromosome VI (TEL06R) was used as a negative control locus, since these regions 
are hypoacetylated in wild type yeast (Suka et al. 2001). The ability of each antibody to 
enrich for its target at the positive loci (anti-H4K12ac at INO1; anti-H3K9ac at GAL1) 
compared to the negative loci (TEL06R) demonstrates its suitability to distinguish the 
acetylation status of these loci (Figure 3.4A). From the titration experiment, 2μg was 
identified as the optimal amount of anti-H4K12ac, showing 15-fold higher enrichment at 
INO1 locus compared to TEL06R (Figure 3.4A). Likewise, 3μg was identified as the 
optimal amount of anti-H3K9ac, showing 35-fold higher enrichment at GAL1 locus 
compared to TEL06R (Figure 3.4A). Having prepared chromatin from wild type yeast 
and shown that both antibodies work for ChIP, the effect of sodium butyrate treatment  
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Figure 3.2. Treating yeast cells with HDAC inhibitors has no effect on global H4K12 
acetylation. A: changes in global H4K12 acetylation was examined by probing whole cell 
extracts of untreated, rpd3Δ and HDAC inhibitor treated cells with anti-H4K12ac antibody. 
Detection of α-tubulin was carried out as a normalising control. B: fold-change in H4K12ac signal 
calculated as a ratio over α-tubulin and normalised to the untreated sample. TSA – Trichostatin 
A, Na-B – sodium butyrate; VPA – valproic acid. Band intensities are quantified using 
densitometry (Image J). n = 2. (Raw data available in Appendix, I). 
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was then examined. Figure 3.4B shows that in response to 100mM sodium butyrate no 
increase in H4K12ac at the INO1 gene and H3K9ac at the GAL1 gene is observed, relative 
to the untreated cells. Together with the results of the western blot analysis this indicates 
that the HDAC inhibitors tested have no significant effect on histone H4K12 and H3K9 
acetylation.  
3.7 The effects of HDAC inhibition on gene expression 
 
Another major hallmark of HDAC inhibitors is their ability to induce changes in 
gene expression due to changing histone acetylation. While treatment with an array of 
HDAC inhibitors appeared to have no significant effect on histone H3K9 and H4K12 
acetylation levels, efforts to further examine the effect on gene expression were made by 
attempting to reproduce the results of a more recently published finding. Wan et al. used 
DNA microarrays to identify global changes in transcription in response to TSA in a yeast 
strain of the same genetic background (BY4742). This effectively allows relevant 
comparisons to be made with the current study and for this reason TSA will be used here 
onwards. Select genes showing varying degrees of fold change were chosen from the 
results of the microarray study conducted by Wan et al. as the objective of this study 
(FRE1, FRE7 and CTR1) and normalised to the same reference gene (ACT1). 
Additionally, the experiment was performed exactly as described, using the same primer 
sequences and treatment regimen (10μM TSA, 1h in YPD under standard yeast culture 
conditions) (Wan et al. 2011).  
In order to measure changes in these gene transcripts, total RNA was first isolated 
from log phase cells treated with 10μM TSA for 1h. As an initial assessment of yield and 
purity, the absorbance of samples was measured on a NanoDrop spectrophotometer 
(Thermo Scientific, Hempstead, UK) at 230, 260 and 280nm. Nucleotides absorb at 
260nm, while contaminating protein and carbohydrates absorb at 230nm and 280nm, 
respectively. Therefore, the ratios of these are commonly used to assess sample purity. In 
addition, uracil has a higher absorbance at 260nm compared to thymine and so an A260/280 
ratio of ~2 is generally considered pure for RNA, whereas a ratio of ~1.8 is considered 
pure for DNA. The A260/230 is also expected to be higher than the A260/280 for samples free 
of residual contamination. Moreover, the integrity of extracted RNA in the sample is 
indicated by the presence of two distinct 26S and 18S ribosomal RNA bands when 
examined by denaturing gel electrophoresis. Total RNA was extracted from yeast cells  
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Figure 3.3. Sonicated whole cell chromatin prepared from wild type yeast cells. Whole cell 
chromatin extracted from wild type yeast cells are fragmented using an ultrasound sonicator at 4, 
6, 8 and 10 cycles of 30s on/off. Samples were de-crosslinked and DNA resolved by gel 
electrophoresis showing the fragment sizes achieved at each cycle. unson – unsonicated 
chromatin. Representative image shown. 
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Figure 3.4. Treating yeast cells with sodium butyrate does not lead to an increase in histone 
acetylation at INO1 and GAL1 genes. A: titration using 0 - 5μg of anti-H4K12ac and anti-
H3K9ac antibodies, showing enrichment at positive loci, INO1 and GAL1, relative to the negative 
control loci, TEL06R. n = 1. B: no hyperactylation detected at predicted loci in response to 
100mM sodium butyrate. n = 2. (Raw data available in Appendix, I). 
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using the hot acid phenol method (Chapter II, 2.2.7), demonstrating high yield, an A260/280 
above 2 (Table 3.1) and intact RNA bands (Figure 3.5). Apart from the presence of these 
bands, the ratio (derived from the nucleic acid size) is also commonly used as an indicator 
of integrity. The theoretical ratio between 26S (~3.8kbp) and 18S (~2kbp) is ~1.9 (3.8/2) 
(Agilent Application Note 2005). To investigate this, different amounts of RNA were 
loaded on a denaturing gel and the intensities of the two bands clearly observed bands at 
3μg was selected for quantification (Figure 3.5). The average 26S:18S ratio quantified 
from 3 independent extractions was estimated to be ~1.3, slightly lower than the expected 
ratio (Figure 3.5). A smaller band/smear is visible below the 18S band when larger 
amounts of the sample are loaded (Figure 3.5), possibly representing smaller RNA species 
or degraded RNA. Though, a lack of smearing between the 26S and 18S bands indicates 
an overall high RNA integrity within the extract (Figure 3.5). Together these results show 
that RNA of high quality can be effectively isolated from yeast cells which can be used 
subsequently to generate complementary DNA (cDNA). 
In order to perform reverse transcription quantitative PCR (RT-qPCR) analysis of 
these transcripts by exploiting the ability of DNA polymerase to exponentially amplify 
DNA, mRNA is first converted into cDNA through the process of reverse transcription 
(Chapter II, 2.2.8). During this process, multiple copies of cDNA are produced from the 
mRNA templates, yielding ~900ng/μl of cDNA from a starting concentration of ~25ng/μl 
total RNA (Table 3.1). Moreover, a shift in the A260/280 ratio from ~2 to ~1.8 indicated the 
presence of mostly DNA in the sample. Next, the optimal annealing/extension 
temperature for each set of primers (FRE1, FRE7, CTR1 and ACT1) was calculated by 
running a temperature gradient (50 - 650C) and melt curves were assessed for any non-
specific amplification. The efficiency of the qPCR reaction was calculated to be > 90% 
for all primers across a template concentration ranging from 16pg - 10ng. The relative 
abundance of each transcript was then measured using RT-qPCR and normalised to ACT1 
(Chapter II, 2.1.6.4). Following treatment with 10μM TSA, the mRNA levels of FRE1, 
FRE7 and CTR1 showed no significant change relative to ACT1 (Figure 3.6B). These 
results are also not comparable with the findings reported by Wan et al., where FRE1 
showed a 2.5-fold decrease in mRNA levels after TSA treatment (Figure 3.6A). To 
investigate if a higher dose may lead to greater changes in transcript levels, cells were 
treated with 50μM TSA. However, increasing the TSA dose by 5-fold also did not result 
in a further decrease in transcript levels (Figure 3.6B). Therefore, the experiment 
conducted here to measure and compare the effect of treating yeast cells with TSA on the  
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Figure 3.5. Successful extraction of total RNA from yeast. Successful isolation of total RNA 
using the hot acid phenol method. Denaturing gel electrophoresis of extracted total RNA, showing 
the expected 26S (~3.8kbp) and 18S (~2kbp) yeast ribosomal bands. The average 26S:18S ratio 
estimated at 1.3 using densitometry for 3 biological replicates.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.1. Spectrophotometer sample readings before and after reverse-transcription. Pre-
RT: RNA extracts prepared using hot acid phenol method for untreated and 10μM TSA treated 
cells. A260/280 ~2 indicates the presence of RNA. Post-RT: spectrophotometer readings following 
reverse transcription using 500ng total RNA shows an A260/280 ~1.8 indicating the successful 
conversion of RNA to cDNA. 
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Figure 3.6. Effect of TSA on the transcription of select genes is inconsistent with published 
findings. A: Yeast genes showing the greatest change in mRNA expression in response to 10μM 
TSA from the microarray study as validated by Wan et al (Wan et al. 2011). B: Changes in FRE1, 
FRE7 and CTR1 mRNA, normalised to ACT1 mRNA, in response to 10μM TSA measured in the 
current study using methods described by Wan et al. Additionally 50μM TSA was also examined. 
Error bars as standard error of the mean, n = 3. (Raw data available in Appendix, I). 
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expression of certain genes reported in the literature did not find evidence for any 
significant changes to gene expression. Overall, these results show that in the current 
study, HDAC inhibitors have no measurable effect on chromatin-associated events, 
thereby lacking evidence to support their use in the yeast model. 
3.8 Discussion 
  
With the aim of trying to understand how HDAC inhibitors induced DNA 
damage, the initial aim was to conduct genome-wide measurements of its effects on 
histone acetylation, transcription, replication and the DNA damage response in the yeast 
model organism.  
A panel of HDAC inhibitors was selected based on published work citing their 
use in yeast to study their potential to illicit DNA damage. Short-chain fatty acids such 
as sodium-butyrate and valproic acid both inhibit the growth of yeast cells (Nguyen et al. 
2011), while the hydroxamic acid Trichostatin A has been shown to affect mRNA 
expression in yeast (Wan et al. 2011). To demonstrate the effects of selected HDAC 
inhibitors in the commonly used BY4742 yeast strain, their ability to affect normal cell 
growth was measured as an indicator of general cytotoxicity (Figure 3.1). The ability of 
selected HDAC inhibitors to inhibit cells growth shown here indicates that these 
compounds are cytotoxic in yeast and is consistent with studies done in human cell lines 
where they are described as potent cytotoxic agents (Bose, Dai, and Grant 2014). The 
yeast cell wall has been known to pose a barrier towards entry for many chemicals, given 
the initial observations of cytotoxicity this does not appear to be a problem for the HDAC 
inhibitors tested here.  
In the main interest of trying to understand how epigenetic changes can lead to 
genetic damage, the effect of HDAC inhibition on histone acetylation was investigated. 
Both in vitro and in vivo studies have shown that a major hallmark of HDAC inhibitors 
is their ability to elicit hyperacetylation of lysine residues on histone tails (Bose, Dai, and 
Grant 2014). The yeast HDACs Rpd3 and Hda1 are described as Trichostatin A-sensitive 
and RPD3 mutants show the greatest increase in acetylation at H4K5 and K12. Therefore, 
HDAC inhibitor treatment is expected to inhibit the activities of both Rpd3 and Hda1, 
leading to an increase in histone acetylation. However, treating yeast cells with HDAC 
inhibitors did not show a higher level of global H4K12 acetylation measured by western 
blotting (Figure 3.2). It is possible that the effects of drug treatment are much subtler 
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compared to the rpd3Δ strain. Therefore a more sensitive approach was taken, using 
chromatin immunoprecipitation (ChIP) and qPCR, to study the INO1 gene, which is 
hyperacetylated at H4K12 in RPD3 mutants (Rundlett et al. 1998) and similarly GAL1, 
hyperacetylated at H3K9 in HDA1 mutants (Wu J 2001). ChIP experiments using the anti-
H4K12ac and anti-H3K9ac antibodies (Figure 3.3) showed enrichment at the expected 
INO1 and GAL1 genes, respectively (positive control loci), compared to the telomeric 
region (TEL06R), which is hypoacetylated in wild type cells (negative control loci) (Suka 
et al. 2001) (Figure 3.4A). However, comparing H4K912ac at INO1 and H3K9ac at GAL1 
between untreated and 100mM sodium butyrate treated cells showed no increase in 
acetylation at these sites for two biological repeats (Figure 3.4B). In both yeast and human 
cells, HDAC mutants and HDAC inhibitor treatment share common features such as 
slower/inhibited growth and global increase in histone acetylation. While HDAC 
inhibition impeded yeast cell growth (Figure 3.1), an increase in histone acetylation was 
not observed (Figure 3.2 and Figure 3.4). It is unclear to what extent, if at all, Rpd3 and 
Hda1 are inhibited by the concentration of drugs used here since the affinities of these 
drugs for yeast HDAC enzymes have not been reported. Histone hyperacetylation is a 
well-known phenomenon linked to HDAC inhibition and has been described in fission 
yeast treated with Trichostain A (Ekwall et al. 1997). It is possible that under the treatment 
conditions presented here, increases in global histone acetylation are subtle and difficult 
to reproduce when western blots are analysed by densitometry. While ChIP is a more 
sensitive technique by comparison, histone acetylation at INO1 and GAL1 has not been 
studied previously in response to sodium butyrate and may therefore be different from 
that observed in RPD3 and HDA1 mutants. Reports also cite the induction of histone 
acetylation when spheroplasts (yeast cells with the cell wall removed), are treated with 
10μM TSA (Carmen, Rundlett, and Grunstein 1996). It is unclear if removal of the yeast 
cell wall was required for detecting the chromatin-associated effects of TSA in this case, 
but generating spheroplasts severely compromises cell integrity and was therefore not 
performed here in this study. Interestingly, another study did not find any changes in 
histone acetylation when 2μM TSA was added to whole cell budding yeast, isolated yeast 
nuclei, spheroplasts or even crude cell extracts (Alonso and Nelson 1986). An increase in 
histone acetylation was only noted when partially purified histone deacetylases were 
treated with TSA (Alonso and Nelson 1986). The authors suggest that the organisation of 
HDACs in multi-protein complexes may obscure the drug-binding site and only revealed 
following purification (Alonso and Nelson 1986). Similar studies also support this 
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showing that the short chain fatty acid n-butyrate has no effect on deacetylase activity in 
yeast in vitro (Vu Q.A 1987). It is possible that such contradictory observations stem from 
a combination of using different yeast strains as either whole cells or manipulated in some 
way. Additionally, the techniques used to detect changes in response to HDAC inhibition 
vary, ranging from radiolabelling of HDAC substrates to immunostaining.   
In light of this, focus was turned towards a more recent study showing changes in 
the transcriptomic profile elicited by Trichostatin A (Wan et al. 2011). Since the 
experiment was conducted using the same yeast strain (BY4742) the results of their study 
would be comparable. The experiment outlined by Wan et al. was repeated as described 
and the expression of FRE1, FRE7, CTR1 and ACT1 mRNA in response to 10μM TSA 
was selected for analysis in this study (Figure 3.6A) (Wan et al. 2011). Following the 
extraction of RNA (Figure 3.5) and conversion to cDNA (Table 3.1), qPCR analysis 
showed that the results of the published data could not be reproduced here in this study 
(Figure 3.6). When normalised to the same ACT1 control the levels of FRE1, FRE7 and 
CTR1 did not show a considerable change (Figure 3.6B). Additionally, increasing the 
dose of TSA to 50μM also had no effect on the expression of these genes (Figure 3.6B). 
Interestingly, genes selected for qPCR validation in the published study represented those 
that displayed the greatest change in response to TSA from microarray analysis (Wan et 
al. 2011). Amongst these FRE1 showed a 2.7-fold decrease in mRNA relative to ACT1 
and was the greatest difference reported (Figure 3.6A), suggesting that in their studies the 
effects of 10μM TSA on mRNA expression is very subtle. Arguably, for such subtle 
changes in expression, genes measured here can be normalised to the geometric means of 
several internal control genes, which may improve the sensitivity (Carmen, Rundlett, and 
Grunstein 1996). However, collectively the data presented here suggests that while 
HDAC inhibition can inhibit the growth of budding yeast, no significant changes in global 
or gene specific histone acetylation is observed. Additionally, changes in mRNA 
expression presented in published data could not be reproduced. Therefore, under the 
conditions of the current study, of the drugs tested, it is possible that HDAC inhibitor-
induced cytotoxicity is a result of its actions in the cytoplasm and that these compounds 
are unable to exert its effects on chromatin.  
Even though chemical means of inhibiting HDAC enzymes proved unsuccessful, 
the fact that rpd3Δ cells show a higher level of histone acetylation compared to the wild 
type, allows for an alternative genetic approach to be taken using yeast to address some 
of the issues raised in human studies (Chapter V).  
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Chapter IV – Establishing the ChIP-chip methodology for TK6 cells as a genome-
wide assay to measure the genotoxic effects of HDAC inhibitors  
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4.1 TK6 as a model cell line  
 
As chemical inhibition of HDACs in yeast proved technically challenging, 
parallel work undertaken to establish the ChIP-chip method in TK6 cells is reported in 
this chapter. The aims are to set the foundations for examining the mechanisms of HDAC 
inhibitor-induced DNA damage in mammalian cells by focusing on optimising and 
validating the ChIP-chip assay for the human TK6 B lymphoblastoid cell line. Given the 
role played by HDACs in regulating chromatin architecture, it is likely that changes in 
cellular processes that rely heavily on histone acetylation, may be the cause of genome 
instability. Therefore, to question how epigenetic mechanisms can affect these changes 
in humans, existing ChIP-chips developed in the lab for yeast needs to be established in 
a relevant human cell line.   
 While many different types of cell lines exist, for the purposes of examining the 
genotoxic effects of HDAC inhibitors, it is important to use cells capable of displaying a 
normal DNA damage response through the expression of a fully functioning p53 pathway. 
Surmounting evidence has also stressed the importance of using p53 competent cells to 
reduce ‘false positive’ results in genotoxicity testing (Fowler et al. 2012). The 
immortalised human TK6 B lymphoblastoid cell line stably expresses wild-type p53 (Xia 
et al. 1995) and was originally derived from Epstein-Bar transformed WI-L2 spleen 
lymphoblasts (Levy, Virolain.M, and Defendi 1968).  
 Further to this, the pan-HDAC inhibitor Trichostatin A has demonstrated 
genotoxic effects in TK6 cells (Olaharski et al. 2006). These include: (i) early induction 
of γH2A, (ii) increase in chromosome breaks and (iii) micronuclei formation (Olaharski 
et al. 2006). Such effects are widely described in other cell lines and are characteristic of 
HDAC inhibitors (Yoo and Lee 2005). Together with the described p53-proficiency and 
its application in genotoxicity testing, these features make TK6 cells an ideal candidate 
cell line for use in this study.   
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4.2 Use of small molecule inhibitors to determine the status of TP53 
 
The tumour suppressor protein p53 is a crucial determinant of genetic integrity, 
preventing the proliferation of cells that may be carrying mutations as a result of DNA 
damage and stress. Under physiological conditions, p53 is constantly expressed in cells, 
which consequently upregulates the E3 ubiquitin ligase Mdm2 (mouse double minute 2 
homologue) (Momand et al. 1992). Mdm2, in complex with the transcriptional co-
activator p300/CBP, polyubiquitinates p53 for proteasomal degradation (Momand et al. 
1992). Therefore, p53 is very unstable in unstressed cells owing to the negative 
autoregulatory mechanism. Cells harbouring mutant p53 lose the ability to maintain the 
feedback loop and as a result display high levels of inactive p53. Small molecule 
inhibitors of Mdm2 such as nutlin-3 were originally developed to reactivate p53 in human 
cancers still retaining wild type p53 (Shangary and Wang 2009). Its inhibitory effect leads 
to apoptosis and is exclusively dependent on the presence of wild type p53. Based on this, 
clinical proposals have been put forward for using nutlin-3 as a fast and efficient means 
of screening cells with TP53 mutations, evaluating the induction of apoptosis as the end 
point (Pozzo et al. 2013). Therefore, this method can similarly be used in this study to 
validate the TP53 status of TK6 cells.  
4.3 Challenges of mammalian ChIP-chip 
 
 ChIP-chip has been utilised in a variety of different organisms to estimate the 
genome-wide locations of chromatin-associated events. While general methods have been 
published (Lee, Johnstone, and Young 2006), these are only sufficient to describe certain 
protocols. The differences in cell type and sonication equipment used, requires that 
optimal conditions are established for the specific cell line used. In addition, this process 
can be particularly challenging for mammalian cells due to the complexity of the human 
genome (Lee, Johnstone, and Young 2006). Several key steps such as crosslinking, 
sonication and antibody washes require most attention, as these variables tend be crucial 
for the experiment to succeed. Protein-DNA cross-linking using formaldehyde (FA) for 
too long can result in protein aggregation and denaturation while insufficient fixing can 
lead to inefficient protein capture (Lee, Johnstone, and Young 2006). Arguably, the 
fixation step can be avoided when studying histone modifications, since histones proteins 
are tightly bound to DNA. However, it is recommended to introduce FA cross-linking as 
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some genomic regions can undergo nucleosome rearrangements during chromatin 
preparation in the absence of FA. For microarray analyses, chromatin should ideally be 
fragmented to a range of 200-1000bp with an average of 500bp, to provide the optimal 
signal resolution. Sonication greatly depends on the type of equipment, cell type, cell 
density, chromatin concentration and volume. Under-sonicated chromatin consists of 
large DNA fragments which do not hybridise well to the array, on the other hand, over-
sonicating chromatin can damage epitopes. Following immunoprecipitation, washing the 
superparamagnetic bead-bound antibody is necessary to remove non-specific binding, 
though the number of washes and salt concentration used is entirely dependent on the 
antibody. The success of a ChIP assay is frequently determined by measuring enrichment 
at specific gene(s) where the target of interest is known to be bound (positive control loci) 
along with a region where it’s not bound (negative control loci) using qPCR. 
Consequently, troubleshooting a failed ChIP experiment can be challenging due to a lack 
of endpoints and contributions from multiple factors. 
4.4 Whole human chromosome 17 microarrays 
 
 With the intention of measuring biological events such as histone acetylation, 
transcriptional elongation and replication that span large regions of chromatin, the use of 
arrays with features representing continuous sections of the genome is preferred. In 
addition, the Agilent array platform has proven performance in past studies conducted in 
yeast (Powell 2014b) and forms a seamless workflow with the ‘Sandcastle’ R-package. 
For these reasons, Agilent SurePrint G3 2x400K arrays were custom designed to cover 
whole human chromosome 17 (hg19) (Chapter II, 2.1.7.7). The inclusion of TP53, located 
on the short arm of chromosome 17 (17p13.1), would also serve as a useful control gene 
in this context. Juan and colleagues presented evidence for the involvement of HDAC 
enzymes in supressing p53 transcription (Juan et al. 2000). Later studies conducted by 
Sonnemann and others confirmed this by detecting an increase in p53 expression, 
normally triggered in response to DNA and/or cellular stress, in the presence of the 
HDAC inhibitor Vorinostat (Sonnemann et al. 2014), which is a synthetic TSA derivative. 
Therefore, based on the expected increase at TP53 following HDAC inhibition and the 
‘known’ pattern of RNA Pol II (pSer2) occupancy (Hsin JP 2012), mapping transcription 
across chromosome 17 can be used as a means of validating the ChIP-chip assay in TK6 
cells.  
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4.5 Chapter aims 
 
 In the interests of understanding how HDAC inhibitors generate DNA damage for 
the purposes of human risk assessment, this chapter aims to establish and validate the 
ChIP-chip assay in a suitable human cell line, such as TK6 lymphoblasts. Continuing on 
from the previous yeast chapter where attempts to demonstrate the effects of HDAC 
inhibition were largely unsuccessful, it will therefore be important to show some of the 
primary effects of HDAC inhibitors in the newly introduced human cell line. The outcome 
of this chapter will be an optimised human cell line-specific ChIP-chip protocol that can 
then be applied to make the necessary measurements to test the main hypothesis set out 
by the thesis. 
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4.6 Confirming the p53 proficiency of TK6 cells  
 
 Since the focus lies in trying to understand how HDAC inhibitors induce DNA 
damage, it is important that cells can respond to DNA damage in a normal manner. 
Therefore, the TP53 status of TK6 cells used in this study was first assessed by measuring 
apoptosis in response to nutlin-3. For comparison, the p53-mutant MDA-MB-231 breast 
cancer cell line (Hui et al. 2006) and the p53-null PC3 prostate cancer cell line (Scott, 
Earle, and Gumerlock 2003) were selected as negative controls. Apoptosis was measured 
using Annexin-V (Chapter II, 2.1.4.1), which has a strong Ca2+-dependent affinity for 
phosphatidylserine residues externalised on the plasma membrane during the onset of 
programmed cell death. When treated with increasing concentrations of nutlin-3 (1μM, 
5μM; 10μM) for up to 48 hours, a significant increase in the number of cells expressing 
Annexin-V was observed in TK6 cells (P < 0.05, 5μM; P < 0.01, 10μM), indicating the 
onset of apoptosis (Figure 4.1A). In contrast to this, neither MDA-MB-231 nor PC3 cells 
showed noticeable changes in Annexin-V (Figure 4.1B; C). To further examine changes 
in the expression of p53, lysates prepared from cells treated with 10μM nutlin-3 for 24h 
were probed for p53 protein levels by immunoblotting (Chapter II, 2.1.5). An increase in 
p53 protein expression was observed only in TK6 cells and absent from PC3 cells lacking 
p53 (Figure 4.2). MDA-MB-231 cells expressed high levels of mutant p53 and were 
insensitive to the effects of nutlin-3 (Figure 4.1). Together these results demonstrate that 
TK6 cells used here are p53-proficient.  
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Figure 4.1. Nutlin-3 promotes apoptosis in TK6 cells. A: TK6 cells, with that of control cell 
lines B: MDA-MB-231 (p53 mutant) and C: PC3 (p53 null). Percentage of cells in population 
undergoing apoptosis quantified using flow cytometry, gating on populations staining positive for 
Annexin-V (early apoptosis) and Annexin-V + PI (late apoptosis). Statistical analysis (one-way 
ANOVA with Turkey’s Post-hoc analysis) was performed using SPSS v22.0. n = 3. *P < 0.05, 
**P < 0.01. Error bars as SEM. (Raw data in Appendix, II). 
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Figure 4.2. Immunoblot of p53 expression in select cell lines in response to nutlin-3. The 
expression of p53 was probed from whole cell extracts of cells treated with 10μM nutlin-3 for 
24h. Histone H3 was used as a loading control. 
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4.7 Examining the toxicity of TSA in TK6 cells to establish a suitable treatment 
regimen 
 
 Since previous attempts to use HDAC inhibitors in yeast proved unsuccessful, it 
is important to ensure that the effects of HDAC inhibition can be reproduced in the 
mammalian TK6 cell line. The toxicity of HDAC inhibitors are most pronounced 
following a 24h treatment, with cells showing a dose-dependent increase in DNA damage 
and cell cycle arrest (Olaharski et al. 2006). Particularly, Olaharski and others noted that 
the pan-HDAC inhibitor Trichostatin A induced a significant increase in micronuclei 
formation in addition to the number of cells arrested in G1 phase (Olaharski et al. 2006). 
While TSA proved ineffective in yeast cells due to various complications, it has been 
extensively used in a number of different mammalian cell lines with demonstrated effects 
(Mogal and Abdulkadir 2006; Finnin MS 1999; Cong et al. 2013; Hrebackova et al. 2009).  
Therefore, the aim was to first use an HDAC inhibitor such as TSA which has previously 
been used in TK6 cells (Olaharski et al. 2006) and demonstrate its genotoxic effects here 
in this study. Furthermore, this would also allow the establishment of a treatment regimen 
to study the mechanisms of DNA damage induction by HDAC inhibitors.  
 To do this, micronuclei (MN) formation and cell cycle changes were measured 
using the InVitro MicroFlow® assay (Chapter II, 2.1.4.3), which has comparable 
performance to the conventional micronuclei assay carried using microscopy (Collin J.E. 
et al.). Using the InVitro MicroFlow® assay, the percentage of cells in the population 
exhibiting micronuclei can be determined through SYTOX Green staining. Ethidium 
monoazide (EMA) binds to DNA of lysed cells and serves as an indicator of cell death 
and in combination with relative cell count (RCC) was used as indicators of cytotoxicity. 
Firstly, the InVitro MicroFlow® assay was validated using the aneugenic compound 
Vinblastine (Collin J.E. et al.). TK6 cells treated with increasing concentrations of 
Vinblastine for 24h showed a significant increase (P < 0.05) in the percentage of cells 
positive for MN for the two top doses (Figure 4.3A). In addition, the highest level of 
cytotoxicity observed did not exceed 30%. This confirms Vinblastine as a genotoxic agent 
and successfully validates the assay.  
Next, to examine ability of TSA to induce MN formation in TK6 cells as an 
indication of its genotoxicity, cells were subjected to increasing concentrations of the 
drug over a 24h period. TK6 cells treated with 313nM and 625nM TSA showed a 
significant increase in MN formation (P < 0.05, P < 0.01, respectively) (Figure 4.3A). 
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However, these doses also display a high level of cytotoxicity as shown by the reduction 
in RCC (⁓50%) and EMA negative cells (⁓60%) (Figure 4.3A). This shows that 
concentrations of TSA displaying genotoxicity occurs at the acceptable limit of 
cytotoxicity (55 ± 5%) ('OECD (2014). Test No. 487: In Vitro Mammalian Cell 
Micronucleus Test ').  Concurrently, analysis of the same EMA data showed that a 
significant proportion of TK6 cells were arrested in G0/1 with increasing concentration of 
TSA (P < 0.01) (Figure 4.4). Nevertheless, these results show that because TSA 
demonstrates borderline genotoxicity, measured using the InVitro MicroFlow® assay, it 
would not suitable to use such a treatment regimen for studying DNA damage induction. 
Therefore, to avoid this problem, a shorter treatment time point will be used.  
4.8 Examining the short-term effects of TSA in TK6 cells using induction of 
γH2AX as a marker of DNA damage  
 
Olaharski and others also reported in their studies that TSA was able to induce 
phosphorylation of histone H2AX Serine 139 (γH2AX), an epigenetic marker of DNA 
damage (Kuo LJ 2008), in TK6 cells within hours of treatment (Olaharski et al. 2006). 
Additionally, this coincided with the increase in histone acetylation, a hallmark of HDAC 
inhibitors (Zhou et al. 2000). Therefore, to examine these early effects, TK6 cells were 
treated with a fixed dose of TSA (400nM) across a range of time points leading up to 24h, 
with changes in histone H3 lysine 9 acetylation (H3K9ac) and γH2AX measured using 
flow cytometry (Chapter II, 2.1.4.2).  
Following 400nM TSA treatment, TK6 cells displayed an increase in H3K9ac up 
to 12h and decreased at 24h, with the H3K9ac response being most significant at 6h (P < 
0.05) and 12h (P < 0.01) (Figure 4.5A). In parallel with this, is a significant time-
dependent increase in γH2AX up to 24h (P < 0.01) (Figure 4.5B). This shows that TSA 
is able to provoke a significant effect on both histone acetylation and γH2AX in TK6 cells 
6h following treatment, which is consistent with those reported previously in the literature 
(Leea J.H 2010; Olaharski et al. 2006; Zhou et al. 2000).  
Next, to examine the extent of cytotoxicity induced over the 6h exposure period, 
TK6 cells were treated with TSA up to 400nM and changes in the Annexin-V levels, an 
early marker of apoptosis, and cell cycle G0/1 arrest were measured using flow cytometry 
(Chapter II, 2.1.4.1 and 2.1.4.4). In comparison to the vehicle control, TK6 cells treated  
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Figure 4.3. Trichostatin A shows high levels of cytotoxicty in TK6 cells following 24h 
treatment as measured using the In Vitro MicroFlow® assay. A: TK6 cells treated with 
Vinblastine for 24h was used to validate the In Vitro MicroFlow® assay. Significant increase in 
MN-induction at higher doses of 0.6mM and 1.2mM showing low levels of cytotoxicity (RCC 
and EMA negative) confirms that Vinblastine tests positive in the micronucleus flow assay, 
consistent with published findings (Collin J.E. et al.). B: TK6 cells treated with Trichostatin A for 
24h tested using the In Vitro MicroFlow® assay shows a significant increase in MN-induction at 
0.313mM and 0.625mM which coincides with high levels of cytotoxicity (≥50% RCC or EMA 
negative). DMSO used as a vehicle control. Statistical analysis (Dunnett's multiple comparison 
test) was performed using SPSS v22.0 on the %MN DATA. n = 3. *P < 0.05, **P < 0.01. Error 
bars as SEM. (Raw data in Appendix, II). 
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Figure 4.4. Trichostatin A induces G1 cell cycle arrest in TK6 cells following 24h treatment. 
EMA data from flow assay used to assess changes in cell cycle profile in response to TSA, 
showing an increase in G1 arrest P < 0.01 (Trend analysis). DMSO used as a vehicle control. n = 
3, Error bars as SEM. (Raw data in Appendix, II). 
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Figure 4.5. TSA increases global H3K9 acetylation and H2AX phosphorylation in TK6 cells. 
Nuclei from TK6 cells treated with TSA were extracted and stained with either A: anti-H3K9ac-
PE or B: anti-γH2AX-FITC conjugated antibodies and analysed by flow cytometry. Percentage 
population of cells staining positive for either antibody is shown. Statistical analysis (Dunnett's 
multiple comparison test) was performed using SPSS v22.0. *P < 0.05, **P < 0.01. Error bars as 
SEM, n = 3. (Raw data in Appendix, II). 
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Figure 4.6. Treating TK6 cells with 400nM TSA for 6h does not trigger early apoptosis or 
G1 arrest. Results of flow cytometry analysis showing A: no significant difference in percentage 
of cell population staining positive for Annexin V-FITC (P > 0.9), as a marker of apoptosis. 
Forward and side scatter gating was performed on DMSO treated cells. B: propidium iodide (PI) 
staining was used to examine changed in cell cycle profile and showed no significant increase in 
G1 phase cells in response to TSA (P > 0.4). Fold change calculated by normalising against the 
DMSO control. Statistical analysis (Dunnett's multiple comparison test) was performed using 
SPSS v22.0. Error bars as SE, n =3. (Raw data in Appendix, II). 
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with TSA for 6 hours showed no significant increase in Annexin-V up to a dose of 400nM 
(P > 0.9) (Figure 4.6A).  Similarly, no significant increase in G1 arrest was observed under 
the same conditions (P > 0.4) (Figure 4.6B). Together these results show that γH2AX 
detected at 6h using 400nM TSA is independent of cytotoxicity. Taken together, these 
results show that treating TK6 cells with 400nM TSA for 6h displays indications 
genotoxicity in the absence of cytotoxicity and therefore represents a suitable treatment 
regimen to be used for studying the mechanisms of HDAC inhibitor-induced DNA 
damage using genome-wide approaches. 
4.9 Optimising the ChIP-chip assay for TK6 cells  
 
4.9.1 Effect of formaldehyde fixation on sonication efficiency  
 
 Having demonstrated a clear cellular response to TSA, the next step was to 
optimise sonication conditions in which chromatin from TK6 cells can be reliably 
fragmented to an average size of 500bp. To test if fixation time affects sonication 
efficiency, untreated TK6 cells were fixed in formaldehyde for 5, 8 and 15mins before 
being sonicated at different cycles. Under these conditions the distribution of de-
crosslinked chromatin appears to be even at the higher cycles, ranging from genomic to 
100bp (Figure 4.7). Fixation time therefore does not appear to affect sonication but rather, 
other factors are preventing the chromatin from being sheared effectively.  
 
4.9.2 Investigating the effect of isolating nuclei to promote efficient shearing of 
TK6 cell chromatin  
 
 Inefficient cell lysis and a high cell density during sonication can potentially 
inhibit efficient chromatin shearing. To address the possibility that cells are not lysed 
properly prior to sonication, a ‘two-step’ lysis was adopted, which is sometimes used in 
commercial kits as opposed to the generally reported single-step lysis that uses a shearing 
buffer (Chapter II, 2.1.6). The results show a clear improvement in shearing from 10 – 30 
cycles, producing a dense collection of fragments just under 500bp (Figure 4.8A). The 
remaining pellet for samples sonicated for 15 and 30 cycles following high-speed 
centrifugation shows that most of the chromatin remains in the supernatant, with 
negligible loss (Figure 4.8A). 
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Figure 4.7. Effects of formaldehyde fixation time on shearing efficiency. TK6 cells were fixed 
in formaldehyde for 5, 8 and 15mins. Chromatin was then extracted and sonicated from 5 to 20 
cycles (30s on/off per cycle), before being de-croslinked at 65oC. DNA fragment sizes were 
analysed by gel electrophoresis using 1.2% agarose gels. M – NEB 100bp ladder; nd – non-
decrosslinked sample. 
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Figure 4.8. Cytoplasmic pre-clearing is required to efficiently shear chromatin from varying 
densities of TK6 cells. Following changes to the protocol, separating the cytoplasmic and nuclear 
lysis into two steps, A: chromatin can be successfully sheared using a range of cycles ranging 
from 10 to 30. Pellets gathered from samples sonicated for 15 (15'p) and 30 (30'p) cycles show 
negligible loss of fragmented chromatin. B: chromatin from TK6 cells can be sheared in different 
densities at a fixed volume of 100μl per 1.5ml tube. M – NEB 100bp ladder. 
 
 
 
 
 
 
 
Figure 4.9. 10 cycles yield the optimal fragment length at a density of 4x106 cells per tube. 
Chromatin sonicated using the 4x106 cells per tube for A: 4 – 10 cycles and B: 12 – 18 cycles. M 
– NEB 100bp ladder, U – unsonicated de-crosslinked sample.  
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 Provided that the lysis conditions are established, the maximum cell density 
allowed per tube in a fixed volume of buffer was investigated. Identifying the highest cell 
density that can be used would allow for greater numbers of cells to be processed each 
time. For 2, 3 and 4 million cells sonicated for 20 and 30 cycles, successful shearing was 
observed up to the highest density of cells tested (Figure 4.8B). To identify the optimal 
cycle that would yield an average fragment size of 500bp, different cycles were tested 
with a density of 4x106 cells per 100μl of shearing buffer. A decrease in fragment size 
was observed with increasing cycles, with the average desired fragment size achieved at 
10 cycles with no further reduction in fragment size when using more than 12 cycles 
(Figure 4.9). 
 
4.9.3 Assessing the reproducibility of shearing chromatin from TK6 cells 
 
 Further attempts to reproduce the shearing observed at 10 cycles however resulted 
in inconsistencies (Figure 4.10). To rectify this, the cell density used during sonication 
was reduced from 4x106 to 3x106, which previously was also shown to be viable (Figure 
4.8B). Since the cell density parameter has been altered, sonication cycle was re-
optimised (Figure 4.10B). Under the newly established conditions, 3x106 cells sonicated 
for 7 cycles produced the desired average fragment length and these results can be reliably 
reproduced between both technical (Figure 4.11A) and biological (Figure 4.11B) repeats.   
 
4.9.4 Examining the ability to enrich for RNA polymerase II (pSer2) using ChIP  
 
 Having successfully identified a robust means of fragmenting chromatin from 
TK6 cells to the optimal size required for ChIP, the ability to immunoprecipitate proteins 
of interest using the prepared material was assessed by enriching for RNA polymerase II 
phospho-serine 2 (RNA Pol II pSer2). The house keeping genes GAPDH and RPL10 were 
selected as positive control loci where RNA Pol II is known to bind (Aithal MG 2015). 
On the other hand, GAD1 and MYOD1 were used as negative controls. GAD1 encodes 
for glutamic acid decarboxylase that is responsible for the production of the inhibitory 
neurotransmitter GABA (γ-Aminobutyric acid) and is expressed only in neurons. 
Similarly, MYOD1 is required for muscle cell differentiation and therefore not expressed 
in TK6 cells. These two genes are often silenced in commonly used cell lines and serve 
as suitable negative control genes for RNA Pol II occupancy (Sigma-Aldrich 2006).  
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Figure 4.10. Sonicating with a high cell density affects reproducibility. A: two independent 
repeats at 10 cycles using 4x106 cells per tube shows variability in shearing. B: sonication cycles 
were re-optimised using a lower cell density (3x106 per 100μl per 1.5ml tube). M – NEB 100bp 
ladder, U – unsonicated de-crosslinked sample. 
 
 
 
 
 
 
 
 
 
 
Figure 4.11. Reducing cell density significantly improves the reproducibility of sonication. 
Chromatin from TK6 cells can be reliably sheared to the optimal length using 7 cycles at a density 
of 3x106 per tube, demonstrating reproducibility between A: technical and B: biological repeats. 
M – NEB 100bp ladder, U – unsonicated de-crosslinked sample. 
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RNA Pol II (pSer2) immunoprecipitation using chromatin from untreated TK6 
cells was carried out as described (Chapter II, 2.1.6) using the optimal antibody amount 
identified from a titration experiment (Appendix, II). Fold enrichment of RNA Pol II 
(pSer2) at each gene was calculated by dividing the IP (immunoprecipitated DNA) by the 
input (IN) (non-immunoprecipitated background) and normalised against the IgG control 
(raised in the same species but lacking antigen specificity). An average 50 and 70-fold 
enrichment in RNA Pol II (pSer2) was detected at GAPDH and RPL10 (Figure 4.12A). 
In contrast, the negative control loci GAD1 and MYOD1 showed less enrichment in 
comparison (Figure 4.12A), indicating that the immunoprecipitation experiment was 
successful in enriching for RNA Pol II (pSer2) at the expected genes and that the 
conditions for performing chip on TK6 derived chromatin were fully optimised. 
Following this, amplification of the ChIP DNA is required to generate enough 
material for microarray hybridisation. This is commonly done through PCR-based 
methods. Though the exponential nature of the technique can lead to bias if the ChIP’d 
DNA is of low quantity (< 10ng) (Sigma-Aldrich 2006). Since it is difficult to reliably 
quantify low nanograms quantities of DNA typically yielded from ChIP experiments, the 
ability to retain high RNA Pol II (pSer2) enrichment at positive control loci over negative 
control loci was investigated to determine if PCR amplification significantly alters 
representation of the original ChIP DNA. RNA Pol II (pSer2) immunoprecipitated 
samples were amplified following instructions provided by the GenomePlex® WGA2 kit 
(Chapter II, 2.1.7.1) and qPCR was performed to evaluate enrichment at the same control 
genes. Post-whole genome amplification analysis showed an overall reduction in RNA 
Pol II (pSer2) enrichment (Figure 4.12B). Particularly, a 2-fold decrease (50 to 25) at 
GAPDH and a 2.3-fold decrease (70 to 30) at RPL10 was observed (Figure 4.12). 
Additionally, the negative control loci also showed a drop in enrichment. However, RNA 
Pol II (pSer2) enrichment is still higher at the positive compared to the negative control 
genes. This suggests that even though the overall enrichment level may be less, the 
relative enrichment is still effectively maintained and therefore RNA Pol II (pSer2) 
occupancy patterns observed from microarray experiments would still reflect the original 
ChIP sample.  
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RNA Pol II (pSer2) enrichment pre-whole genome amplification  
 
F
o
ld
 R
N
A
 P
o
l 
II
 (
p
S
er
2
) 
en
ri
ch
m
e
n
t 
n
o
rm
al
is
ed
 t
o
 I
g
G
 (
IP
/I
N
) 
RNA Pol II (pSer2) enrichment post-whole genome amplification  
 
F
o
ld
 R
N
A
 P
o
l 
II
 (
p
S
er
2
) 
en
ri
ch
m
e
n
t 
n
o
rm
al
is
ed
 t
o
 I
g
G
 (
IP
/I
N
) 
A  
B  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12. Whole genome amplification retains relative RNA Pol II (phospo-Ser2) 
enrichment at select genes. A: Results of qPCR showing RNA Pol II (phospho-Ser2) enrichment 
at genes where occupancy expected (GAPDH and RPL10) verses gene where it’s not expected 
(GAD1 and MYOD1). n = 4. B: following amplification using the WGA2 kit (Sigma-Aldrich) the 
relative RNA Pol II (phospho-Ser2) enrichment is maintained between positive and negative 
control genes. n = 3. Error bars and SEM. (Raw data in Appendix, II). 
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4.9.5 Examining the quality of RNA Pol II (pSer2) ChIP-chip data 
 
 Next, to examine RNA Pol II (pSer2) occupancy in greater detail on chromosome 
17 in TK6 cells, IN and IP samples were differentially labelled with fluorescent dyes and 
hybridised onto the custom designed DNA microarrays (Chapter II, 2.1.7.2). After 48h, 
the microarrays are removed and scanned in an Agilent Type-C scanner. The fluorescent 
intensities of each probe on the array is captured and returned as an image file. To quantify 
this as relative IN and IP ratios, the image was analysed using the Agilent Feature 
Extraction software (Chapter II, 2.1.7.5). The final output is a large datafile containing 
the raw IP/IN log2 ratios of each probe in the array along with their identifiers (ie. Probe 
ID, ProbeName; GeneName).  
 Before further analysis can take place, the raw data must first be normalised. This 
is important as it minimises technical bias while allowing relative comparisons of 
biological differences to be made. To do this, the raw data file is loaded into Sandcastle, 
which is a software developed in the statistical programming language R, specifically for 
the purposes of normalising and analysing microarray data from two or more related 
experiments (Bennett 2015). Figure 4.13 illustrates the normalisation process 
implemented by ‘Sandcastle’ for the raw RNA Pol II (pSer2) array data generated from 
untreated and TSA treated cells. The raw data is visualised as a kernel density plot of 
IP/IN log2 ratios (x), verses density (y). This type of plot is an effective way of 
representing the overall distribution of the data. The two biological repeats of RNA Pol 
II (pSer2) array data from untreated cells are shown in red and black, while those from 
TSA treated cells are shown in green and blue, with highly reproducible data overlapping 
each other (Figure 4.13, raw). The next step is to remove redundant probe values in each 
dataset, for instance those that fail to generate an IP/IN log2 ratio (Figure 4.13, rmNAs).  
A key assumption of the normalisation process is that the background sub-
population (non-enriched array data) follows a standard normal distribution with the 
enriched sub-population (enriched array data) displaying higher than average IP/IN log2 
ratios and therefore tends towards the right-tail of the distribution (Bennett 2015). The 
normalisation process takes two stages, the first being quantile normalisation which 
imposes the same distribution on each of the biological repeats (Figure 4.13, Quantile). 
Secondly, the distribution of each dataset is shifted so that the centres of the densest 
distribution (background sup-population) aligns on the x = 0 axis (Figure 4.13, Shift: 
dashed line). In this case, as the RNA Pol II (pSer2) data gathered from untreated cells 
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are normalised with the data from TSA treated cells, the background sub-population of 
all four datasets are centred on x = 0 (Figure 4.13, Shift: dashed line).  Lastly scaling is 
used to control for variability arising in the microarray workflow (Figure 4.13, Scale), for 
instance differences in labelling and hybridisation efficiencies, array artefacts, changes in 
the environment. This is done by using all the probe values in the estimated background 
to adjust the remaining probe values so that the data follows a standard normal 
distribution (SND) with mean = 0 and standard deviation = 1 (Bennett 2015).  
 The ability of any two or more sets of data to be normalised together depends 
entirely on their background sub-populations being similar to that of a SND. Should this 
not be the case then comparisons would be restricted to binary rather than relative changes 
in signal, limiting the potential of the data. Therefore, to assess if the array data generated 
in untreated and TSA treated cells can be normalised together, a post-normalisation test 
is carried out to visually evaluate if: 1) the averaged data for a single treatment group 
satisfies the assumptions for normalisation, 2) the averaged data between two treatment 
groups satisfy the assumptions for normalisation.  
 To test the first assumption using the RNA Pol II (pSer2) array data, the quantiles 
of the data from untreated and TSA treated cells are compared independently against the 
SND as a Q-Q plot. Such plots are commonly used to check if the data collected follows 
a normal distribution. Figure 4.14A shows the normalised data for each treatment group 
with the mirrored background sub-population and the SND. In each case the left-hand 
side (x < 0) follows a SND, whereas the right-hand side (x > 0) deviates from the SND 
by a varying extent. This is therefore reflected in the Q-Q plots as the data that match the 
SND fall on the x = y line and those values that do not deviate significantly from the x = 
y line (Figure 4.14B). Typically, any data deviating from the SND on the right-hand side 
have higher IP/IN log2 ratios and represent biological signal. Moreover, since a greater 
deviation is observed in the data collected from TSA treated cells compared to that of 
untreated cells, this provides an early indication that there is an increase in RNA Pol II 
(pSer2) signal following TSA treatment (Figure 4.14B). Next, only the mirrored 
background sub-population data is compared to the SND in the Q-Q plot and since the 
majority of this data lie on the line, showing that the mirrored background sub-population 
is similar to the SND, the first assumption for normalisation are met (Figure 4.14C). 
Lastly, to test the second assumption and see if the RNA Pol II (pSer2) data from 
untreated and TSA treated cells can be normalised together, a Q-Q plot of the mirrored 
background sub-population data of each is compared. Figure 4.14D shows that since the  
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Figure 4.13. Normalisation procedure for RNA Pol II (pSer2) microarray data. Two 
biological replicates showing raw data from: untreated cells – black and red; TSA treated cells – 
blue and green. Raw – kernel densities of two raw biological repeats for each treatment condition 
shown in the same colour. rmNAs – raw data after removing probes with missing values. Quantile 
– biological repeats from the same treatment condition are quantile normalised together. Shift – 
aligns data from both treatment conditions to the central point of the background population. Scale 
– the standard deviation for the estimated background sub- population is adjusted to 1 for both 
datasets. 
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Figure 4.14. RNA Pol II (pSer2) microarray data meets the assumptions for normalisation. 
First dataset – from untreated cells. Second dataset – from TSA treated cells. A: density plots of 
the mirrored background approximating to the standard normal distribution (SND). B: density 
plots shown in A represented as Q-Q plots. Data in the background (shaded) region should closely 
follow the SND, whereas deviations of the right tail represents the enriched sub-population. C: 
Q-Q plot of only the mirrored background data. D: Q-Q plot of the mirrored background for both 
datasets. Little/no departure from the SND indicates that the two datasets are suitable to be 
normalised together. 
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Figure 4.15. Results of RNA Pol II (pSer2) chromosome 17 arrays are reproducible. 
Normalised IP/IN log2 ratios between two biological repeats of A: untreated TK6 cells and B: 
TSA treated (400nM, 6h) TK6 cells shown as smooth scatter plots. A high correlation was 
observed between biological repeats. The effect of atmospheric ozone on reproducibility 
demonstrated in C: technical replicates hybridised on different days and D: technical replicates 
hybridised on the same day. Pearson’s correlation calculated using functions in the base R 
package. x = y line shown in black. 
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background sub-populations of these two datasets are similar, they can effectively be 
normalised together allowing further in-depth analysis of the relative changes. Together 
these results show that successfully immunoprecipitated targets in human TK6 cells, such 
as RNA Pol II (pSer2) can be reliably mapped using the establish ChIP-chip protocol. 
Following this, correlation between replicates were analysed to determine if the 
results of the human microarrays are reproducible (Figure 4.15). For both experimental 
conditions tested, biological replicates showed a high degree of correlation (r > 0.8) 
(Figure 4.15A; B). To question the technical reproducibility of the arrays, labelled DNA 
from the first TSA treated sample was re-hybridised onto new arrays. Doing so showed 
that the technical replicates display a lower correlation (Figure 4.15C). As expected, 
microarray data tend to correlate better when post-hybridisation washes are carried out 
simultaneously (Figure 4.15A; B). To confirm this, an additional technical repeat using 
chromatin from TSA treated cells was performed. Matching samples were then hybridised 
and washed together, resulting in a higher correlation (Figure 4.15D), suggesting that 
external factors may contribute to the variability of the readout from the arrays. Together 
these results show that successfully immunoprecipitated targets, such as RNA Pol II 
(pSer2) occupancy, in human TK6 cells can be reliably mapped using microarrays. 
 
4.9.6 Validating chromosome 17 microarrays of RNA Pol II (pSer2) occupancy in 
TK6 cells  
 
 RNA polymerase II serine 5 and serine 2 phosphorylation are conserved marks of 
transcriptional initiation and elongation, respectively (Hsin JP 2012). RNA Pol II is 
phosphorylated at Serine 2 (pSer2) along the open reading frame (ORF) and ends of 
transcribed genes whereas Serine 5 is phosphorylated primarily at transcription start sites 
(TSS) (Hsin JP 2012). Given the distinct pattern of distribution, the average RNA Pol II 
(pSer2) occupancy was plotted +/- 1500bp relative to the ORFs of all genes on 
chromosome 17 for untreated TK6 cells (Figure 4.16). The observed pattern is consistent 
with what was expected (Hsin JP 2012), showing lower occupancy at the TSS compared 
to the ORF and downstream of the transcription end site (TES) (Figure 4.16).  
 To assess the impact of treating with TSA on RNA Pol II (pSer2) enrichment at 
TP53 gene, genome plots of untreated and TSA treated data are presented, showing an 
overall higher level of RNA Pol II (pSer2) binding following TSA treatment (Figure 
4.17A). The change in RNA Pol II (pSer2) enrichment at TP53 gene due to the effect of 
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TSA is illustrated by subtracting untreated data from treated data (Figure 4.17B). The 
relative increase in ‘elongating’ RNA Pol II (pSer2) at TP53 observed here is consistent 
with results presented by Sonnemann and others (Sonnemann et al. 2014) and may signify 
increased transcription of p53 as a result of genetic stress and or DNA damage. An 
alternative means of validating these results would be to make comparisons with those of 
published data available from the NCBI GEO repository (Barrett et al. 2013). To this end, 
chromosome 17 genes enriched for RNA Pol II in HepG2 (Hepatocellular carcinoma), 
H9 (pluripotent embryonic stem cells), U87 (glioblastoma astrocytoma) and TK6 cells 
were identified and the significance of the overlap examined using the hypergeometric 
test. The Venn diagram (Figure 4.18) shows a significant overlap (p < 0.01) in genes 
enriched for RNA Pol II between all cell lines, suggesting that the results observed in 
TK6 cells are consistent with previous observations.  
The phosphorylated state of RNA Pol II was demonstrated to reflect mRNA levels 
(Odawara et al. 2011), therefore changes in RNA Pol II (pSer2) measured following TSA 
treatment in TK6 cells are expected to correlate with changes in gene expression. 
However, a lack of suitable data complicates comparisons by introducing caveats such as 
different cell lines, HDAC treatment time and doses used. This was revealed by attempts 
to compare the TK6 RNA Pol II (pSer2) occupancy data generated here with expression 
data from THP-1 cells (human monocytic cell line, treated with 300nM TSA for 150mins) 
and HUVECs (human umbilical vein endothelial cell, treated with 500nM TSA for 24h) 
(Barrett et al. 2013), where a significant correlation was only observed for down regulated 
genes (P < 0.05, FDR < 0.05) (Appendix, II). These results show that use of several 
methods to validate the RNA Pol II (pSer2) microarray data have been successful, 
demonstrating the establishment of the ChIP-chip protocol for TK6 cells.  
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Figure 4.16. Average RNA Pol II (pSer2) enrichment around all genes on chromosome 17 
displays the expected biological patterns. The average of two biological repeats of RNA Pol II 
(pSer2) occupancy plotted +/- 1500 bp of the open reading frame (grey box) for all genes on 
chromosome 17 in untreated TK6 cells. Enrichment is pronounced within transcribed regions and 
downstream of TES. Total of 1932 protein coding and non-coding genes on chromosome 17 
(hg19). RNA Pol II (pSer2) enrichment corresponds to 6.85% of total probes. TSS – transcription 
start site, TES – transcription end site. n = 2.  
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Figure 4.17. TSA promotes RNA Pol II (pSer2) occupancy at TP53 in TK6 cells. A: genome 
plot showing RNA Pol II (pSer2) enrichment in two biological repeats of untreated and TSA 
treated (400nM, 6h) samples. B: the effect of TSA treatment shown, calculated from subtracting 
the untreated data away from the TSA treated data. Probes enriched in the treated sample are 
shown in red along the x-axis.  
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Figure 4.18. Chromosome 17 genes enriched for RNA Pol II (pSer2) correlate with those 
identified in difference cell lines. Venn diagram showing significant overlaps (P < 0.01) between 
chromosome 17 genes enriched for: RNA Pol II (pSer2) in TK6 cells, un-phosphorylated RNA 
Pol II in H9 cells and RNA Pol II (pSer5) in HepG2 and U87 cells. Publicly available data 
retrieved from the NCBI GEO repository under the series GSE39312 for H9 cells and GSE18499 
for HepG2 and U87 cells. Genes in TK6 cells were considered enriched for RNA Pol II (pSer2) 
when two or more peaks were detected within the open reading frame. Enriched peaks for data 
retrieved from GEO were presented in BED (browser extensible data) format. The coordinates 
were converted to UCSC gene names using the table browser function from UCSC Genome 
Browser (available at http://genome-euro.ucsc.edu/). Overlaps were identified base on matching 
gene names using a web-based tool (available at http://bioinformatics.psb.ugent.be/webtools/ 
Venn/) and drawn using R-based ‘VennDiagram’ package v1.6.17. Statistical analysis 
(Hypergeometric test) was performed using the R-based ‘stats’ package v3.2.4.  
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4.10 Discussion  
 
The aim of this chapter was to establish the ChIP-chip method for TK6 cells as a 
genome-wide tool for assessing the mechanisms of genotoxicity imposed by HDAC 
inhibitors. Initially, it was important to validate the wild type status of p53 in the TK6 
cells used in this study for the purposes of confirming a normal DNA damage response 
following TSA treatment. This was performed by taking advantage of the unique effects 
of nutlin-3, an MDM2 inhibitor, which only induces apoptosis in cells containing wild-
type p53; evident in the marked increase in Annexin-V observed only in TK6 cells 
compared to either PC-3 cells lacking p53 or MDA-MB-232 cells with mutant p53 
(Figure 4.1). Although unrelated tumour cell lines were used here to control for the 
lymphoblast cell line, the outcomes of the assay are primarily dependent on the TP53 
status rather than the cell type. The detection of Annexin-V using flow cytometry also 
allowed for simple and quick method of determining p53 status in different cell lines. 
These results are further supported with the detection of p53 protein expression (Figure 
4.2).    
Since the use of HDAC inhibitors proved unsuccessful in yeast, attempts to 
demonstrate its effects in human cells focused on TSA, a pan-HDAC inhibitor which has 
published genotoxic effects in TK6 cells (Olaharski et al. 2006). In addition, it was also 
important to establish a treatment regimen from the initial dose-response studies which 
would be used to examine the mechanisms of DNA damage induction by TSA using 
ChIP-chip. The capability of HDAC inhibitors to induce DNA damage has been studies 
in genotoxicity assays measuring its effects at 24h. Particularly for TSA, a significant 
increase in micronuclei formation and cells arrested in G1 is observed at 24h, following 
its treatment in TK6 cells (Olaharski et al. 2006). To reproduce this, the InVitro 
MicroFlow® assay was first validated using the known genotoxic compound Vinblastine 
(Figure 4.3A). However, treating TK6 cells with increasing concentrations of TSA for 
24h showed a borderline genotoxic response for the top doses as the cytotoxicity response 
(both RCC and EMA negative cells) was near the limit of 50% (Figure 4.3B). Therefore, 
the results of the InVitro MicroFlow® assay did not conclusively demonstrate the 
genotoxicity of TSA in TK6 cells at 24h. While an alternative approach would be to 
conduct the same experiment using the conventional microscopy assay, given the highly 
cytotoxic nature of HDAC inhibitors it is possible that longer treatment times may result 
in cytotoxicity-induced genotoxicity. This can potentially lead to confounding results 
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when studying the mechanisms of TSA that directly induce DNA damage. In light of this, 
attention was directed at using shorter treatment times. Since the micronuclei endpoint 
requires cell division to take place, a shorter TSA treatment would entail a prolonged 
incubation period for cell division to occur. During this time, it is perceivable that some 
of DNA damage resulting from drug treatment may be repaired, and so a treatment 
regimen based on this would not be suitable for analysis on the microarrays. Although 
DNA repair inhibitor can be added to prevent this, since the type of DNA damage elicited 
by HDAC inhibitors are unknown combined with the possibility that inhibitors 
themselves can be toxic to the cells would only complicate the results of the assay. 
Therefore, instead of using the micronuclei endpoint as a marker of DNA damage for 
short TSA treatments, γH2AX, which is another well-characterised epigenetic marker of  
DNA damage was used (Kuo LJ 2008). Moreover, the ability of TSA to induce early 
(within hours) induction of histone acetylation and γH2AX in TK6 cells were also 
described by Olaharski and others, measured using western blotting (Olaharski et al. 
2006). To show these effects in the current study, flow cytometry (Chapter II, 2.1.4.2) 
was used as a faster alternative assay to western blotting. TK6 cells treated with a fixed 
dose of 400nM TSA showed a significant increase in global H3K9ac, which coincided 
with significant increases in global γH2AX at 6h and 12h (Figure 4.5). To examine if the 
γH2AX response is due to TSA and independent of cytotoxicity, markers of early 
apoptosis and changes in cell cycle were monitored using flow cytometry (Chapter II, 
2.1.4.1; 2.1.4.4). No significant increase in either annexin-v or cells arrested in G1 were 
observed (Figure 4.6) and therefore collectively shows that TK6 cells treated with 400nM 
TSA for 6h displays an effect at the epigenetic level, inducing markers of DNA damage 
that is independent of cytotoxicity. These observations are also consistent with those 
published showing the ability of HDAC inhibitors to induce early DNA damage and 
histone acetylation (Leea J.H 2010; Olaharski et al. 2006; Zhou et al. 2000). Under these 
conditions, the treatment regimen established will be used to study the mechanisms of 
TSA-induced DNA damage using the genome-wide method ChIP-chip.  
 Successful application of ChIP-chip for TK6 cells entails optimisation in key 
areas of the workflow such as chromatin preparation, immunoprecipitation and post-DNA 
amplification. To first optimise the conditions for preparing chromatin from TK6 cells a 
series of parameters such as fixation time, cycle number and cell densities were examined. 
Gel electrophoresis was used to assess the impact on chromatin shearing following 
changes made to each parameter (Figure 4.7 – 4.11). Of particular importance was the 
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proper use of a lysis buffer (Figure 4.8) and the appropriate cell density (Figure 4.10) 
which proved critical in shearing chromatin from TK6 cells to the desired size, an 
important factor in achieving a good resolution of the signal on the microarrays. Such 
extensive modifications to the standard protocol may be due to the small size of 
lymphoblastoid cells having ‘coarser’ chromatin with greater tendencies to aggregate 
(Kumar 2010). Blood-derived suspension cells such as monocytes and T/B lymphocytes 
have also been reported as being ‘difficult to shear’ (Diagenode). In conclusion, efforts 
to optimise the ChIP protocol for use with TK6 cells were successful and are described 
fully in Chapter II 2.1.7. 
In eukaryotes, RNA polymerase II (pSer2) elongation is well studied and found 
at housekeeping genes, with a distinct distribution around actively transcribed genes, 
primarily occupying the open reading frame and 3-prime ends of genes. For this reason, 
the chromatin immunoprecipitation procedure for TK6 cells was assessed by using ChIP-
qPCR of RNA Pol II (pSer2) enrichment at gene loci where it is known to be present. 
RNA Pol II (pSer2) enrichment at positive control genes in comparison to negative 
control genes, demonstrates that the ChIP protocol can detect abundant protein-DNA 
binding events (Figure 4.12A) and that these relative differences can still be observed 
following whole genome amplification (Figure 4.12B). This data also provided early 
assurances of the validity of the amplification method, since amplifying small amounts 
of DNA could potentially introduce amplification bias. For amplification of human ChIP 
DNA, the LM-PCR method used for yeast was substituted with the GenomePlex® 
Complete Whole Genome Amplification kit (WGA2) from Sigma-Aldrich. While both 
methods seek to amplify DNA representative of the starting material, LM-PCR ligates 
the same linker sequences to all fragments and PCR amplifies using linker specific-
primers (Agilent). WGA2 on the other hand, uses a set of universal oligonucleotide 
adapters, annealing randomly and uniformly to all fragments, generating an OmniPlex 
‘library’ which is then PCR amplified (Sigma-Aldrich 2006). Previous investigation in 
the lab concluded that LM-PCR performed better using yeast samples while WGA2 
performed better with human sample (Powell 2014a). O’Geen and colleagues also 
reported the superior signal to noise ratio observed using the WGA2 kit over LM-PCR 
for amplifying human DNA in a study using microarray to detect rare transcription factor 
binding events (O'Geen et al. 2006). For these reasons the WGA2 kit was used in this 
study for subsequent microarray work with TK6 cells.   
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For untreated and TSA treated (400nM, 6h) TK6 cells, quality controls were 
carried out to ensure that the data can be normalised together using Sandcastle (Figure 
4.14). Additionally, a linear relationship for RNA Pol II (pSer2) occupancy was shown 
for each of the two biological repeats on chromosome 17 (Figure 4.15), highlighting the 
reproducibility of the arrays. The finding that post-hybridisation washes of the arrays 
accounts for the majority of variability detected in technical rather than biological 
replicates (Figure 4.15) suggested that other experimental actors were accountable. It has 
been noted that this can be caused by the fluctuating levels of ozone (O3) which can 
degrade cyanine 5 (Cy5)-labelled IP samples. This issue has also been addressed in gene 
expression arrays studies employing the same two-dye system using cyanine 3 and 
cyanine 5 (Branham et al. 2007). To rectify this in the present study, biological repeats of 
the same ChIP experiment were performed separately from different cell batches but 
entered the hybridisation workflow on the same day and improvements to reproducibility 
were evident in the increase in correlation (Figure 4.15C; D).  
To validate the patterns of RNA Pol II (pSer2) observed on chromosome 17 
arrays, the average signal distribution was plotted around gene structure, which showed 
the expected pattern of RNA Pol II (pSer2) enrichment inside and at the ends of genes 
(Figure 4.16). In addition, changes in RNA Poll II (pSer2) activity following TSA 
treatment at TP53 indicated an increase in occupancy (Figure 4.17), consistent with 
previously predicted (Juan et al. 2000) and observed (Sonnemann et al. 2014) data. 
Comparing genes enriched for RNA Pol II (pSer2) on chromosome 17 detected in TK6 
cells with those in 3 other cell lines showed a significant overlap (P < 0.01), suggesting a 
similar set of genes may be transcribed. A greater number of genes showing RNA Pol II 
(pSer2) enrichment were identified in TK6 cells by comparison (Figure 4.18). This could 
be a reflection of the different data normalisation, peak calling algorithms and antibodies 
used. Affymetrix tiling arrays were used to generate ‘initiating’ RNA Pol II (pSer5) data 
for U87 and HepG2 cells (Barrett et al. 2013) analysed using the ‘Model-based Analysis 
of Tiling arrays’ (MAT) algorithm where probe values are standardised by cross-
referencing sequence and copy number on each array, avoiding the need for sample 
normalisation (Johnson 2006). In contrast, non-phosphorylated RNA Pol II was mapped 
in H9 cells using Nimblegen arrays and data processed using the NimblegenScan software 
(Barrett et al. 2013).  Along with the protocol presented in this chapter and data analysis 
using the novel ‘Sandcastle’ approach, these disparities are likely to result in the 
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differences in enrichment observed. Nevertheless, there is a statistically significant 
overlap in genes regarded as enriched for RNA Pol II between the different cell lines.  
The results of this chapter demonstrate that while the use of HDAC inhibitors 
were ineffective in budding yeast, their chromatin associated effects can be clearly seen 
in the human TK6 lymphoblastoid cell line. Following this, a dose of TSA was selected 
for microarray analysis which showed the presence of DNA damage in the absence of 
cytotoxicity. Finally, a working ChIP-chip protocol was established for TK6 cells and 
validated using RNA Pol II (pSer2) through a number of different methods that showed 
a strong agreement with the expected outcomes. This allows for further measurements of 
changes in histone acetylation and replication to be made in response to TSA at a high 
resolution on chromosome 17 in the succeeding chapter, with focus on examining the 
mechanisms of HDACi-induced DNA damage.  
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Chapter V – Investigating transcription-replication conflicts as a source of HDAC 
inhibitor induced DNA damage in TK6 cells 
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5.1 Eukaryotic replication origins  
 
 The coordinated firing of replication origins is key to ensuring stability and proper 
duplication of the genome. In eukaryotes, the origin recognition complex (ORC) is 
required for initiating DNA replication and consists of six highly conserved subunits 
(ORC1 – 6) (Duncker BP 2009). Its recruitment precedes the formation of the pre-
replication complex (pre-RC) and serves to load additional factors such as the putative 
Mcm2-7 helicase (Duncker BP 2009). In budding yeast, ORC shows a high affinity for 
consensus 11bp ‘A-elements’ known as autonomously replicating sequences (ARSs) in 
addition to 10 – 15bp ‘B-elements’ (Bell 2002). Conserved basic residues (Lys-362 and 
Arg-367) on the ORC1 subunit was recently shown to function in origin recognition 
(Kawakami et al. 2015). This is in contrast to fission yeast in which ORC recognises AT-
rich sequences lacking a conserved motif (Clyne and Kelly 1995). In humans, ORC1 is 
ubiquitinated and dissociates from chromatin following entry into S-phase (Li and 
DePamphilis 2002), while other ORC subunits (2 – 5) remain intact. In this way, the 
binding of ORC1 is thought to confer selection of active origins (DePamphilis ML 2006). 
Recent work by Dellino and colleagues supported this idea by showing that ORC1 sites 
identified in HeLa cells using ChIP-seq correlated with actively replicating DNA, 
measured by repli-seq (Dellino et al. 2013). Additional efforts aimed at characterising 
replication origins in greater detail involve a range of genome-wide approaches such as 
the sequencing of short nascent DNA strands (SNS-seq) (Besnard et al. 2012), 
transcription bubbles (bubble-seq) (Mesner et al. 2013), Okazaki fragments (OK-seq) 
(Kahli P.N. 2016) and in vitro initiating sites (ini-seq) (Langley A.R. 2016). Nevertheless, 
a lack of correlation between datasets generated thus far using the various methods paints 
an obscure picture of replication initiation in humans. Additionally, it appears that origin 
specification in human cells do not depend on a consensus sequence compared to yeast 
(Vashee et al. 2003). A study comparing different cell lines showed that replication 
origins are not randomly distributed but rather utilised at different frequencies and may 
be defined by unique replication programs established during development for that 
particular cell type (Besnard et al. 2012). On top of this, studies in human and hamster 
cells indicate that ORC can be re-established at different sites following each round of 
cell division (Dimitrova and Gilbert 1999; Gerhardt et al. 2007), further complicating 
their identification. In this respect, initiation of replication is described to occur within 
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specific ‘zones’, estimated to range from 2.6 – 150kb or greater (Kahli P.N. 2016; 
Crosetto et al. 2013) 
The early pioneering work of Huberman and Riggs, combining pulse labelling 
and DNA radiography, identified around 40,000 potential origins sites in the human 
genome (Huberman J.A. 1968). Current data from short nascent DNA strand sequencing 
places the estimate at around 120,000 to 250,000 (Mesner et al. 2013; Kahli P.N. 2016). 
Studies show that the numbers of established origins are far in excess of those used at any 
given time, giving rise to ‘dormant’ and ‘active’ origins. Dormant origins remain silent 
in normally dividing cells and can be activated in response to replication stress (Yekezare, 
Gomez-Gonzalez, and Diffley 2013). Such mechanisms help compensate for the timely 
completion of replication during S-phase. While the exact mechanisms of origin 
utilisation are still unknown, emerging evidence suggests that DNA structure; such as 
ssDNA and G-quadruplex (G4) motifs (tertiary DNA structures that form in guanine-rich 
regions) may have a role in origin selection (Hoshina et al. 2013). Additionally, 
replication initiation correlates with regions of open chromatin (Mesner et al. 2013), 
which favours the formation of G4 structures and is commonly characterised by 
susceptibility to DNAse I cleavage (DNAse I hypersensitive sites, DHS) or nucleosome 
free regions (NFRs) (Dellino et al. 2013). The latter is also commonly found at the 
promoters of actively transcribed genes, in comparison to actively transcribed regions 
downstream, which tend to be relatively accessible (Livaja R. 2010).  
5.2 Histone acetylation and replication origin firing  
 
There is a strong body of evidence linking histone acetylation/deacetylation to the 
organisation and firing of origins, through shaping of the chromatin landscape. Early 
replicating sites tend to correlate with euchromatin, whereas late replicating sites correlate 
with heterochromatin (Lygerou 2012). A more open structure of chromatin is likely to be 
more accessible to factors involved in replisome assembly. Since histone acetylation is a 
well-known post-translational modification linked to chromatin relaxation, changes in 
acetylation have been shown to affect origin activity. In yeast, the association of ORC 
with histone acetyltransferase Hat1p, which acetylates H4K5 and K12, provides a novel 
link between acetylation status and replication (Suter et al. 2007). Histone 
hyperacetylation is also essential in maintaining replication, as demonstrated in yeast 
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where mutations to bulk lysines on histone H3 and H4 tails severely compromised cell 
growth (Unnikrishnan, Gafken, and Tsukiyama 2010).  
HDAC enzymes have also been shown to affect the distribution of replication 
origins. RPD3 deletions in yeast alter replication timing by promoting the early loading 
of initiation factors and origin firing (Vogelauer et al. 2002). Similar evidence is also 
presented in human studies, where G1 synchronised HeLa cells cultured in the presence 
of the HDAC inhibitor TSA progressed through S-phase faster than non-TSA treated 
cells, suggesting that late-firing origins may have been activated earlier (Kemp et al. 
2005). Moreover, replication timing of the β-globin gene can be altered by 
promoting/supressing HDAC activities locally (Kemp et al. 2005). 
5.3 Chapter aims 
 
 Published evidence shows that increases in histone acetylation induced by HDAC 
inhibitors alters transcription profiles and the organisation of replication sites in the 
genome, implicating these events in the generation of DNA damage (Chapter I, 1.8). To 
test the possibility that these changes may promote transcription-replication conflicts as 
a source of DNA damage in human cells, work in the current chapter will employ the 
ChIP-chip method established in TK6 cells (Chapter IV) to examine at high resolution, 
TSA-induced changes in markers of histone acetylation (Histone H4 acetylation), 
transcription (RNA Pol II phospho-Serine 2), replication (Origin replication complex 1) 
and extend this to markers of DNA damage such as γH2AX and R-loops. 
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5.4 Measuring the effect of TSA on H4 acetylation, RNA Pol II (pSer2) and 
ORC1 occupancy on chromosome 17 in TK6 cells 
 
Using the previously identified dose of TSA (400nM, 6h), showing indications of 
DNA damage in the absence of cytotoxicity, ChIP-chip data is firstly generated to 
compare the overall effect that TSA has on histone H4 acetylation, transcriptional 
elongation and replication initiation on chromosome 17 in TK6 cells. 
 
5.4.1 Examining changes in Histone H4 acetylation in response to TSA  
 
 HDAC inhibitors increases global levels of histone acetylation, which is thought 
to promote a more open chromatin structure allowing association of transcription and 
replication factors. Therefore, it is expected that transcription and replication may be 
more active in regions of high acetylation. To study this in greater detail, changes in 
histone H4 acetylation were measured on chromosome 17 using previously designed 
microarrays (Chapter II, 2.1.7.7) as a marker of euchromatin, in response to the pre-
determined TSA treatment (Chapter IV, 4.8). Different amounts of the anti-pan H4 
acetylation antibody (K5, K8, K12, K16) were firstly titrated with chromatin prepared 
from TK6 cells to identify the optimal amount and to show that the antibody is suitable 
for use in ChIP (Appendix, III). ChIP-chip was carried out using established conditions 
(Chapter IV) with untreated and TSA treated (400nM, 6h) TK6 cells. Quality control was 
carried out as before (Chapter IV, 4.9.5) to show that the histone H4 acetylation (H4ac) 
array data from untreated and TSA treated cells can be normalised together (Appendix, 
III). 
 To first examine the overall effect of treating with TSA, the average H4ac signal 
was compared between untreated and TSA treated cells. To demonstrate this, firstly the 
mean IP/IN log2 ratios are calculated for each condition and plotted as a histogram to 
compare the net change. Figure 5.1A shows that TK6 cells treated with TSA exhibit 
significantly higher level of H4ac on chromosome 17 (P < 0.01). Next, to gain a better 
idea of the extent of the increase observed, the number of gene regions enriched for H4ac 
before and after TSA treatment was compared. The venn diagram shows as a result of 
TSA treatment, a large number of genes are hyperacetylated on histone H4 (Figure 5.1B). 
To examine where the increase in H4ac signal occurs in these gene regions, the average 
H4ac enrichment measured before and after TSA treatment was plotted +/- 1500bp  
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Figure 5.1. TSA increases histone H4 acetylation on chromosome 17. A: average H4ac 
enrichment calculated from normalised array data from untreated (mean = 0.73, SEM = 0.002) 
and TSA treated (mean = 1, SEM = 0.002) cells showing a significant increase in H4ac following 
treatment (P < 2.2x10-16, Welch’s t-test). Small SEMs are due to the large sample size (~400,000) 
and are omitted from the plot. n = 3. B: a large number of genes show H4ac enrichment in response 
to TSA treatment. Diagrams drawn using R base package v3.2.4 and the ‘VennDiagram’ package 
v1.6.17.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. TSA increases histone H4 acetylation in the ORFs of genes in chromosome 17. 
A: pattern of H4ac plotted around gene structure in untreated (U: grey) and TSA treated (400nM, 
6h) TK6 cells (T: green). B: TSA increases H4ac primarily around ORFs of genes, calculated by 
subtracting untreated data away from TSA treated data. SEM plotted as error shapes around the 
average of 3 biological replicates.  
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around the open reading frame (ORF) of genes on chromosome 17. The result is a profile 
plot showing that in untreated TK6 cells, H4ac is enriched upstream of the TSS and 
downstream of the TES. However, following TSA treatment, an increase in H4ac is 
observed in the ORFs of genes (Figure 5.2A). To identify the net change in distribution 
of H4ac, the data from untreated cells was subtracted from the data generated from TSA 
treated cells, showing that TSA promotes H4 hyperacetylation mainly in the ORFs of 
genes on chromosome 17 (Figure 5.2B).     
 
5.4.2 Examining changes in transcription in response to TSA  
 
 Following this, to inspect how TSA treatment affects normal transcription in TK6 
cells, RNA Pol II (pSer2) ChIP-chip data generated previously to validate the established 
technique (Chapter IV) was examined here in greater detail. Comparison of the data 
shows that TSA significantly increases the levels of RNA Pol II (pSer2) enrichment in 
treated TK6 cells (P < 0.01) (Figure 5.3A) and is detected in a large number of genes 
previously un-enriched in untreated TK6 cells (Figure 5.3B). The enrichment of RNA Pol 
II (pSer2) is higher overall following TSA treatment (Figure 5.4A), with the greatest 
increase observed up- and down-stream of the TSS and TES, respectively (Figure 5.4B).  
 
5.4.3 Examining changes in replication initiation in response to TSA  
 
 To characterise replication, ORC1 was selected to mark zones of replication 
initiation (Duncker BP 2009). Since replication origins have not been identified in TK6 
cells and these reportedly vary between different cell types, the specificity of the anti-
ORC1 antibody was tested by performing a western blot of the denatured ChIP sample 
(Chapter II, 2.1.6.5). The observed single band at the expected molecular weight indicates 
that the antibody is highly specific for ORC1, justifying its use in ChIP-chip (Appendix, 
III).   
Quality control was performed on the ORC1 ChIP-chip data as before to show 
that the normalisation procedure could be applied to the data from untreated and TSA 
treated cells (Appendix III). Since previous attempts by Dellino and colleagues reported 
difficulties in enriching for ORC1 using whole cell chromatin (Dellino et al. 2013), the 
validity of the data generated here was first assessed by comparing replicates of the ORC1  
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Figure 5.3. TSA increases RNA Pol II (pSer2) enrichment on chromosome 17. A: average 
RNA Pol II (pSer2) enrichment calculated from normalised data from untreated (mean = 0.7, 
SEM = 0.003) and TSA treated (mean = 2.21, SEM = 0.003) cells showing a significant increase 
following treatment (P < 2.2x10-16, Welch’s t-test). Small SEMs are due to the large sample size 
(~400,000) and are omitted from the plot. n = 3. B: a larger number of genes show RNA Pol II 
(pSer2) enrichment in response to TSA treatment. Diagrams drawn using R base package v3.2.4 
and the ‘VennDiagram’ package v1.6.17.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4. TSA increases RNA Pol II (pSer2) enrichment outside the ORFs of genes on 
chromosome 17. A: pattern of RNA Pol II (pSer2) enrichment plotted around gene structure in 
untreated (U: grey) and TSA treated (400nM, 6h) TK6 cells (T: red). B: TSA increases RNA Pol 
II (pSer2) enrichment primarily upstream of TSS and downstream of TES, calculated by 
subtracting untreated data away from TSA treated data. Standard deviation error shapes plotted 
around the average of 2 biological replicates. 
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microarray data from untreated TK6 cells with that of a negative control (background 
binding data) generated using a species-specific anti-IgG antibody (Figure 5.5). 
Consequently, biological replicates of ORC1 microarray data showed a high level of 
correlation (Pearson’s correlation r = 0.95), compared to the biological replicates of IgG 
microarray data (Pearson’s correlation r = 0.27) (Figure 5.5), which failed to detect peaks 
and do not display any pattern of enrichment (Figure 5.6). This suggests that the ORC1 
microarray data generated here is highly reproducible and is representative of putative 
ORC1 sites found on chromosome 17 in TK6 cells.  
Chromatin structure is known to play an important role in defining how 
transcription and replication are organised in cells. Relaxed chromatin regions and G-
quadruplex structures have emerged as reliable predictors of replication initiation zones 
(Hertsch R.H. 2016; Kahli P.N. 2016) To examine if the replicating zones identified here 
map to these locations, ORC1 microarray data is plotted around DNAse I hypersensitive 
sites from the ENCODE database identified in human K562 (myelogenous leukemia) 
cells (Dunham et al. 2012), which represent regions of open chromatin susceptible to 
DNAse I cleavage, in addition to G4-sites recently mapped by sequencing in HaCat 
(human keratinocyte) cells (Hertsch R.H. 2016). Figure 5.7 shows that the ORC1 data 
generated from untreated TK6 cells map to both DNAse I hypersensitive sites and G4 
sites, in comparison to a set of randomly generated sites showing no particular pattern. 
This demonstrates that ORC1 sites identified in untreated TK6 cells correlate with open 
chromatin regions and G4 sites, which are predictive of replication initiation zones.  
Closer inspection of the normalised data shows that in untreated TK6 cells 
replication initiating zones are distributed downstream of the TSS, in the ORFs of genes 
(Figure 5.8A). This is consistent with previously published studies also showing 
replication origins to be enriched downstream of the TSS (Dellino et al. 2013; Martin et 
al. 2011). However, in response to TSA treatment, these initiating zones are altered and 
re-distributed upstream of the TSS and downstream of the TES (Figure 5.8B). The net 
effect is a small but significant increase in ORC1 occupancy on chromosome 17 of TK6 
cells treated with TSA (Figure 5.9).  
In summary, these results show that treating TK6 cells with the pan-HDAC 
inhibitor TSA alters the distribution, as well as significantly increasing the levels of 
histone H4 acetylation, RNA Pol II (pSer2) and ORC1 enrichment on chromosome 17.  
 
 
  143 
  
 -
2
  
  
  
  
  
  
  
  
  
0
  
  
  
  
  
  
  
  
 2
 
E
n
ri
ch
m
e
n
t 
(I
P
/I
N
 l
o
g
2
) 
   -1500            TSS              TES          +1500 
Background noise 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5. Biological replicates of ORC1 microarray data display a strong positive 
correlation compared to background IgG microarray data. A: smooth scatter plot comparing 
two biological repeats of ORC1 microarray data generated in untreated TK6 cells, showing a 
strong positive correlation. B: Smooth scatter plot comparing two biological repeats of data 
generated using a species-specific IgG antibody as background control, showing a weak positive 
correlation. Pearson’s correlation calculated using functions in the base R package. x = y line 
shown in black.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6. Background IgG microarray data does not display enrichment. Normalised IgG 
data plotted around gene structure. 
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Figure 5.7. ORC1 occupancy on chromosome 17 in untreated TK6 cells consistently map to 
sites predictive of replication initiation. ORC1 data from untreated (U: grey) and TSA treated 
(T: yellow) TK6 cells plotted around A: DNAse I hypersensitive sites identified in K562 cells 
(ENCODE: ENCSR527IGO) B: G4-sites identified in HaCat cells (NCBI GEO: GSE76688) and 
C: list of randomly generated site on chromosome 17 (n = 1000) using the BEDTools extension 
in Galaxy (Afgan et al. 2016). SEM plotted around the average of 3 biological repeats.            
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Figure 5.8. TSA treatment re-distributes ORC1 occupancy away from the ORFs of genes 
on chromosome 17. A: pattern of ORC1 occupancy plotted around gene structure in untreated 
(U: grey) and TSA treated (400nM, 6h) TK6 cells (T: yellow). B: TSA reduces ORC1 occupancy 
within the ORFs of genes, calculated by subtracting the array data from untreated TK6 cells away 
from TSA treated TK6 cells. SEM plotted as error shapes around the average of 3 biological 
replicates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9. TSA treatment increases ORC1 occupancy on chromosome 17. Average ORC1 
enrichment calculated from normalised array data generated from untreated (mean = 2.11, SEM= 
0.004) and TSA treated (mean = 2.3, SEM = 0.003) cells showing a significant increase in ORC1 
occupancy following treatment (P < 2.2x10-16, Welch’s t-test). Small SEMs are due to the large 
sample size (~400,000) and are omitted from the plot. n = 3. Diagram drawn using R base package 
v3.2.4.  
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5.5 Analysing the impact of TSA-induced changes in H4 acetylation on RNA Pol 
II (pSer2) and ORC1 occupancy on chromosome 17 in TK6 cells 
 
 An increase in histone acetylation is associated with higher levels of 
transcriptional and replication activity in cells. Therefore, to examine how changes in 
H4ac induced by TSA treatment might alter transcription and replication on chromosome 
17 in TK6 cells their correlations will be examined. Scatter plots are a useful way of 
examining the overall change/relationship between two sets of array data. When the 
normalised array data is plotted in the form of a scatter plot, each probe value in the first 
dataset is matched with the corresponding value in the second dataset. In this way, the 
correlation of two datasets can be estimated using the Pearson’s’ coefficient (-1 < r < 1). 
A low r value would indicate that a weak relationship, whereas a high r value would 
indicate a strong relationship. Also, r can either be positive or negative, with positive 
representing a tendency of one variable to increase as the other increases and vice versa.  
Additionally, by smoothing the scatter plot, the distribution of data points on the graph 
can be easily discerned by observing the colour density. Darker regions (Figure 5.10) 
represent high concentration of data points whereas lightly coloured or white regions 
represent little or no data points respectively. Following a general analysis, the 
relationship shown in smoothed scatterplots can be examined in detail by plotting the 
same data in the context of a collection of binding sites in the form of a profile plot.  
Following this method of analysis, to examine how TSA-induced changes in H4ac 
affect cellular processes such as transcription and replication on chromosome 17 in TK6 
cells, correlations between the normalised H4ac data are compared to the normalised data 
of RNA Pol II (pSer2) and ORC1 independently in untreated and TSA treated conditions 
(Figure 5.10). In untreated TK6 cells, the H4ac data shows a weak positive correlation 
with RNA Pol II (pSer2) (Pearson’s correlation r = 0.18) and a negative correlation with 
ORC1 (Pearson’s correlation r = -0.57) (Figure 5.10A; C). Following TSA treatment, 
H4ac shows a strong negative correlation with both RNA Pol II (pSer2) and ORC1 
(Pearson’s correlation r < -0.8) (Figure 5.10B; D). This suggests that TSA-induced 
changes in H4ac do not associate directly with the changes in RNA Pol II (pSer2) and 
ORC1 occupancy on chromosome 17. This is also consistent with the general changes in 
distributions observed previously, where TSA-induced H4ac hyper-acetylation around 
the ORFs of genes on chromosome 17 (Figure 5.2) is accompanied by enrichment of RNA 
Pol II (pSer2) (Figure 5.4) and ORC1 (Figure 5.6) outside of the ORFs. 
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 To investigate this in greater detail, the H4ac data from both untreated and TSA 
treated cells were plotted around ORC1 peak centres identified in untreated TK6 cells 
(Figure 5.11A). The results show that in untreated cells, H4ac is enriched around ORC1 
peaks but not at ORC1 peaks (Figure 5.11A, grey line). However, in response to TSA, an 
overall increase in H4ac was observed which is most pronounced at ORC1 peak centres 
(Figure 5.11A, green line). Similarly, to examine the impact of TSA-induced changes 
H4ac on RNA Pol II (pSer2) occupancy, H4ac data from untreated and TSA treated cells 
were plotted in relation to RNA Pol II (pSer2) peaks identified in untreated and TSA 
treated cells, respectively. In contrast to the relationship between H4ac and ORC1, for 
RNA Pol II (pSer2) peaks detected in untreated cells, H4ac measured in untreated cells 
are mostly enriched at the centres of these peaks (Figure 5.12A, grey line). Conversely, 
following TSA treatment this pattern is inverted, resulting in the re-distribution of H4ac 
away from these sites (Figure 5.12A, green line). Comparing with RNA Pol II (pSer2) 
peaks detected in TSA treated cells, in the absence of TSA these sites show a high level 
of H4ac enrichment (Figure 5.12B, grey line). Subsequently, the reciprocal is observed 
in response to TSA and suggests that a loss of H4ac from these sites associates with the 
accumulation of RNA Pol II (pSer2) (Figure 5.12B, green line). Taken together, these 
results show that the TSA-induced changes H4ac correlates with the re-distribution of 
RNA Pol II (pSer2) and ORC1 observed following TSA treatment.  
 As evidence in the literature point towards the involvement of NFRs at promoter 
regions over transcribed regions (Livaja R. 2010), RNA Pol II (pSer2) data from untreated 
and TSA treated cells were plotted around the same DHS used earlier to examine ORC1 
occupancy (Figure 5.7A). The results show that RNA Pol II (pSer2) is not enriched at 
these sites (Figure 5.13, grey line), confirming the published reports (Livaja R. 2010).  
To gain an idea of where changes in transcription and replication are taking place 
in relation to the TSA-induced changes in H4ac, RNA Pol II (pSer2) and ORC1 
enrichment were both plotted independently around genes showing H4 hyper-acetylation 
and H4 hypo-acetylation following TSA treatment (Figure 5.14). As a result, RNA Pol II 
(pSer2) and ORC1 are highly enriched at genes showing H4 hypo-acetylation in response 
to TSA (Figure 5.14A; B). By contrast, at genes showing H4 hyper-acetylation in 
response to TSA, RNA Pol II (pSer2) and ORC1 show reduced occupancy in the region 
of ORFs (Figure 5.14C; D). Interestingly, closer examination shows that TSA promotes 
the co-enrichment of RNA Pol II (pSer2) and ORC1 downstream of the TES at H4 hyper-  
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Figure 5.10. TSA-induced changes in H4ac inversely correlates with transcription and 
replication. Smooth scatterplots showing: A: a weak positive correlation between H4ac and RNA 
Pol II (pSer2) in untreated TK6 cells. B: a strong negative correlation between H4ac and RNA 
Pol II (pSer2) in TSA treated TK6 cells. C and D: H4ac and ORC1 do not correlate in both 
untreated and TSA treated TK6 cells, respectively.  
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Figure 5.11. TSA induces changes in H4ac at ORC1 sites in untreated and TSA treated TK6 
cells. A: H4ac data from untreated (U: grey) and TSA treated (T: green) TK6 cells plotted around 
ORC1 peaks identified in untreated TK6 cells, showing an increase in H4ac at these sites 
following TSA treatment and B: H4ac data from untreated (U: grey) and TSA treated (T: green) 
TK6 cells plotted around ORC1 peaks identified in TSA treated TK6 cells, showing decrease in 
H4ac at these sites following TSA treatment. SEM plotted as error shapes around the average of 
3 biological replicates.  
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Figure 5.12. TSA induces changes in H4ac at RNA Pol II (pSer2) sites in untreated and TSA 
treated TK6 cells. A: H4ac data from untreated (U: grey) and TSA treated (T: green) TK6 cells 
plotted around RNA Pol II (pSer2) peaks identified in untreated TK6 cells, showing a decrease in 
H4ac at these sites following TSA treatment and B: H4ac data from untreated (U: grey) and TSA 
treated (T: green) TK6 cells plotted around RNA Pol II (pSer2) peaks identified in TSA treated 
TK6 cells, showing an increase in H4ac at these sites following TSA treatment. SEM plotted as 
error shapes around the average of 3 biological replicates.  
 
 
 
 
 
 
 
 
 
 
Figure 5.13. RNA Pol II (pSer2) occupancy does not correlate with DNAse I hypersensitive 
sites. RNA Pol II (pSer2) data from untreated (U: grey) and TSA treated (T: red) TK6 cells plotted 
around DNAse I hypersensitive sites showing a lack of enrichment. DNAse I hypersensitive sites 
identified in K562 cells were downloaded from the ENCODE database (ENCSR527IGO). 
Standard deviation error shapes plotted around the average of 2 biological replicates.  
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Figure 5.14. TSA promotes specific-patterns of RNA Pol II and ORC1 co-enrichment at 
hyper- and hypo-H4ac genes. A and B: TSA-induced H4 hypo-acetylated genes show an 
increase in RNA Pol II and ORC1, primarily downstream of the TES. C and D: TSA-induced H4 
hyper-acetylated genes show an increase in RNA Pol II and ORC1 upstream of the TSS. TSS – 
transcription start site. TES – transcription end site. Standard deviation error shapes plotted 
around the average of 2 biological replicates of RNA Pol II data. SEM plotted as error shapes 
around the average of 3 biological replicates of ORC1 data. 
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acetylated genes (Figure 5.14C; D, dashed boxes), whereas at H4 hypo-acetylated genes, 
they are both co-enriched upstream of the TSS (Figure 5.14C; D, dashed boxes). The 
results of the analysis therefore show that TSA can potentially promote the co-localisation 
of transcription and replication in certain regions, dependent on the hyper- or hypo-H4ac 
status of genes present on chromosome 17 in TK6 cells.  
5.6 Examining TSA-induced co-localisation of transcription and replication on 
chromosome 17 
 
  To determine if the predicted co-enrichment of RNA Pol II (pSer2) and ORC1 
observed in response to TSA-induced changes in H4 acetylation represents an increase in 
co-localisation of transcription and replication events on chromosome 17, the correlations 
between RNA Pol II (pSer2) and ORC1 microarray data was compared between untreated 
and TSA treated cells (Figure 5.15). In untreated TK6 cells, a low correlation was 
observed (Pearson’s correlation r = -0.19), suggesting that RNA Pol II (pSer2) and ORC1 
do not occupy the same genomic regions (Figure 5.15A). However, after treating TK6 
cells with TSA, a strong positive correlation was observed instead (Pearson’s correlation 
r = -0.19), suggesting that RNA Pol II (pSer2) and ORC1 now occupy the same genomic 
regions (Figure 5.15B). Therefore, this shows that TSA promotes the co-localisation of 
transcription and replication on chromosome 17 in TK6 cells.  
 To estimate the extent to which TSA affects the distribution of transcription on 
chromosome 17 in TK6 cells, the correlation between RNA Pol II (pSer2) array data was 
compared before and after TSA treatment. In comparison to a negligible effect, which 
would be represented by a Pearson’s correlation of 0, comparing RNA Pol II (pSer2) 
microarray data shows a weak positive correlation (Pearson’s correlation r = 0.32), 
indicating that TSA has a minor effect in altering the occupancy of RNA Pol II (pSer2) 
on chromosome 17 (Figure 5.16A). The same analysis performed with ORC1 microarray 
data shows a strong negative correlation between untreated and TSA treated conditions 
(Pearson’s correlation r = -0.94), indicating that TSA significantly alters the distribution 
of ORC1 and that their locations on chromosome 17 in treated TK6 cells is drastically 
different compared to untreated TK6 cells (Figure 5.16B).  
To confirm these observations, both the normalised ORC1 data from untreated 
and treated cells are plotted around putative sites of ORC1 (peaks) detected in the 
untreated cells. In response to TSA, ORC1 is lost from its original sites found in untreated  
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Figure 5.15. TSA promotes the co-localisation of transcription and replication on 
chromosome 17 in TK6 cells. A: Smooth scatter of RNA Pol II (pSer2) data plotted against 
ORC1 data generated from untreated TK6 cells showing a lack of correlation (Pearson’s r = -
0.19). B: Smooth scatter of RNA Pol II (pSer2) data plotted against ORC1 data generated from 
TSA treated TK6 cells showing a strong positive correlation (Pearson’s r = 0.95). Average 
normalised data plotted, n = 2 for RNA Pol II (pSer2); n = 3 for ORC1. 
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Figure 5.16. TSA promotes the re-distribution of transcription and replication on 
chromosome 17 in TK6 cells. A: Smooth scatter of untreated vs. TSA treated RNA Pol II (pSer2) 
data showing a weak correlation (Pearson’s r = 0.32). B: Smooth scatter of untreated vs. TSA 
treated ORC1 data showing a strong negative correlation (Pearson’s r = -0.94). Average 
normalised data plotted, n = 2 for RNA Pol II (pSer2); n = 3 for ORC1. 
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Figure 5.17. TSA significantly alters the distribution of ORC1 on chromosome 17 in TK6 
cells. A: ORC1 data from untreated (U: grey) and TSA treated cells (T: yellow) plotted around 
ORC1 peaks identified in untreated cells, showing a loss of ORC1 occupancy at these sites in 
response to TSA. B: ORC1 data from untreated (U: grey) and TSA treated cells (T: yellow) plotted 
around ORC1 peaks identified in treated cells, showing a gain of ORC1 occupancy at these sites 
in response to TSA. SEM plotted as error shapes around the average of 3 biological replicates.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.18. TSA alters the distribution of RNA Pol II (pSer2) on chromosome 17 in TK6 
cells. A: RNA Pol II (pSer2) data from untreated (U: grey) and TSA treated cells (T: red) plotted 
around RNA Pol II (pSer2) peaks identified in untreated cells, showing a partial loss of RNA Pol 
II (pSer2) occupancy at these sites in response to TSA. B: RNA Pol II (pSer2) data from untreated 
(U: grey) and TSA treated cells (T: red) plotted around RNA Pol II (pSer2) peaks identified in 
treated cells, showing a gain of RNA Pol II (pSer2) occupancy at these sites in response to TSA. 
SEM plotted as error shapes around the average of 2 biological replicates.  
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Figure 5.19. Proposed model of TSA-induced co-localisation of transcription and 
replication. Top: in untreated TK6 cells, transcription and replication processes are spatially 
separated into different regions of the chromosome. Bottom: In response to TSA treatment, 
changes in H4 acetylation disrupts the spatial organisation and promotes the co-localisation of 
transcription and replication processes to the same chromatin region.  
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TK6 cells (Figure 5.17A). Doing the same for putative sites of ORC1 detected in TSA 
treated cells, shows a gain of ORC1 occupancy at these sites (Figure 5.17B). Likewise, 
TSA promotes a partial loss of RNA Pol II (pSer2) enrichment at its original sites in 
untreated TK6 cells (Figure 5.18A) and a gain of RNA Pol II (pSer2) enrichment 
elsewhere on chromosome 17 (Figure 5.18B). Overall, these are consistent with the 
results observed in Figure 5.15, demonstrating that TSA promotes the co-localisation of 
transcription and replication events on chromosome 17 (Figure 5.19) and as a result, may 
lead to an increase in the probability of these two processes colliding with one another, 
potentially resulting in DNA damage and the formation of R-loops. 
5.7 Determining the potential for DNA damage induction and R-loop formation 
at sites of TSA-induced transcription and replication co-localisation 
  
The discovery that TSA promotes the co-localisation of transcription and 
replication activity presents the possibility that these may conflict and lead to the 
formation of DNA damage. To measure this, changes in phosphorylation of histone 
H2AX (γH2AX) in response to TSA was used as a marker of DNA double strand breaks 
(similar to the work described in Chapter III). ChIP performed with the anti-γH2AX 
antibody using chromatin from untreated and TSA treated TK6 cells demonstrated 
enrichment following treatment at both RPL10 and GAD1 genes, showing that the 
antibody is suitable for ChIP. However, examining the reproducibility of γH2AX 
microarray data shows a low level of correlation between three biological repeats of 
γH2AX in untreated and TSA treated cells (Appendix, III). Additionally, plotting the 
γH2AX data measured in untreated cells around the ORFs of genes showed no enrichment 
(Appendix, III), similar to background levels previously observed in the IgG control 
(Figure 5.6). This shows that no γH2AX signal was detected from the ChIP-chip 
experiments.  
 Since γH2AX is expected to be less abundant than any of the signals measured 
beforehand, the lack of enrichment may be caused by insufficient amounts of antigen or 
antibody. To address this, two further biological repeats of γH2AX ChIP-chip was 
performed using greater amounts of chromatin (108 instead of 107 cell equivalent) and 
anti-γH2AX antibody (20μg instead of 8μg) per experiment. Doing so however, does not 
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improve the sensitivity of the ChIP-chip experiment and as before, no enrichment was 
observed (Appendix, III).  
 On the other hand, the occupancy of RNA Pol II and ORC1 upstream of TSS and 
downstream of TES regions coincides with regions of known R-loop formation (Chapter 
I, 1.10.1). While titration of the anti-DNA-RNA hybrid [S9.6] antibody demonstrated 
enrichment, a lack of correlation was observed between three independent replicates and 
similar to γH2AX ChIP-chip data, no enrichment was detected (Appendix, III). These 
results show that attempts were unsuccessful in mapping γH2AX and R-loop formation 
to the same genomic locations using the current ChIP-chip protocol established in TK6 
cells.  
5.8 Discussion 
 
 Studies reported in this chapter aimed to examine if TSA may alter cellular 
processes such as transcription and replication in a way that would increase the frequency 
of potential collisions between them. Using the established ChIP-chip method for TK6 
cells reported previously (Chapter IV), the initial steps focused on examining the effect 
of TSA on: 1) H4ac, a marker or euchromatin, 2) ORC1, a marker of replication initiation 
and 3) RNA Pol II (pSer2), a marker of transcriptional elongation.  Comparisons showed 
that overall, TSA treatment led to a significant increase in H4ac, RNA Pol II (pSer2) and 
ORC1 enrichment on chromosome 17 of TK6 cells (Figures 5.1, Figure 5.3 and Figure 
5.9). Plotting the data in the context of gene structure showed that this increase in signal 
was detected in ORFs for H4ac (Figure 5.2), in contrast to RNA Pol II (pSer2) (Figure 
5.4) and ORC1 (Figure 5.8) which tend to occupy regions around ORFs.  
Previous reports highlighted difficulties in being able to enrich for ORC1 binding 
from whole cell chromatin (Dellino et al. 2013). However, comparing the replicates of 
ORC1 data generated here and the replicates of background binding data (IgG negative 
control) demonstrated a strong reproducibility between ORC1 data, relative to the IgG 
data (Figure 5.5). Additionally, plotting the ORC1 data around gene structure, showed 
distinct enrichment (Figure 5.8) above the background levels detected in IgG data (Figure 
5.6). This shows that ORC1 occupancy can be successfully mapped using the ChIP-chip 
method presented here. The reported associated of open chromatin and G4 structures with 
replication initiating zones promoted the analysis of ORC1 data at these sites (Hoshina et 
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al. 2013). Plotting ORC1 enrichment from both untreated and TSA treated TK6 cells 
around DNAse I hypersensitive sites (DHS identified in K562 cells, ECODE: 
ENSR527IGO), used to denote open regions of chromatin potentially free of nucleosomes 
and at G4 sites (identified in HaCat cells, NCBI GEO: GSE76688), showed that ORC1 
sites in untreated TK6 cells correlate with both these features (Figure 5.7A; B). The broad 
nature of these peaks suggests that only a subset of ORC1 sites detected in this study co-
localise with DHS and G4 structures. This could simply be due to DHS and G4 sites 
playing a partial role in defining initiation zones, or more likely that these sites vary from 
one type of cell to another but still share a common set of sites. It is also possible that 
some of these G4 sites overlap with DHS, since G4 mostly form in open chromatin 
regions (Hertsch R.H. 2016). Conversely, following TSA treatment there is a loss of 
ORC1 at these sites (Figure 5.7A; B), indicating a redistribution in occupancy.  
In an attempt to understand the relationship between TSA-induced changes in 
H4ac with that of transcription and replication; the correlation between data from 
untreated and TSA treated cells were compared for an idea of the strength of the 
relationship. Firstly, to assess transcription, RNA Pol II (pSer2) data plotted against H4ac 
data from untreated cells showed a weak positive correlation (Pearson’s correlation r = 
0.18) (Figure 5.10A). Following TSA treatment, RNA Pol II (pSer2) and H4ac become 
inversely correlated (Pearson’s correlation r = -0.82) (Figure 5.10B). By the same token, 
comparison of ORC1 and H4ac data showed that in untreated cells these two signals 
inversely correlated with one another, becoming more so upon TSA treatment (Figure 
5.10C; D). Therefore, these results suggest that in regions of chromosome 17 showing 
H4ac after TSA, there is at the same time a loss of RNA Pol II (pser2) and OCR1 
occupancy at these sites.   
Surprisingly such observations appear contradictory to the proposed role of 
histone acetylation in promoting transcription and replication, as supported by evidence 
from the literature (Chapter V, 5.2). However, a closer analysis of the patterns of H4ac at 
RNA Pol II (pSer2) and ORC1 sites found in untreated verses TSA treated cells suggests 
that a possibility for the observed inverse correlation may be the result of RNA Pol II 
(pSer2) and ORC1 accumulating within nucleosome free regions, since the lack of 
histones would account for a lack of H4ac at these sites (Figure 5.11; 5.12). An alternative 
explanation is that these sites contain non-acetylated H4 histones. Although given the 
strong association of ORC1 data in untreated TK6 cells with DNAse I hypersensitive sites 
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(Figure 5.7A), this is strongly suggestive of NFRs rather than non-acetylated histone H4 
(Figure 5.11A).  
Examining the relationship between H4ac and RNA Pol II (pSer2), showed that 
RNA Pol II (pSer2) sites identified in untreated cells displayed a high level of H4ac 
enrichment (Figure 5.12A). As evidence in the literature point towards the involvement 
of NFRs at promoter regions over transcribed regions (Livaja R. 2010), this could explain 
the enriched H4ac pattern observed here. To support this, RNA Pol II (pSer2) data from 
untreated cells plotted around the same DHS do not show particular patterns of 
enrichment (Figure 5.13), suggesting that NFRs are not essential for RNA Pol II (pSer2) 
occupancy. Additionally, an inversion of the H4ac pattern to a ‘V-shape’ at the sites of 
RNA Pol II (pSer2) occupancy found in TSA treated cells suggests the possibility of 
nucleosome depletion (Figure 5.11A). Hence, further experiments mapping changes in 
nucleosome positioning in TK6 cells using the same TSA treatment would shed light on 
the current speculation. In summary, examination of the relationships between the 
variables measured here is strongly suggestive and supports the idea that TSA promotes 
the redistribution of RNA Pol II (pSer2) and ORC1 to potentially NFRs, and while H4ac 
is absent at these site, it is highly enriched in the surrounding regions.  
Although TSA treatment promotes an overall increase in H4ac on chromosome 
17, a small number of genes however, show lower levels of H4ac in response to TSA 
(Figure 5.1). Therefore, to examine the change in RNA Pol II (pSer2) and ORC1 patterns 
at H4 hyper- and hypo-acetylated genes following treatment, the data was plotted around 
gene structure. Overall, both RNA Pol II (pSer2) and ORC1 enrichment appear to be 
higher downstream of TES at H4 hypo-acetylated genes (Figure 5.14A; B) and also higher 
upstream of TSS at H4 hyper-acetylated genes (Figure 5.14C; D). While the regions 
extending away from the gene body may or may not display the same level of H4ac, they 
are nevertheless related to those genes. Therefore, irrespective of the H4ac levels at TSS 
and TES’s, these results indicate a scenario where RNA Pol II (pSer2) and ORC1 may 
co-localise outside of the ORFs.  
To investigate this prospect, the correlation between RNA Pol II (pSer2) and 
ORC1 data was compared in untreated verses TSA treated cells (Figure 5.15). Evidently 
the increase in correlation from untreated (Pearson’s correlation r = -0.19) to TSA treated 
cells (Pearson’s correlation r = 0.95) strongly indicates that transcription and replication 
events co-localise to the same regions on chromosome 17 following treatment. 
Additionally, the impact of TSA on transcription and replication was demonstrated by 
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comparing the correlations between each dataset before and after treatment (Figure 5.16). 
The results showed that TSA had a significant effect on ORC1 occupancy, with almost a 
complete re-distribution of replicating sites (Figure 5.15B). This is consistent with the 
published work of Conti and colleagues showing that HDAC inhibition promotes 
activation of dormant origins (Conti et al. 2010). Therefore, it is possible that the ORC1 
changes here reflect a shift in activity in origins sites. On the other hand, TSA had a less 
pronounced effect on RNA Pol II distribution (Figure 5.15A). Detailed analysis of the 
changes in RNA Pol II (pSer2) and ORC1 at sites identified in untreated and TSA treated 
cells also support the changes in correlation observed (Figure 5.17; 5.18). 
Taken together, these results show that TSA promotes the localisation of 
transcription and replication to the same regions of chromosome 17, prompting the 
analysis of potential conflicts as a mechanism of generating DNA damage. However, 
attempts to map γH2AX in TK6 cells proved unsuccessful in detecting enrichment. This 
was demonstrated by the fact that biological replicates did not correlate strongly and 
showed no enrichment when plotted in relation to gene structure (Appendix, III), even 
though γH2AX enrichment was detected by ChIP at different sites in response to TSA 
(Appendix, III). It is possible that the ChIP DNA was sufficient for qPCR analysis but 
below the required amount for whole genome amplification. To address this, larger 
amounts of chromatin and antibody were used, yet no improvement was observed, 
suggesting that other factors are limiting its detection of the microarrays (Appendix, III). 
Possibilities to improve this include optimising the post-IP washes to remove potential 
background, or the use of an alternative anti-γH2AX antibody.  
The pattern of RNA Pol II (pSer2) and ORC1 co-accumulation at upstream TSS 
and downstream TES regions presents evidence to suggest that if transcription-replication 
conflicts do occur then R-loop formation is likely, since coincidently these regions favour 
the formation of R-loop under physiological settings (Sollier J 2015). Yet, attempts to 
map R-loops in TK6 cells using RDIP-chip resulted in the same outcome as γH2AX 
(Appendix, III). Titration of the anti-DNA-RNA [S9.6] antibody at positive control loci 
showed a small but distinguishable enrichment (5-fold) over the negative control loci, 
suggesting that the antibody is suitable for ChIP (Appendix, III). Since both γH2AX and 
R-loop signals are predicted to be less abundant than H4ac, RNA Pol II (pSer2) and 
ORC1, it is possible that the currently established ChIP-chip protocol for TK6 cells lacks 
the sensitivity to detect these and require further optimisation.  
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6.1  Chapter aims 
 
Given the technical difficulties in trying to measure γH2AX and R-loops by ChIP-
Chip in TK6 cells, studies in this chapter seek instead to model these in yeast. The 
previously identified rpd3Δ strain (Chapter III) will be used here to mimic the effects of 
treating with an HDAC inhibitor, and γH2A (ortholog of γH2AX) and R-loops will be 
mapped to investigate if a loss in HDAC function leads to the possibility of an increased 
level of transcription-replication collisions. The results of these findings may help to 
support the observations made in TK6 cells.   
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6.2 Validation of γH2A and R-loop ChIP-chip data  
 
 To map genome-wide γH2A enrichment, chromatin was prepared using 
previously optimised conditions (Chapter III) and immunoprecipitated with the anti-
histone H2A (phospho-S129) ChIP-grade antibody. For R-loop microarrays, genomic 
DNA was extracted from cells and digested with RNAse A under high salt conditions to 
remove single and double stranded RNA. R-loops are then enriched using the anti-DNA-
RNA hybrid [S9.6] antibody (Chan et al. 2014). For both targets, the ChIP reaction was 
performed with genetic material obtained from wild type and rpd3Δ yeast cells. 
Immunoprecipitated DNA was then amplified and labelled prior to array hybridisation. 
For this study, S. cerevisae whole genome arrays are used (Chapter II, 2.2.4.3).   
Following data normalisation and quality control (Appendix, IV), biological 
replicates were first compared to examine reproducibility. A high correlation (Pearson’s 
r > 0.9) was observed between the two biological replicates generated in both WT and 
rpd3Δ strains measuring γH2A (Figure 6.1A) and R-loops (Appendix, IV). This is also 
evident when examining data plotted along a small section of chromosome 1 (100kbp - 
150kbp) (Figure 6.1B), demonstrating that these results are highly reproducible in yeast. 
To validate the results of the γH2A microarray, normalised data from the wild type strain 
was compared to γH2A data mapped in W303 strains published by Szilard and colleagues 
(Szilard et al. 2010). Visual comparison of γH2A for chromosome 1 shows a very similar 
pattern of enrichment between the two datasets (Figure 6.2A). Furthermore, a comparison 
of all the γH2A peaks detected throughout the yeast genome showed that the majority of 
γH2A peaks identified in this study match those previously identified by Szilard and 
colleagues (Szilard et al. 2010) (Figure 6.2B). C-rich DNA and G-rich RNA are important 
factors that favour the formation of stable DNA:RNA hybrid structures (Skourti S.K., 
Kamieniarz G.K., and Proudfoot N. J. 2014). Recent evidence has also shown that R-
loops are prevalent throughout the genome and are preferentially found at CpG-
containing promoters (Ginno et al. 2012) and G-rich transcription termination regions 
(Skourti-Stathaki, Proudfoot, and Gromak 2011). To validate the R-loop microarray data 
generated here, motif enrichment analysis was carried out in MEME-ChIP (Ma, Noble, 
and Bailey 2014) using sequences of identified R-loop peaks in the wild type strain. The 
motif with the highest statistical significance (Figure 6.3A Top panel: E = 2.1x10-27) is 
defined by the greatest number of sequences that express the highest logarithmic ratio of 
a given motif compared to a null background model (Ma et al., 2014). From the list of  
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Figure 6.1. Biological repeats of yeast γH2A microarray data show high reproducibility. A: 
smoothed scatter plots showing the Pearson’s correlation coefficient between two biological 
repeats for wild type (left) and rpd3Δ (right). B: normalised array data plotted along a section of 
chromosome 1 (100 – 150kb). Array probes are shown in grey along the annotation line with 
enriched regions in red. n = 2. 
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Figure 6.2. γH2A microarray data generated in this study is consistent with published 
microarray data. A: γH2A peaks detected in wild type W303 strain from published findings 
(Chan et al. 2014) (top, dashed line), compared to γH2A peaks detected in the current study using 
wild type BY4742 strain (bottom, sold line), plotted along the full length of yeast chromosome 1. 
B: majority of γH2A peaks identified in the yeast genome (red circle) overlap with those 
identified in the W303 strain (blue circle) (Chan et al. 2014). Peak matching analysis conducted 
using ChIPpeakAnno v3.4.6 in R with maxgap = 1000bp.  
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Figure 6.3. R-loop microarray data generated in this study is characteristic of DNA:RNA 
hybrid structures. A: motif-enrichment analysis detects high GA-skew in the RNA component 
and a high CT-skew in the DNA component of R-loop peak sequences in the wild type strain 
(Skourti-Stathaki and Proudfoot 2014) (E-value  = 2.1x10-27). Analysis was carried out using 
meme-chip scripts (Ma, Noble, and Bailey 2014) in Perl v5.22.1. B: R-loops detected in the wild 
type strain plotted in the context of gene structure (+/- 15kb up and downstream of the open 
reading frame, grey box) showing higher distribution at promoter and transcription end sites. 
Standard deviation error shapes plotted around the average of two biological repeats. TSS – 
transcription start site. TES – transcription end site. n = 2. 
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peaks analysed, the RNA component is highly GA-rich (Figure 6.3A: Top panel), 
whereas the corresponding template DNA is CT-rich (Figure 6.3A: Bottom panel), 
suggesting that these peaks do indeed display sequences that can contribute to the 
described thermostability of R-loop structures (Lynda Ratmeyer 1994). Plotting the 
normalised wild type strain data in the context of gene structure (+/- 1500bp up and 
downstream of the open reading frame) for all genes in the yeast genome, showed 
elevated levels of enrichment in the promoter and transcription end sites (TES) (Figure 
6.3B), which is consistent with previous findings (Ginno et al. 2012). Together these 
results demonstrate that both genome-wide γH2A and R-loop microarray data generated 
in this study agrees with published findings, warranting further analysis. 
6.3 Analysis of yeast γH2A and R-loop data  
 
 Having normalised and validated the microarray data, the following section aims 
to examine firstly the overall effect of RPD3 deletion on γH2A and R-loops in the yeast 
genome, followed by analysis of possible co-localisation between the two as a potential 
indicator of transcription-replication conflicts.  
 
6.3.1 Effect of RPD3 deletion on genome-wide γH2A and R-loop signals in yeast 
 
 To investigate if the RPD3 deletion significantly affected γH2A and R-loop 
formation in yeast, the net change between wild type and mutant cells was examined. 
Comparing the IP/IN log2 ratios of peaks detected, rpd3Δ strain showed a significant 
increase in γH2A (P < 2.2x10-16) relative to the wild type, on the other hand, no significant 
difference in R-loop formation was observed (P = 0.148) (Figure 6.4A). These differences 
are also highlighted when examining enriched genes. Approximately half the genes 
showing γH2A enrichment (Figure 6.4B: 197/347 = 57%) are unique in rpd3Δ, whereas 
the majority of R-loop enriched genes remain the same in both the wild type and rpd3Δ 
strains (Figure 6.4B).  
To demonstrate where in the genome these changes in both these signals occur, 
the relative difference in enrichment was calculated by subtracting the wild type data  
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Figure 6.4. RPD3 deletion significantly increases genome-wide γH2A enrichment with little 
effect on R-loop formation. A: left – significant increase in global γH2A enrichment in the rpd3Δ 
strain compared to the wild type (P < 2.2x10-16, Welch’s t-test); right – no significant difference 
observed in R-loop formation between the rpd3Δ and the wild type strains (p = 0.148, Welch’s t-
test). B: Overlap of genes enriched for γH2A (left) and R-loops (right) in the wild type compared 
to the rpd3Δ strain. Peak enrichment values used to calculate relative increase/decrease. Diagrams 
drawn using R base package v3.2.4 and the ‘VennDiagram’ package v1.6.17.  
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Figure 6.5. rpd3Δ cells display an increase in γH2A enrichment primarily in ORFs compared 
to the wild type. Profile plots around gene structure averaged for all genes in the yeast genome 
showing: A: distribution of γH2A signal in the wild type strain (grey). B: change in γH2A 
enrichment, calculated by subtracting wild type data away from rpd3Δ data (red). Standard 
deviation error shapes plotted around the average of two biological repeats. 
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Figure 6.6. R-loops identified in rpd3Δ cells compared to the wild type are enriched in the 
ORFs of genes. Profile plots around gene structure averaged for all genes in the yeast genome 
showing the change in overall R-loop enrichment, calculated by subtracting wild type data away 
from rpd3Δ data (blue, 2260 genes) and the change in R-loop enrichment for a subset of genes 
identified only in rpd3Δ cells (dark orange, 189 genes). Standard deviation error shapes plotted 
around the average of two biological repeats. 
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away from the rpd3Δ data. The change in γH2A signal plotted in the context of gene 
structure can be compared to the pattern observed in the wild type to identify regions 
showing changes in enrichment when RPD3 is lost (Figures 6.5B; 6.6). Comparison of 
γH2A profiles show that the significant overall increase observed in Figure 6.4A occurs 
predominantly within the open reading frames (ORFs) of genes (Figure 6.5). The lack of 
a significant change in R-loop formation between the strains is shown in Figure 6.6, where 
the overall profile lies around 0, reflecting the results observed in Figure 6.4A. However, 
for a small subset of genes exclusively enriched for R-loops in rpd3Δ cells, a significant 
increase is noted in the ORFs (as the IP/IN log2 ratio is >1, equating to a relative fold 
change of > 2). Interestingly, this suggests that R-loops identified in the subset of genes 
in rpd3Δ cells may co-localise with γH2A, given that they are both enriched within the 
ORFs (Figure 6.5B; 6.6). 
 
6.3.2 Examining the co-localisation of γH2A and R-loop in yeast as a marker of 
transcription-replication conflicts 
 
Since γH2A and R-loop formation are the predicted outcomes of transcription and 
replication collisions (Skourti-Stathaki and Proudfoot 2014), the co-localisation of both 
signals might be expected under these circumstances. Although previous results 
demonstrated an overall increase in γH2A with no significant change in R-loop formation, 
closer examination shows a similar number of genes enriched for γH2A (197) and R-
loops (189) only in the rpd3Δ strain (Figure 6.4B). In addition, genes enriched for γH2A 
in the wild type show higher levels of γH2A in rpd3Δ (Figure 6.1B), whereas R-loops in 
the wild type and rpd3Δ strains remain mostly unchanged (Figure 6.4A), apart from those 
appearing only in the rpd3Δ strain (Figure 6.4B). To identify genes showing an increase 
in both γH2A and R-loop enrichment following RPD3 deletion, the average peak 
enrichment (log2 IP/IN) was first calculated for each gene in both wild type and rpd3Δ 
strains. Comparing the two lists, genes in rpd3Δ showing a 2-fold relative increase in the 
average peak enrichment (IP/IN) over the wild type was selected. As a result, 320 genes 
are identified, showing a 2-fold or greater level of γH2A enrichment in rpd3Δ compared 
to the wild type and 189 genes identified as showing a 2-fold or greater level of R-loop 
enrichment in rpd3Δ compared to the wild type. By matching both lists, only 9 genes 
show an increase (2-fold or greater) in both γH2A and R-loop (Figure 6.7). However, 
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such a small number of genes do not represent a statistically significant overlap (P = 0.73), 
suggesting that co-localisation of the two signals do not appear abundantly throughout 
the genome.  
To investigate if these regions might represent potential sites where transcription 
and replication machineries may conflict, the bidirectional spreading of γH2A across 
large genomic regions, a well-described phenomenon linked to DNA double strand 
breaks, was examined (Szilard et al. 2010). For an estimate of γH2A spread, the genomic 
range between γH2A peaks lying within 1kb of each other was calculated and considered 
part of the same γH2A signal. From the data, the average estimated γH2A signal (spread) 
is similar in both wild type (mean = 873bp) and rpd3Δ (mean = 924bp) strains (Figure 
6.8), with no significant difference (P = 0.354, Welch’s t-test). Although the average 
probe spacing on the microarray is calculated to be ~273bp, the actual distribution varies, 
with gene rich regions abundantly represented while other regions are less populated with 
probes. This is because regions containing repetitive DNA sequences cannot be 
accurately represented and is particularly apparent at telomeres and sub-telomeres, which 
lack representation on the arrays. Even so, γH2A is highly enriched in these areas, 
covering ~30kb on all chromosome ends in the yeast genome of wild type cells (Figure 
6.9). This phenomenon was also reported in previous studies in yeast (Szilard et al. 2010) 
and human cell lines (Siow et al. 2012). Intriguingly, rpd3Δ significantly elevates the 
γH2A signal observed in the wild type at telomere and sub-telomeric regions of all yeast 
chromosomes, although R-loops do not appear to show the same level of change 
(representative data for chromosome I shown in Figure 6.9). Also, of the 9 genes showing 
co-occurrence of γH2A and R-loops, 4 are found within telomere regions, which are 
known to exhibit high levels of replication stress (Szilard et al. 2010).   
 
6.3.3 Examining γH2A and R-loops at sites of replisome impedance  
 
Work by Szilard et al. demonstrated that in addition to telomeres, γH2A map to 
other sites susceptible to replication fork stalling/collapse, such as replication origins, 
tRNA genes, long terminal repeats (LTRs), a small number of coding-genes and rDNA 
sequences (Szilard et al. 2010). To examine how rpd3Δ affects γH2A and R-loop 
formation at some of these sites, microarray data is plotted (+/- 1500bp) around the 
starting positions of known replication origins, tRNA genes and LTRs (Figure 6.10). The 
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results show that γH2A in wild type cells are enriched at replication origins and LTRs but 
not at tRNA genes. In comparison with rpd3Δ cells, γH2A levels are highly elevated and 
retain the same pattern of distribution (Figure 6.10, left). R-loops are enriched at 
replication origins and tRNA genes but not at LTRs although the level and pattern of R-
loop enrichment in both wild type and rpd3Δ cells remain the same. Interestingly, R-loop 
enrichment at replication origins sites coincides with high levels of γH2A (Figure 6.10A), 
which suggests that in wild type cells, transcription may be interfering with replication at 
a subset of common fragile sites located close to replication origins. 
 
6.3.4 Significance of R-loop enriched genes in rpd3Δ cells 
 
While R-loop formation is not as greatly affected by the loss of RPD3 as γH2A, a 
small group of genes (189) show R-loop enrichment only in rpd3Δ cells Figure 6.7. To 
examine the significance of this, the molecular processes associated with these genes were 
surveyed by carrying out a Gene Ontology search using the Saccharomyces genome 
database (SGD) (Siow et al. 2012). Consequently, an over-representation in genes coding 
for small nucleolar RNA (snoRNA)-binding proteins was observed (P < 0.01) (Figure 
6.11). The products of these genes are constituents of small nucleolar RNA-protein 
complexes (snoRNP), which function in pre-ribosomal RNA (rRNA) processing. As 
genes in this group display an accumulation of R-loops in ORFs (Figure 6.6), this pattern 
is distinct from the physiological accumulation of R-loops at CpG promoter (Ginno et al. 
2012) and transcription termination sites (Skourti-Stathaki, Proudfoot, and Gromak 2011) 
(Figure 6.3B) and may have a negative effect on cellular processes such as transcription 
and possibly replication. It is therefore possible that the expression of these snoRNA-
binding proteins may be suppressed.  
Overall, these results comparing γH2A and R-loop formation in wild type and 
rpd3Δ cells present evidence to suggest that the loss of RPD3 does not significantly 
increase the prevalence of transcription-replication conflicts in the yeast genome. Instead, 
a significant increase in γH2A observed throughout the genome is likely to reflect 
elevated levels of replication stress.     
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Figure 6.7. γH2A and R-loops co-localise in the region of 9 genes as a result of RPD3 
deletion. Calculating the difference between rpd3Δ and wild type data identified 320 genes and 
189 genes showing an increase in γH2A and R-loop formation, respectively. Within these genes 
only 9 displaed a significant increase in both γH2A and R-loops but do not represent a 
statistically significant overlap (P = 0.73). Diagram drawn using R-based ‘VennDiagram’ 
package v1.6.17. Statistical analysis (Hypergeometric test) was performed using the R-base 
package v3.2.4. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8. γH2A detected as a result of RPD3 deletion do not resemble DNA-damage 
induced γH2A signals. Boxplot showing the distribution of γH2A peak ranges for wild type 
(mean = 873bp) and rpd3Δ (mean = 924bp). Diagram drawn using the R-base package v3.2.4. 
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Figure 6.9. γH2A and R-loops plotted at telomeric and sub-telomeric ends of yeast 
chromosome 1 in wild type and rpd3Δ cells. Section of a genome plot showing γH2A and R-
loop formation on the ends of yeast chromosome 1 (from 0 – 40kb and 190kb – 230,218bp). 
Average of two biological repeats shown.  
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Figure 6.10. γH2A and R-loop microarray data plotted around sites known to impede 
replication fork progression. A: Replication origins, B: tRNA genes and C: long terminal 
repeats (LTRs) are locations in the yeast genome identified to potentially inhibit replication forks, 
leading to cell stress. Starting coordinates for consensus replication origins in wild type yeast are 
obtained from OriDB (DNA replication origin database) (Siow et al. 2012). Starting coordinates 
for tRNA genes and LTRs are obtained from YeastMine (Balakrishnan et al. 2012). Standard 
deviation error shapes plotted around the average of two biological repeats. 
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Figure 6.11. Genes exhibiting R-loop formation only in rpd3Δ cells are highly over-
represented for those encoding for snoRNA-binding proteins. R-loop formation is detected in 
189 genes exclusive to rpd3Δ but not in wild type cells. Gene Ontology analysis (GO term) of 
molecular function was performed in SGD (Cherry et al. 2012) using the 189 identified genes, 
showing a significant over-representation of genes coding for small nucleolar RNA binding 
(snoRNA) proteins: 6 of 21 (P = 0.002). 
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6.4 Discussion 
 
Using genome-wide analysis tools to identify associations between the products 
of transcription-replication conflicts, such as γH2A and R-loops the yeast RPD3 HDAC 
mutant, provides a useful way of identifying if and where these events occur throughout 
the genome, affording potential evidence to support a mechanism by which HDAC 
inhibitors could induce DNA damage.  
While earlier chemical means of inhibiting HDAC enzymes proved unsuccessful 
(Chapter III), an alternative genetic approach was taken to make use of an HDAC deletion 
strain to mimic the effects of treating yeast cells with an HDAC inhibitor. As RPD3 most 
resembles mammalian class I nuclear HDAC enzymes, the BY4742 strain harbouring an 
RPD3 deletion was selected. To examine if the loss of RPD3 would lead to an increase 
in the frequency of transcription and replication conflicts as predicted with HDAC 
inhibitors in TK6 cells, markers of these events are mapped throughout the yeast genome 
using ChIP-chip. γH2A is an epigenetic marker of DNA double strand breaks and R-loop 
structures are formed co-transcriptionally. Both of these have been associated with DNA 
damage arising from conflicts between transcription and replication and therefore are of 
interest in this study.    
Since target enrichment is key to ChIP-chip and depends almost exclusively on 
the availability and quality of the antibody, ‘ChIP-grade’ antibodies were preferentially 
selected based on published studies referencing their use. In this case, both commercially 
available anti-γH2A and anti-DNA:RNA-hybrid (R-loop) antibodies have been used in 
microarray studies, warranting their application (Chan et al. 2014; Stirling et al. 2012).  
Several changes were made to the DRIP-Chip protocol described by Chan et al. for 
mapping R-loops in yeast to reflect developments made surrounding the methodology 
since its publication. Firstly, since DNA-bound proteins are not the targets of DRIP-Chip, 
DNA is used instead of chromatin, which is easier to prepare and quantify. Secondly, 
RNAse A digest was carried out at high salt concentrations (400mM NaCl) to remove 
only single and double stranded RNA but not RNA present in DNA:RNA hybrids prior 
to immunoprecipitation, as this was previously shown to result in false positive signals 
(Zheng Z Zhang 2015). Next, a high degree of reproducibility was shown between the 
two biological repeats (Pearson’s > 0.9) of γH2A (Figure 6.1) and R-loop (Appendix, IV). 
The data was then validated against previously published work. γH2A enrichment 
detected in this study followed a similar pattern to those reported by Szilard and 
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colleagues (Figure 6.2) (Szilard et al. 2010), while R-loop peak sequences are purine-rich 
and displayed the expected distribution around gene structure (Figure 6.3). Together these 
observations establish that the data generated is of sufficient quality for further analysis.   
For an indication of the overall effect of rpd3Δ on γH2A and R-loop formation in 
yeast, the net change was examined by comparing peak enrichment between wild type 
and rpd3Δ cells. Figure 6.4 and Figure 6.5 show that RPD3 deletion significantly 
increases in the genome-wide γH2A signal primarily within the open reading frames of 
genes, maintaining the pattern of distribution. However, the effect of RPD3 deletion does 
alter the global levels R-loops (Figure 6.4). Instead, a small number of genes identified 
in rpd3Δ cells express R-loops that are not found in wild types cells and these 
preferentially accumulate over the open reading frames of genes (Figure 6.6), similar to 
the observed γH2A signal (Figure 6.5). This raises the possibility that a small number of 
regions may show a co-localisation of the two signals, indicative of transcription-
replication conflicts.   
To investigate this idea, genes showing a 2-fold or greater enrichment in γH2A or 
R-loops were compared (Figure 6.7). As a result, a very small subset of genes (9) shows 
both γH2A and R-loops enrichment but proved statistically insignificant (P = 0.73) 
(Figure 6.7). To examine whether γH2A signal exhibited by deletion of RPD3 are 
reminiscent of DNA-damage induced γH2A signals, which can cover regions in excess 
of 10kb (Szilard et al. 2010; Chan et al. 2014), the average spread was compared. To 
calculate γH2A spreading and to account for the uneven probe distribution on the arrays, 
γH2A peaks within 1kb were considered to be part of the same signal. Doing so shows 
no significant increase in γH2A spreading comparing rpd3Δ with wild type cells (Figure 
6.8). Relaxing the peak windows beyond 1kb was not considered since γH2A peaks 
separated by 2kb or greater may represent two independent signals. However, telomeric 
and sub-telomeric regions, typically covering ~30kb on either end of each chromosome, 
show high levels of continuous γH2A enrichment. These regions are not picked up in the 
analysis since they contain numerous repeat sequences not represented by array features, 
resulting in ‘gaps’ in the data, but are apparent upon visual inspection (Figure 6.9). 
Interestingly these patterns observed in the wild type strain, consistent with previous 
reports (Szilard et al. 2010), show significant increase upon RPD3 deletion, which may 
reflect elevated levels of endogenous stress owing to changes in replication and possibly 
transcription. Yeast telomeres are hotspots for replication stress as identified by high 
levels of γH2A in previous studies (Szilard et al. 2010). In addition, γH2A is found at 
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sites with the potential to pose as barriers to replisome progression (Szilard et al. 2010). 
Further analysis of this shows that γH2A is highly elevated at replication origins and 
LTRs in the wild type and that the loss of RPD3 further promotes γH2A at these sites 
(Figure 6.10). Examination of R-loops show that in wild type cells, the observed R-loop 
enrichment at replication origins co-localise with high levels of γH2A (Figure 6.10A), 
suggesting that transcription may be interfering at these sites prone to replication fork 
stalling and collapse. The same origins sites in wild type cells are enriched for γH2A in 
rpd3Δ cells, in contrast to R-loops between the two strains. Evidence in yeast and human 
suggests that inhibiting/deleting HDACs places cells under replication stress and as a 
result dormant origins are activated (Mantiero et al. 2011; Conti et al. 2010). It would 
therefore be interesting to examine if the 9 genes where γH2A and R-loops co-localise 
upon RPD3 deletion map to dormant origins, in which case it would represent HDAC 
liable fragile sites. However, the locations of replication origins activated following 
RPD3 deletion have not yet been reported. While previous studies also reported γH2A 
enrichment at tRNA genes, this was only observed in rpd3Δ but not in wild type cells in 
the current study.  
Given the emerging implication of R-loops in a range of neurological disorders 
and cancer, the molecular function of genes showing R-loop formation only in the rpd3Δ 
strain was examined. The GO term analysis identified a significant over-representation 
of genes whose products are involved snoRNA-binding (Figure 6.11). Additionally, the 
pattern of R-loop accumulation in these genes is more pronounced in the ORF (Figure 
6.6) and raises the possibility that these genes may be suppressed, given the 
heterochromatin state enforced by R-loops (Castellano-Pozo et al. 2013). The role of 
snoRNAs focuses mainly on applying modifications to pre-rRNA, guided by proteins 
forming an RNA/protein complex known as the small nucleolar ribonucleoproteins 
(snoRNPs). Coincidently Meskauskas and colleagues highlighted the importance of the 
repressive yeast HDAC complex Sin3-Rpd3 in aiding early ribosome biogenesis, as 
mutations in RPD3 results in rRNA processing delays (Meskauskas et al. 2003). The 
authors speculate that exclusion of histone deacetylase activity silences the transcription 
of snoRNAs (Meskauskas et al. 2003), though evidence for this is lacking. Instead in the 
context of evidence presented in this chapter, a possible epigenetic-driven-R-loop based 
mechanism, leading to the suppression of snoRNA-binding proteins may similarly 
diminish the activity of snoRNP, thereby affecting rRNA processing. Additional 
experiments to confirm R-loop formation at these loci in combination with repressive 
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histone marks and gene expression studies would help to clarify these underlying 
mechanisms. 
Together, the results of the γH2A and R-loop microarray analysis between wild 
type and rpd3Δ yeast cells suggest transcription and replication collisions to be largely 
absent, following deletion of RPD3, at least in regions of the genome where R-loops can 
be mapped (non-repetitive sites). However, such events may be prevalent at telomeres 
and sub-telomeres of chromosomes which exhibit high levels of γH2A spanning the full 
length of these regions. While the precise role of γH2A at telomeric and sub-telomeric 
regions is not entirely understood, Seo et al. found that in lymphocytes, sub-telomeres are 
more prone to endogenous stress than to external DNA-damaging sources such as γ-
irradiation and is suggested to mirror transcription and replication induced stress in 
cycling cells (Jungmin Seo 2012). Furthermore Kim et al. suggested that these regions 
could contain transient double strand breaks (Kim et al. 2007). Therefore, it would be 
interesting to determine if the γH2A observed here, which tend to be in excess of 30kb, 
constitute to DSB induced by transcription-replication conflicts. Chan and others also 
detected high levels of R-loops at telomeres in yeast using genome wide tiling arrays 
(Chan et al. 2014). Intriguingly, 4 of the 9 genes identified in this study where γH2A and 
R-loops co-localise (Figure 6.7) are found on the ends of chromosomes. Given the 
limitation of not being able to map events in regions containing repetitive DNA, it is 
reasonable to assume based on the work by Chan and others that R-loops could be highly 
enriched at telomeres in the cells used in this study, thereby implicating transcription as 
a barrier to replication (Chan et al. 2014). Further work mapping proteins involved in 
transcription, replication, double strand break repair factors such as MRE11 as well as R-
loops using tiling arrays could help determine if a loss of HDAC function significantly 
affects these processes giving rise to the formation of double strand breaks. 
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The current study aimed to address aspects of drug safety concerned with efforts 
to utilise epigenetic-targeting HDAC inhibitors for non-life threatening illnesses, 
following substantial evidence from genotoxicity studies indicating their potential to elicit 
genetic damage. Central to this is the basic need for a better understanding of the 
biological mechanisms underpinning these genotoxic effects. Only then can we begin to 
identify more informative endpoints that could be used to assess risk.  
To approach the problem at hand, it is first important to recognise the possible 
connections between HDAC inhibitors and the onset of DNA damage. To this end, a 
review of the literature surrounding the effects of HDAC inhibition led to identification 
of several potential mechanisms of DNA damage induction, namely cytoplasmic effects 
leading to the generation of reactive oxygen species and nuclear effects resulting in the 
dysregulation of existing cellular processes to generate damage. With interests in trying 
to understand the more direct connection between the epigenome and the genome, focus 
was directed towards examining the nuclear effects of HDAC inhibitors, particularly on 
chromatin and how these changes may lead to the formation of damage at the genetic 
level. Chromatin structure plays an important role in regulating transcription and 
replication, two key processes involved in the expression and propagation of genetic 
information stored within cells, and because of this, they both compete for the same DNA 
template. Interestingly, studies have shown that collisions between transcription and 
replication are inevitable, occurring in prokaryotes as well as eukaryotes (Helmrich, 
Ballarino, and Tora 2011; Brambati A 2015; Mirkin and Mirkin 2005). The result of such 
collisions is the presumed formation of DNA double strand breaks along with co-
transcriptional by-products such highly stable RNA:DNA hybrid structures, otherwise 
known as R-loops (Stathaki K.S. 2014). Surmounting evidence in the past few years 
suggests that while R-loops have regulatory roles within cells, their locations in the 
genome are closely regulated by a range of mechanisms. Aberrant formation of R-loops 
on the other hand, can be detrimental to the cell of not resolved properly (Sollier and 
Cimprich 2015). Not only can R-loops impede the passage of proteins which required 
access to the DNA but the exposed single stranded DNA is highly susceptible to 
mutations. As a consequence, aberrant R-loops can lead to various pathological outcomes 
such as the onset of cancer and certain neurodegenerative diseases (Groh M. and Gromak 
N. 2014; Groh M. et al. 2014). Therefore, based on what is currently known, the work 
presented in this thesis aims to investigate the possibility that HDAC inhibitors may 
elicited DNA damage through changes in the chromatin, resulting in higher incidences of 
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transcription-replication collisions throughout the genome. If shown to be the case, then 
a combination of DNA damage and R-loops may lead to genome instability and 
predispose cells to a disease prone state.  
To best answer this question, ChIP-chip was selected as the method of choice for 
several reasons. Firstly, the technique allows genome-wide measurements of both 
epigenetic (histone modifications) and genetic (DNA-binding proteins) targets of interest 
in a ‘top-down’ approach. This is a key advantage since the sites where transcription and 
replication collisions may take place following HDAC inhibitor treatment are unknown, 
so it is important to survey large regions of the genome in a non-biased manner. Secondly, 
bioinformatic tools developed within the lab present a novel method of data 
normalisation, thus allowing relative comparisons to be made between data gathered from 
untreated and HDAC inhibitor treated cells. This is important since biological signals 
such as histone acetylation are present at a basal level in cells and may increase/decrease 
after HDAC inhibition. In the absence of proper normalisation, interpretation of the data 
would strictly be limited to binary states, either present or absent (Bennett 2015). Last but 
more importantly, the ability to combine and analyse several ‘layers’ of genomic data 
allows the information-rich data to be broken-down, revealing the unique relationships 
between the seemingly complex biology and is used as the basis of the mechanistic study 
presented here. 
ChIP-chip, nevertheless still has its drawbacks, namely lacking in resolution 
compared to ChIP-seq. ChIP-chip also suffers from signal saturation, where each probe 
on the array has a limited binding capacity. By contrast, ChIP-seq sequences all the 
fragments present in the sample and therefore does not possess the same limitations. 
While ChIP-seq is rapidly replacing ChIP-chip as the genome-wide method of choice, 
Agilent’s offer of cost-efficient custom array designs along the aforementioned 
advantages make ChIP-chip the ideal method for this project. Additionally, since the aim 
here is mainly concerned with identify changes in the distribution and patterns of 
biological signals rather than their precise locations within the genome, the resolution of 
the microarrays are more than adequate for this requirement.  
 To initially gain an idea of the genome-wide effects of HDAC inhibition, namely 
to compare changes in histone acetylation and markers of transcription, replication and 
DNA damage, the decision was taken to study these in yeast. This presented several 
advantages, mainly because the ChIP-chip protocol has already been established in yeast 
(Yu et al. 2011), and since yeast cells grow much faster than mammalian cells yeast array 
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data can be generated much more quickly than human array data. Therefore, the results 
of the yeast study were expected to shed light on potential effects that may be observed 
in human cells following HDAC inhibitor treatment. Early attempts aimed to show the 
key effects of HDAC inhibitors in yeast cells prior to the use of microarrays. As such the 
type of inhibitor and doses tested were chosen based on those published in the literature. 
However, several attempts to measure the effects of HDAC inhibition on histone 
acetylation and transcription proved unsuccessful (Figure 3.2 – Figure 3.6). Although 
reduction in cell growth was observed, this may be due to HDAC inhibitors having an 
effect on the integrity of the cell wall (Figure 3.1). Hence the results of these studies show 
that in the current study, HDAC inhibitors failed to have any effect at on the chromatin. 
One possibly is that the yeast cell wall posed as a barrier, limiting the uptake of the drug. 
A potential solution to this would be to digest the yeast cell wall and treat the resulting 
spheroplasts with HDAC inhibitors. However, removal of the cell wall would severely 
compromise cell integrity and the notion of treating ‘sick’ cells with toxic HDAC 
inhibitors may lead to complications in the microarray data. For this reason, the 
spheroplast method was not pursued. On top of this, reports in the literature describe 
varying level of success when trying to use HDAC inhibitors in yeast. The reasons for 
such discrepancies are unknown, however the observation of histone hyperacetylation in 
the RPD3 HDAC mutant strain would provide an alternative genetic approach to study 
the effects of HDAC inhibition (Chapter VI).  
 Work in Chapter IV aimed to facilitate the transmission from yeast to mammalian 
cells by establishing the ChIP-chip method in TK6 cells. The outcome would be the 
development of a genome-wide tool for measuring the genotoxicity of HDAC inhibitors 
in a human relevant cell line. For this purpose, it was important to use a cell line that 
could respond normally to DNA damaging agents. To confirm this, the TP53 status of 
TK6 cells used in this study was examined by measuring p53 protein expression and the 
apoptotic response to nutlin-3. Since the western blot analysis showed p53 expression in 
both TK6 and MDA-MB-231cells, to show that the p53 protein found in TK6 cells were 
active wild-type compared to the inactive mutant found in MDA-MB-231cells, an 
apoptosis assay was carried out following treatment with nutlin-3. Nutlin-3 has been 
shown to induce apoptosis only in cell lines harbouring fully functional wild-type p53 
(Pozzo et al. 2013), and is similarly used here to show that the p53 expressed in TK6 cells 
is indeed functional (Figure 4.1 and Figure 4.2). Next, as attempts to show the effects of 
HDAC inhibitor treatment in yeast were unsuccessful, it was therefore important to show 
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these effects in the TK6 cell line prior to progressing onto the microarrays. Since the 
classical HDAC inhibitor TSA has been previously used in TK6 cells (Olaharski et al. 
2006) and that much of the existing genotoxic measurements on HDAC inhibitors were 
made following a 24h treatment (Johnson and Walmsley 2013; Yoo EJ 2005; Gomez V.P. 
and Vig B.K. 2002; Olaharski et al. 2006), the aim was to confirm some of these 
observations under similar conditions in the current study to show that TSA in indeed 
genotoxic in the TK6 cells used here. To do this, the InVitro MicroFlow® assay was used 
to measure micronuclei induction as a genotoxic endpoint. Although the assay was 
validated with the known genotoxic compound Vinblastine as a proof of performance, 
the result of treating TK6 cells for 24h with TSA showed borderline genotoxicity, given 
the high levels of cytotoxicity observed (Figure 4.3 and Figure 4.4). The InVitro 
MicroFlow® assay measures micronuclei formation by using two fluorescent dyes with 
different staining properties, followed by a series of gating to identify the population of 
micronuclei ‘events’. While this commercial assay has been well validated by the 
manufacturer (Collin J.E. et al.), it is nevertheless an indirect means of measurement. 
Therefore, an alternative method would be to measure micronuclei using the more 
traditional microscopy approach. Given the highly cytotoxic nature of HDAC inhibitors 
in general, the decision was taken not to use 24h treatments to avoid the possibility of 
observing cytotoxicity-induced genotoxicity (i.e. DNA damage resulting from apoptosis), 
which can complicate the actual genotoxic effect of the drug. To take advantage of the 
fact that drug-induced genotoxicity commonly manifests earlier, TK6 cells were exposed 
to TSA for shorter periods of time. To examine the genotoxic response elicited by TSA 
immediately following each time point, γH2AX was used as an epigenetic marker of 
DNA damage and measured using flow cytometry. Since a significant increase in both 
global H3K9ac and γH2AX was observed in TK6 cells after 6h treatment with TSA, 
further assessment of annexin-V and cell cycle changes showed a lack of cytotoxicity, 
leading to the identification of a suitable treatment regimen for studying the genotoxic 
mechanisms using microarrays (Figure 4.5 and Figure 4.6). The main reason for using 
flow cytometry is that it presents a rapid method of confirming many of the characteristic 
effects of HDAC inhibitors, such as cytotoxicity, histone hyperacetylation and 
phosphorylation, which have all been well-described in the literature (Bose, Dai, and 
Grant 2014).   
 Following this, the ChIP-Chip method was successfully established for TK6 cells. 
This involved a series of optimisation steps to ensure that chromatin from TK6 cells could 
  191 
be fragmented to the desired size (Figure 4.7 – Figure 4.11). Enzymatic digestion can also 
be used here to produce chromatin fragments, but sonication is used as it tends to produce 
a more random population of fragments. Further immunoprecipitation of RNA Pol II 
(pSer2) showed that the targets of interest could be enriched from the chromatin and this 
population of DNA fragments (IP) can be PCR amplified with little loss in representation 
(Figure 4.12). Since PCR-based methods of amplification tend to generate bias with 
increasing cycles, one possible method would be to use isothermal amplification which 
overcomes this limitation by amplifying DNA in a linear fashion. The result would 
typically be more representative of the original sample with a greater signal/noise ratio. 
Its performance here however, remains to be tested, since the commercial WGA2 kit still 
provides a reliable signal on the microarray, as shown by the binding of RNA Pol II 
(pSer2) matching the expected patterns (Figure 4.17) (Hsin JP 2012). Although tools 
presented in Sandcastle allow normalisation of data from linked experiments, this feature 
depends solely on the array data having a background-subpopulation which closely 
follows a standard normal distribution (Bennett 2015). If the data lacks this feature, then 
the interpretation would be limited to the presence/absence of proteins at distinct binding 
sites (Bennett 2015). Therefore, a series of quality controls are always carried out to 
ensure that the data generated in this study meet the requirements for Sandcastle 
normalisation (Figure 4.14). Using different approaches to validate the RNA Pol II 
(pSer2) array data (Figure 4.15 – Figure 4.18), showed that the ChIP-chip method 
established for TK6 cells could be used to reliably map other targets.  
Taking this forward, Chapter V describes the work that applies the established 
ChIP-Chip method to further examine changes in histone H4 acetylation as a marker of 
euchromatin and ORC1, as a marker of replication initiating zones, on chromosome 17 
in response to TSA treatment. The aim was to investigate whether TSA could potentially 
increase the frequency of collisions between transcription and replication, as a source of 
DNA damage induction. Although the current study utilises chromosome 17 arrays, the 
observations made here are expected hold true throughout the genome, since these events 
are common to all chromosomes. Comparing these data separately showed that TSA 
promotes changes in the distribution patterns of H4ac (Figure 5.1 and Figure 5.2), RNA 
Pol II (pSer2) (Figure 5.3 and Figure 5.4) and ORC1 (and Figure 5.8; Figure 5.9). To 
investigate if there is a potential relationship between H4ac and RNA Pol II (pSer2) 
occupancy, similarly H4ac and ORC1 occupancy, the correlations between these sets of 
data were plotted for untreated and TSA treated cells. Interestingly, the analysis showed 
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that TSA treatment resulted in a strong negative relationship between H4ac and RNA Pol 
II (pSer2), as well as ORC1 (Figure 5.10 – Figure 5.12). This suggested that in regions of 
chromosome 17 showing higher levels of H4ac as a result of TSA treatment, would 
display a loss/decrease in both RNA Pol II (pSer2) and ORC1 occupancy. This 
observation initially appears to contradict what is widely reported in the literature where 
higher levels of histone acetylation favour transcription and replication initiation (Kemp 
et al. 2005). To explain this observation, it is possible that a lack of H4ac may represent 
either a region occupied by a deacetylated nucleosome or a region which is not occupied 
by a nucleosome. Comparisons of the ORC1 data with published DHS and G4 data, 
indicative of nucleosome free regions, show that ORC1 is enriched at these sites (Figure 
5.7), suggesting that the lack of H4ac observed may well represent a region deprived of 
nucleosome. This would also fit in with the idea of euchromatin, since nucleosome free 
regions would be more accessible to proteins. This proposition would suggest that while 
global measurements associate higher levels of histone acetylation with increased 
transcription and replication activity, high resolution approaches show that histone 
acetylation may in fact be higher in the surrounding regions around transcription and 
replication rather than specifically at those regions (Figure 5.2A, Figure 5.4A and Figure 
5.8A). Although the analysis here supports this view, further experiments mapping 
nucleosome positions on chromosome 17 in untreated and TSA treated cells would help 
to clarify these findings.  
The changes in ORC1 occupancy observed following TSA treatment are 
consistent with published observations (Conti et al. 2010). The study used DNA fibre 
analysis, showed that treating cancer cells with the HDAC inhibitor vorinostat for 4 hours, 
promoted a slowdown in replication fork speed, concomitant with the induction of 
γH2AX and activation of dormant origins (Conti et al. 2010). In relation to the current 
study, TK6 cells treated with TSA for 6 hours display a significant change in the 
distribution of ORC1 on chromosome 17 (Chapter V, 5.4.3). This could indicate that new 
sites of ORC1 binding may similarly represent dormant origin activation. DNA fibre 
analysis could be carried out on stretches of chromosome 17 in response to TSA to 
support this view.  
To examine the data gathered so far in the context of the hypothesis, the 
relationship between transcription and replication was examined. The analysis showed 
that in untreated TK6 cells, transcription and replication processes are spatially separated 
from each other in different regions on chromosome 17 (Figure 5.15A). However, 
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following TSA treatment, this spatial organisation is lost, causing transcription and 
replication processes to be localised to the same regions on chromosome 17 (Figure 
5.15B). As a result, it is reasonable to predict that an increase in transcription-replication 
col-localisation may lead to higher frequencies of collision events taking place between 
the two (Figure 5.19). However, attempts to demonstrate by mapping γH2AX and R-
loops formation in response to TSA proved unsuccessfully, possibly owing to a lack of 
sensitivity of the current ChIP-chip assay. Hence, future studies aimed at optimising the 
assay for the purposes of measuring γH2AX and R-loops would help to determine if sites 
of potential collisions are indeed associated with DNA damage.  
It should also be noted that a major limitation of using an integrative approach 
with ChIP-chip data is that relationships between variables are merely inferred. In this 
case, it is only reasonable to conclude that TSA-induced loss of H4ac is associated with 
a gain in both RNA Pol (pSer2) and ORC1 occupancy, but does not provide the evidence 
to indicate a loss of H4ac causes these changes. To make this type of conclusion, further 
studies abrogating the ability of H4 to undergo acetylation following TSA treatment 
would demonstrate the role of H4ac in altering transcription and replication. 
The adaptability of ChIP-Chip between different organisms opens up the 
possibility of using budding yeast as a model organism to address the shortfalls of Chapter 
V. The observed hyper-acetylation in RPD3 mutants (Chapter III) merits an alternative 
genetic approach to mimic the effects of treating with a chemical HDAC inhibitor. 
Therefore, Chapter VI mapped and compared genome-wide γH2A (ortholog of γH2AX) 
and R-loop formation between wild type and rpd3Δ cells for a possible indication of the 
predicted transcription-replication conflicts observed in TK6 cells. The key results of this 
chapter showed that, rpd3Δ cells displayed a significant increase in genome-wide γH2A 
enrichment compared to wild type cells (Figure 6.4A), similar to the measured global 
γH2AX increase in TK6 cells. However, R-loop formation did not change significantly 
in response to treatment (Figure 6.4A). Comparison of both datasets identified γH2A and 
R-loop co-localisation within the regions of 9 genes as a result of RPD3 deletion. 
However, estimating the peak distribution of the γH2A signal suggested that those 
observed in rpd3Δ cells do not reflect the spreading of the γH2A signal normally 
associated with double strand break formation. Instead, γH2A is highly enriched across 
the sub-telomeric and telomeric regions on all chromosomes in wild type cells (Figure 
6.9) and is consistent with published findings (Chen et al. 2013). Interestingly, in rpd3Δ 
cells these same regions show higher levels of γH2A enrichment, compared to those 
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detected in wild type cells. Genome-wide mapping of γH2A has been reported previously 
as a means of identifying fragile sites (Chen et al. 2013), owing to DNA damage or 
replication fork stalling. Specifically, γH2A enrichment was reported at telomeres, which 
could suggest that these regions are prone to replication stress due to their highly 
repetitive primary structure making is difficult to replicate and prone to recombination. 
Other studies have shown that telomeric γH2A is coupled to downstream heterochromatin 
imposed by the Sir3 HDAC enzyme (Kitada et al. 2011) and that Rpd3 is required to limit 
the actions of Sir proteins at telomeres (Ehrentraut et al. 2010). More recently in fission 
yeast, γH2A was shown to protect against replication fork collapse when cells faced 
difficulties in loading PCNA (Mejia-Ramirez et al. 2015). Taken together, these data 
suggest that, loss of Rpd3 function may result in redundancy, allowing Sir proteins to 
establish larger regions of heterochromatin at telomeres. This may pose as a barrier to 
replication, leading to an increase in the frequency of stalled forks, resulting in the 
elevated levels of γH2A required to maintain these from collapsing. Further work aimed 
at mapping histone methylation as marker of heterochromatin may provide evidence to 
support this idea. Additionally, previous genome-wide studies mapping R-loops in yeast 
using tiling arrays also reported high levels of enrichment at sub-telomeric regions and 
telomeres of chromosomes (Chan et al. 2014). A major limitation of the microarrays used 
in this study is that the locations of a target, which binds to regions of the genome 
containing repetitive sequences, cannot be reliably determined and therefore are not 
represented by probes on the arrays. This potentially explains why R-loops were not 
detected at the ends of chromosomes in the current study, as these tend to contain 
repetitive elements. The high levels of R-loops at telomeres in wild type cells reported by 
Chan and colleagues may be the result of RNA Polymerase II transcribed telomeric 
repeat-containing RNAs (TERA), which forms DNA:RNA hybrids (R-loops) with the 
template strand (Cusanelli E. and Chartrand P. 2015). Therefore, it would be interesting 
to see from future studies if R-loops in these regions are elevated following a loss of Rpd3 
function using tiling arrays and explore the possibility of conflicts with replication in 
these regions. Overall, the results of Chapter VI fail to present evidence in support of the 
claims made in Chapter V using a yeast HDAC mutant. However, since these 
observations were made using a single HDAC mutant, these effects may be less severe 
compared to a strain lacking multiple HDAC enzymes. Moreover, the differences 
between model organisms, create several caveats in the comparison of the yeast mutant 
data with data derived from TSA treated TK6 cells. As such, TSA-induced transcription-
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replication conflicts within the human context remains a possibility, which requires 
further study. As the development of new HDAC inhibitor molecules stresses isoform 
specificity to target non-life threatening ailments, it would be interesting to compare the 
effects of class-specific HDAC inhibitors with those of TSA and see if similar effects are 
elicited. This would help in trying to address the possible risks posed by these drugs when 
used for non-life threatening diseases.   
The results of the current study present strong evidence to support the view that 
the pan-HDAC inhibitor TSA promotes the co-localisation of transcription and 
replication events on chromosome 17 in TK6 cells. As a consequence of this, it is 
reasonable to predict that the chances of transcription-replication collisions occurring 
may be higher and therefore act as a potential mechanism of generating DNA damage 
and R-loops. This may also partly explain why these drugs which were design to target 
the epigenome can generate damage at the genomic level.  
The findings in this thesis has several implications within the field of safety 
assessment which may be in the interests of GSK. First and foremost, there is a potential 
for the mechanistic understanding gained here to be translated into a unique genotoxicity 
assay for risk assessment. As our understanding of R-loops has increased a great deal over 
the last few years, and it is becoming clear that aberrant accumulation of R-loops can lead 
to cancer and neurological diseases (Stathaki K.S. 2014; Santos-Pereira and Aguilera 
2015; Sollier and Cimprich 2015). Since R-loops are susceptible to mutations, further 
work identifying a correlation between R-loop formation and mutations in the genetic 
sequence with sites of transcription and replication collisions identified in the present 
study would provide mechanistic evidence to support R-loops as an endpoint for risk 
assessment. Alternatively, it is conceivable that genomic changes in R-loop formation 
could be a universal indicator of genotoxicity, induced either by direct or indirect effects 
of drug treatment. This could also be analysed. These findings can be translated into 
routine assays, coupled with high-throughput screening. For instance, cells can be stained 
using a fluorescently-tagged R-loop antibody following drug treatment and the signal 
measured using flow cytometry. On top of this thresholds may be set to indicate levels of 
R-loops which represent a genotoxic response. Examples of existing toxicity assay that 
utilise a similar approach include the GreenScreen® HC assay (Cyprotex PLC) and the 
ToxTracker® assay (Toxys).  
A second potential application of these findings is the use of ChIP-chip described 
here for TK6 cells as a genome-wide assay for measuring DNA damage and repair. 
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Optimisations to the protocol would allow γH2AX to be mapped at high-resolutions 
across the genome. Existing genotoxicity assays either examine endpoints at the global 
level (i.e. gross chromosomal changes or γH2AX using flow cytometry or western 
blotting) or at specific loci (i.e. Pig-a assay). A high-resolution approach offers several 
advantages, including the ability of examine events at many different genomic loci that 
would otherwise be refractory to detection my conventional assays. Additionally, by 
normalising the data using Sandcastle, the loss of γH2AX following the removal of the 
drug can be used as an indication of repair. This may serve as an alternative endpoint for 
risk assessment, as this feature is currently lacking in the tests available. It is important 
to note that γH2AX induction is often used as the gold standard for indicating the presence 
of DNA damage (Kuo LJ 2008). However, emerging evidence has shown that γH2AX 
also has a role in protecting replication forks from collapse at fragile sites (Szilard RK 
2010; Turinetto V. and Giachino C. 2015). Based on this, it may be unreliable to interpret 
a higher global level of γH2AX as a sole indication of DNA damage. Therefore a high-
resolution approach would help to map and distinguish between the sites of replication 
stress and DNA damage by way of examining the different γH2AX profiles, since γH2AX 
associated with replication stress tend to be more localised compared to the more diffuse 
γH2AX signal associated with double strand breaks (Szilard RK 2010).  
In conclusion, the work in this thesis has shown that genome-wide approaches 
such as ChIP-chip can be an effective tool for unravelling the potential mechanisms of 
DNA damage induction by a class of epigenome-targeting drugs. It has also provided a 
novel understanding of how interfering with the epigenome in ways which we do not fully 
comprehend, can potentially lead to negative effects in the genome.  
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Appendix I – Raw data for Chapter III 
 
Raw data for: Figure 3.1 
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Raw data for: Figure 3.2 
 
 
 
 
 
 
 
 
Raw data for: Figure 3.4 
 
 
 
 
 
 
 
 
 
Raw data for: Figure 3.6 
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Appendix II – Raw data for Chapter IV 
 
Example data for:  Figure 4.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Detecting apoptosis in TK6 cells following 48h treatment with nutlin-3. DMSO vehicle 
control: A – B and 10µM nutlin-3 48h: C – D. A & C: Gating to exclude events associated with 
debris (P1). B & D: Applying a quadrant gate in a plot of PI vs. Annexin-V in order to distinguish: 
health cells (bottom left), dead cells (top left), dead and dying cells (top right); cells undergoing 
apoptosis (bottom right). PI – propidum iodide used to stain DNA associated with dead cells. 
Annexin-V used as a marker of early apoptosis.  
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Raw data for: Figure 4.1 
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Example data for:  Figure 4.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DMSO control                                                       625nM TSA 
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Gating procedure involved in the InVitro MicroFlow® assay for the representative samples: 
DMSO vehicle control (A – G) and 625nM TSA (H – N). A & H: Gating (G1) to select all 
events in plot. B & I: Doublet discrimination (G2). C & J: All events above 104 are selected (G3) 
to ensure the inclusion of MN events, while events below 104 corresponding to small fragmented 
DNA and are omitted. D & K: The exclusion of events (DNA) falling outside a defined region 
associated with dead/dying cells based on forward scatter (G6). E & L: The exclusion of events 
(DNA) falling outside a defined region associated with dead/dying cells based on side scatter 
(G5). F & M: Events falling below G4 are EMA +. G & N: MN falling within a distinct region 
(P14) can be discerned from the nuclei population (R1). SYTOX Green – stains all DNA, EMA 
– stains DNA associated with dead cells.  
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Raw data for: Figure 4.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ChIP antibodies used in this study 
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Example data for:  Figure 4.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cell cycle analysis using EMA data from the InVitro MicroFlow® assay. A + B: Data 
from DMSO vehicle control. C + D: Data from 0.625µM TSA. A + C: Exclusion of 
aggregated cells or doublets. B + D: Cell cycle profiles fitted using the Watson model, 
with constrains applied CV’s and ratio.  
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0.625µM TSA 
C                                                                    D 
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Raw data for: Figure 4.4 
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Raw data for: Figure 4.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Raw data for: Figure 4.6 
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Raw data for: Figure 4.12 
 
 
 
 
 
 
 
 
 
 
RNA Pol II (pSer2) titration: 
 
 
 
 
 
 
 
 
 
 
 
Titrations of the anti-RNA Pol II (pSer2) antibody from 0 – 4µg against a fixed volume of 
chromatin. Target enrichment was examined at the proximal promoter region of GAPDH and 
genic region of GAD1.  
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Comparison of changes in RNA Pol II (phosphor-Ser2) at genes on chromosome 17 in 
response to TSA with published gene expression data. Venn diagrams examining similarities 
between genes showing in increase in RNA Pol II (phosphor-Ser2) occupancy and expression at 
A: FDR < 0.01 and C: FDR < 0.05 and similarly those showing a decrease at B: FDR < 0.01 and 
D: FDR < 0.05. For ChIP-Chip data, the average log2 IP/IN ratio for each gene is calculated for 
normalised untreated and TSA treated replicates. A t-test is performed on a gene-to-gene basis 
and corrected for multiple testing using the Benjamini & Hochberg method, otherwise known as 
the false discovery rate (FDR). The means before and after treatment are compared to classify 
genes as either showing an increase or decease in relative signal. The same analysis is performed 
online using GEO2R with publicly available data from GEO, for THP-1 cells treated with 300nM 
TSA for 150mins (GSE36323) and HUVEC cells treated with 500nM TSA for 24h (GSE5856). 
Overlaps were identified base on matching gene names using a web-based tool (available at 
http://bioinformatics.psb.ugent.be/webtools/Venn/) and drawn using R-based ‘VennDiagram’ 
package v1.6.17. Statistical analysis (Hypergeometric test) was performed using the R-based 
‘stats’ package v3.2.4. *P < 0.05, **P < 0.01. 
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Appendix III – Raw data for Chapter V 
 
 
Normalisation assumptions for H4ac data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H4ac microarray data meets the assumptions for normalisation. First dataset – from untreated 
cells. Second dataset – from TSA treated cells. First row: density plots of the mirrored background 
approximating to the standard normal distribution (SND). Second row: density plots shown in A 
represented as Q-Q plots. Data in the background (shaded) region should closely follow the SND, 
whereas deviations of the right tail represents the enriched sub-population. Third row: Q-Q plot 
of only the mirrored background data. Fourth row: Q-Q plot of the mirrored background for both 
datasets. Little/no departure from the SND indicates that the two datasets are suitable to be 
normalised together. 
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Correlation values between biological replicates of H4ac and ORC1 microarray data 
 
 
 
 
 
 
 
H4ac titration: 
 
 
 
 
 
 
 
 
Titrations of the anti-pan H4ac antibody from 0 – 5µg against a fixed volume of chromatin. 
Target enrichment was examined at the genes RPL10 and MYOD1.  
 
 
ORC1 post-IP western to check for antibody specificity: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  211 
Normalisation assumptions for ORC1 data 
 
 
 
 
 
 
 
 
 
 
 
ORC1 microarray data meets the assumptions for normalisation. First dataset – from 
untreated cells. Second dataset – from TSA treated cells. First row: density plots of the mirrored 
background approximating to the standard normal distribution (SND). Second row: density plots 
shown in A represented as Q-Q plots. Data in the background (shaded) region should closely 
follow the SND, whereas deviations of the right tail represents the enriched sub-population. Third 
row: Q-Q plot of only the mirrored background data. Fourth row: Q-Q plot of the mirrored 
background for both datasets. Little/no departure from the SND indicates that the two datasets are 
suitable to be normalised together. 
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Biological replicates of γH2AX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Biological replicates of γH2AX – following changes to protocol 
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γH2AX enrichment following TSA treatment measured by ChIP-qPCR 
- Anti-gamma H2A.X (phospho S139) antibody - ChIP Grade (ab2893) 
 
 
 
 
 
 
 
 
 
 
 
R-loop titration: 
 
 
 
 
 
 
 
 
 
 
Titrations of the anti-DNA-RNA hybrid antibody from 0 – 4µg against a fixed volume of 
chromatin. Target enrichment was examined at the genes SENP3-EIF4A1 and ZNF544.  
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Biological replicates of R-loop enrichment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primers used 
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Appendix IV – Raw data for Chapter VI 
 
 
Normalisation assumptions for γH2A data 
 
γH2A microarray data meets the assumptions for normalisation. First dataset – from wild 
type strain. Second dataset – from rpd3Δ strain. First row: density plots of the mirrored 
background approximating to the standard normal distribution (SND). Second row: density plots 
shown in A represented as Q-Q plots. Data in the background (shaded) region should closely 
follow the SND, whereas deviations of the right tail represents the enriched sub-population. Third 
row: Q-Q plot of only the mirrored background data. Fourth row: Q-Q plot of the mirrored 
background for both datasets. Little/no departure from the SND indicates that the two datasets are 
suitable to be normalised together. 
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Biological repeats of yeast R-loop microarray data show high reproducibility. A: smoothed 
scatter plots showing the Pearson’s correlation coefficient between two biological repeats for wild 
type (left) and rpd3Δ (right). B: normalised array data plotted along a section of chromosome 1 
(100 – 150kb). Array probes are shown in grey along the annotation line with enriched regions in 
red. The positions of genes are represented as yellow boxes. 
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Normalisation assumptions for R-loop data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
R-loop microarray data meets the assumptions for normalisation. First dataset – from wild 
type strain. Second dataset – from rpd3Δ strain. First row: density plots of the mirrored 
background approximating to the standard normal distribution (SND). Second row: density plots 
shown in A represented as Q-Q plots. Data in the background (shaded) region should closely 
follow the SND, whereas deviations of the right tail represents the enriched sub-population. Third 
row: Q-Q plot of only the mirrored background data. Fourth row: Q-Q plot of the mirrored 
background for both datasets. Little/no departure from the SND indicates that the two datasets are 
suitable to be normalised together. 
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